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ACC/AHA Guidelines for the
Management of Patients With
Valvular Heart Disease
Preamble
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies in the management or prevention of disease
states. Rigorous and expert analysis of the available data
documenting relative benefits and risks of those procedures
and therapies can produce helpful guidelines that improve the
effectiveness of care, optimize patient outcomes, and favorably
impact the overall cost of care by focusing resources on the
most effective strategies.
The American College of Cardiology (ACC) and the Amer-
ican Heart Association (AHA) have jointly engaged in the
production of such guidelines in the area of cardiovascular
disease since 1980. This effort is directed by the ACC/AHA
Task Force on Practice Guidelines. Its charge is to develop and
revise practice guidelines for important cardiovascular diseases
and procedures. Experts in the subject under consideration are
selected from both organizations to examine subject-specific
data and write guidelines. The process includes additional
representatives from other medical specialty groups when
appropriate. Writing groups are specifically charged to per-
form a formal literature review, weigh the strength of evidence
for or against a particular treatment or procedure, and include
estimates of expected health outcomes where data exist.
Patient-specific modifiers, comorbidities, and issues of patient
preference that might influence the choice of particular tests or
therapies are considered as well as frequency of follow-up and
cost-effectiveness.
These practice guidelines are intended to assist physicians
in clinical decision making by describing a range of generally
acceptable approaches for the diagnosis, management, or
prevention of specific diseases or conditions. These guidelines
attempt to define practices that meet the needs of most
patients in most circumstances. The ultimate judgment regard-
ing care of a particular patient must be made by the physician
and patient in light of all the circumstances presented by that
patient.
The Committee on Management of Patients With Valvular
Heart Disease was chaired by Robert O. Bonow, MD, FACC,
and included the following members: Blase Carabello, MD,
FACC; Antonio C. de Leon, Jr., MD, FACC; L. Henry
Edmunds, Jr., MD, FACC; Bradley J. Fedderly, MD, FAAFP;
Michael D. Freed, MD, FACC; William H. Gaasch, MD,
FACC; Charles R. McKay, MD, FACC; Rick A. Nishimura,
MD, FACC; Patrick T. O’Gara, MD, FACC; Robert A.
O’Rourke, MD, FACC; and Shahbudin H. Rahimtoola, MD,
FACC. In August 1998, the full text of the guidelines was
approved for publication in the November issue of the Journal
of the American College of Cardiology and the executive sum-
mary for publication in the November 3 issue of Circulation.
Reprints of both the full text and the executive summary are
available from both organizations.
I. Introduction
The American College of Cardiology and the American
Heart Association (ACC/AHA) have long been involved in the
joint development of practice guidelines designed to assist
physicians in the management of selected cardiovascular dis-
orders or the selection of certain cardiovascular procedures.
The determination of the disorders or procedures for which to
develop guidelines is based on several factors, including im-
portance to physicians and whether there are sufficient data
from which to derive accepted guidelines. One important
category of cardiac disorders that affect a large number of
patients who require diagnostic procedures and decisions
regarding long-term management is valvular heart disease.
During the past 2 decades, major advances have occurred in
diagnostic techniques, the understanding of natural history,
and interventional cardiological and surgical procedures for
patients with valvular heart disease. These advances have
resulted in enhanced diagnosis, more scientific selection of
patients for surgery or catheter-based intervention versus
medical management, and increased survival of patients with
these disorders. The information base from which to make
clinical management decisions has greatly expanded in recent
years, yet in many situations management issues remain con-
troversial or uncertain. Unlike many other forms of cardiovas-
cular disease, there is a scarcity of large-scale multicenter trials
addressing the diagnosis and treatment of patients with valvu-
lar disease from which to derive definitive conclusions, and the
information available in the literature represents primarily the
experiences reported by single institutions in relatively small
numbers of patients.
The Committee on Management of Patients With Valvular
Heart Disease was given the task of reviewing and compiling
this information base and making recommendations for diag-
nostic testing, treatment, and physical activity. For topics in
which there is an absence of multiple randomized controlled
trials, the preferred basis for medical decision making in
clinical practice (evidence-based medicine), the committee’s
recommendations were based on data derived from single
randomized trials or nonrandomized studies or were based on
a consensus opinion of experts. Where no or few data exist, this
is identified in the text.
The committee membership consisted of cardiovascular
disease specialists as well as representatives of the cardiac
surgery and family practice fields; both the academic and
private practice sectors were represented. This document was
reviewed by 3 outside reviewers nominated by the ACC and 3
outside reviewers nominated by the AHA, as well as numerous
content reviewers and individuals nominated by the American
Academy of Family Physicians and the Society of Thoracic
Surgeons.
The guidelines follow the format established in previous
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ACC/AHA guidelines for classifying indications for diagnostic
and therapeutic procedures:
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or treatment is
useful and effective.
Class II: Conditions for which there is conflicting evidence
and/or a divergence of opinion about the usefulness/efficacy of
a procedure or treatment.
IIa. Weight of evidence/opinion is in favor of useful-
ness/efficacy.
IIb. Usefulness/efficacy is less well established by
evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treatment is not useful
and in some cases may be harmful.
The reference list is not exhaustive or all-inclusive, as this
would be beyond the scope of this publication, but includes
those papers that the committee believes represent the most
comprehensive or convincing data and are necessary to sup-
port its conclusions.
The guidelines attempt to deal with general issues of
treatment of patients with heart valve disorders, such as
evaluation of patients with heart murmurs, prevention and
treatment of endocarditis, management of valve disease in
pregnancy, and treatment of patients with concomitant coro-
nary artery disease (CAD) as well as more specialized issues
that pertain to specific valve lesions. The guidelines focus
primarily on valvular heart disease in the adult, with a separate
section dealing with specific recommendations for valve disor-
ders in adolescents and young adults. The diagnosis and
management of infants and young children with congenital
valvular abnormalities are significantly different from those of
the adolescent or adult and are beyond the scope of these
guidelines.
This task force report overlaps with several previously
published ACC/AHA guidelines about cardiac imaging and
diagnostic testing, including the Guidelines for Clinical Use of
Cardiac Radionuclide Imaging (1), the Guidelines for Clinical
Application of Echocardiography (2), the Guidelines for Ex-
ercise Testing (3), and the Guidelines for Coronary Angiogra-
phy (4). Although these guidelines are not intended to include
detailed information covered in previous guidelines on the use
of imaging and diagnostic testing, an essential component of
this report is the discussion of indications for these tests in the
evaluation and treatment of patients with valvular heart dis-
ease.
The committee emphasizes the fact that many factors
ultimately determine the most appropriate treatment of indi-
vidual patients with valvular heart disease within a given
community. These include the availability of diagnostic equip-
ment and expert diagnosticians, the expertise of interventional
cardiologists and surgeons, and notably the wishes of well-
informed patients. Therefore, deviation from these guidelines
may be appropriate in some circumstances. These guidelines
are written with the assumption that a diagnostic test can be
performed and interpreted with skill levels consistent with
previously reported ACC training and competency statements
and ACC/AHA guidelines, that interventional cardiological
and surgical procedures can be performed by highly trained
practitioners within acceptable safety standards, and that the
resources necessary to perform these diagnostic procedures
and provide this care are readily available. This is not true in all
geographic areas, which further underscores the committee’s
position that its recommendations are guidelines and not rigid
requirements.
II. General Principles
A. Evaluation of the Patient With a
Cardiac Murmur
1. Introduction. Cardiac auscultation remains the most
widely used method of screening for heart disease. The pro-
duction of murmurs is due to 3 main factors: (1) high blood
flow rate through normal or abnormal orifices; (2) forward
flow through a narrowed or irregular orifice into a dilated
vessel or chamber; or (3) backward or regurgitant flow through
an incompetent valve, septal defect, or patent ductus arterio-
sus. Often, several of these factors are operative (5–7).
A heart murmur may have no pathological significance or
may be an important clue to the presence of valvular, congen-
ital, or other structural abnormalities of the heart (8). Most
systolic heart murmurs do not signify cardiac disease, and
many are related to physiological increases in blood flow
velocity (9). In other instances, a heart murmur may be an
important clue to the diagnosis of undetected cardiac disease
(eg, valvular aortic stenosis) that may be important even when
asymptomatic or that may define the reason for cardiac
symptoms. In these situations, various noninvasive or invasive
cardiac tests may be necessary to establish a firm diagnosis and
form the basis for rational treatment of an underlying disorder.
Two-dimensional (2-D) and Doppler echocardiography is par-
ticularly useful in this regard, as discussed in the ACC/AHA
Guidelines for the Clinical Application of Echocardiography
(2). Diastolic murmurs virtually always represent pathological
conditions and require further cardiac evaluation, as do most
Abbreviations used in these guidelines:
AR 5 aortic regurgitation
AS 5 aortic stenosis
AVR 5 aortic valve replacement
CAD 5 coronary artery disease
ECG 5 electrocardiogram
LV 5 left ventricular
MR 5 mitral regurgitation
MS 5 mitral stenosis
MVP 5 mitral valve prolapse
MVR 5 mitral valve replacement
NYHA 5 New York Heart Association
TR 5 tricuspid regurgitation
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continuous murmurs. Continuous “innocent” murmurs include
venous hums and mammary souffle´s.
The traditional auscultation method of assessing cardiac
murmurs has been based on their timing in the cardiac cycle,
configuration, location and radiation, pitch, intensity (grades 1
through 6), and duration (5–9). The configuration of a murmur
may be crescendo, decrescendo, crescendo-decrescendo
(diamond-shaped), or plateau. The precise times of onset and
cessation of a murmur associated with cardiac pathology
depend on the point in the cardiac cycle at which an adequate
pressure difference between 2 chambers appears and disap-
pears (5–9). A classification of cardiac murmurs is listed in
Table 1.
2. Classification of Murmurs. Holosystolic (pansystolic)
murmurs are generated when there is flow between chambers
that have widely different pressures throughout systole, such as
the left ventricle and either the left atrium or right ventricle.
With an abnormal regurgitant orifice, the pressure gradient
and regurgitant jet begin early in contraction and last until
relaxation is almost complete.
Midsystolic (systolic ejection) murmurs, often crescendo-
decrescendo in configuration, occur when blood is ejected
across the aortic or pulmonic outflow tracts. The murmurs start
shortly after S1, when the ventricular pressure rises sufficiently
to open the semilunar valve. As ejection increases, the murmur
is augmented, and as ejection declines, it diminishes.
In the presence of normal semilunar valves, this murmur
may be caused by an increased flow rate such as that which
occurs with elevated cardiac output (eg, pregnancy, thyrotoxi-
cosis, anemia, arteriovenous fistula), ejection of blood into a
dilated vessel beyond the valve, or increased transmission of
sound through a thin chest wall. Most benign innocent mur-
murs occurring in children and young adults are midsystolic
and originate either from the aortic or pulmonic outflow tracts.
Valvular or subvalvular obstruction (stenosis) of either ventri-
cle may also cause a midsystolic murmur, the intensity depend-
ing in part on the velocity of blood flow across the narrowed
area. Midsystolic murmurs also occur in certain patients with
mitral regurgitation (MR) or, less frequently, tricuspid regur-
gitation (TR) resulting from papillary muscle dysfunction.
Echocardiography is often necessary to separate a prominent
and exaggerated (Grade 3 or greater) benign midsystolic
murmur from one due to valvular aortic stenosis (AS).
Early systolic murmurs are less common; they begin with
the first sound and end in midsystole. An early systolic murmur
is often due to TR occurring in the absence of pulmonary
hypertension and in other patients with acute MR. In large
ventricular septal defects with pulmonary hypertension and
small muscular ventricular septal defects, the shunting at the
end of systole may be insignificant, with the murmur limited to
early and midsystole.
Late systolic murmurs are soft or moderately loud, high-
pitched murmurs at the left ventricular (LV) apex that start
well after ejection and end before or at S2. They are often due
to ischemia or infarction of the mitral papillary muscles or to
their dysfunction due to LV dilatation. Late systolic murmurs
in patients with midsystolic clicks result from late systolic
regurgitation due to prolapse of the mitral leaflet(s) into the
left atrium. Such late systolic murmurs can also occur in the
absence of clicks.
Early immediate diastolic murmurs begin with or shortly
after S2, when the associated ventricular pressure drops suffi-
ciently below that in the aorta or pulmonary artery. High-
pitched murmurs of aortic regurgitation (AR) or pulmonic
regurgitation due to pulmonary hypertension are generally
decrescendo, consistent with the rapid decline in volume or
rate of regurgitation during diastole. The diastolic murmur of
pulmonic regurgitation without pulmonary hypertension is low
to medium pitch, and the onset of this murmur is slightly
delayed because regurgitant flow is minimal at pulmonic valve
closure, when the reverse pressure gradient responsible for the
regurgitation is minimal.
Middiastolic murmurs usually originate from the mitral and
tricuspid valves, occur early during ventricular filling, and are
due to a relative disproportion between valve orifice size and
diastolic blood flow volume. Although they are usually due to
mitral or tricuspid stenosis, middiastolic murmurs may also be
due to increased diastolic blood flow across the mitral or
tricuspid valve when such valves are severely regurgitant,
across the normal mitral valve in patients with ventricular
septal defect or patent ductus arteriosus, and across the normal
tricuspid valve in patients with atrial septal defect. In severe,
long-term AR, a low-pitched diastolic murmur (Austin-Flint
murmur) is often present at the LV apex; it may be either
middiastolic or presystolic.
Presystolic murmurs begin during the period of ventricular
filling that follows atrial contraction and therefore occur in
sinus rhythm. They are usually due to mitral or tricuspid
stenosis. A right or left atrial myxoma may cause either
middiastolic or presystolic murmurs similar to tricuspid or
mitral stenosis (MS).
Continuous murmurs arise from high- to low-pressure
shunts that persist through the end of systole and the beginning
of diastole. Thus, they begin in systole, peak near S2, and
continue into all or part of diastole. There are many causes of
continuous murmurs, but they are uncommon in patients with
valvular heart disease (5–9).
a. Dynamic Cardiac Auscultation. Attentive cardiac auscul-
tation during dynamic changes in cardiac hemodynamics often
enables the careful observer to deduce the correct origin and
Table 1. Classification of Cardiac Murmurs
1. Systolic murmurs
a. Holosystolic (pansystolic) murmurs
b. Midsystolic (systolic ejection) murmurs
c. Early systolic murmurs
d. Mid to late systolic murmurs
2. Diastolic murmurs
a. Early high-pitched or low-pitched diastolic murmurs
b. Middiastolic murmurs
c. Presystolic murmurs
3. Continuous murmurs
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significance of a cardiac murmur (10–13). Changes in the
intensity of heart murmurs during various maneuvers are
indicated in Table 2.
b. Other Physical Findings. The presence of other physical
findings, either cardiac or noncardiac, may provide important
clues to the significance of a cardiac murmur and the need for
further testing (Figure 1). For example, a right heart murmur
in early to midsystole at the lower left sternal border likely
represents TR without pulmonary hypertension in an intrave-
nous drug user who presents with fever, petechiae, Osler’s
node, and Janeway lesion.
Associated cardiac findings frequently provide important
information about cardiac murmurs. Fixed splitting of the
second heart sound during inspiration and expiration in a
patient with a grade 2/6 midsystolic murmur in the pulmonic
area and left sternal border should suggest the possibility of an
atrial septal defect. A soft or absent A2 or reversed splitting of
S2 may denote severe AS. An early aortic systolic ejection
sound heard during inspiration and expiration suggests a
bicuspid aortic valve, whereas an ejection sound heard only in
the pulmonic area and left sternal border during expiration
usually denotes pulmonic valve stenosis. LV dilatation on
precordial palpation and bibasilar pulmonary rales favor the
diagnosis of MR in a patient with a grade 2/6 holosystolic
murmur at the cardiac apex. A slow-rising, diminished arterial
pulse suggests severe AS in a patient with a grade 2/6 midsys-
tolic murmur at the upper intercostal spaces. The typical
pulsus parvus and tardus may be absent in the elderly, even
with severe AS secondary to the effects of aging on the
vasculature. Pulsus parvus may also occur with severely low
output from any cause. Factors that aid in the diagnosis of LV
outflow tract obstruction are listed in Table 3.
c. Associated Symptoms. An important consideration in a
patient with a cardiac murmur is the presence or absence of
symptoms (14) (Figure 1). For example, symptoms of syncope,
angina pectoris, or congestive heart failure in a patient with a
midsystolic murmur will usually result in a more aggressive
approach than in patients with a similar midsystolic murmur
who have none of these symptoms. 2-D and Doppler echocar-
diography to rule in or out the presence of significant AS will
likely be obtained. A history of thromboembolism or possible
infective endocarditis will also usually result in a more exten-
sive workup. In patients with cardiac murmurs and clinical
findings suggestive of endocarditis, 2-D and Doppler echocar-
diography is usually indicated (2).
Conversely, many asymptomatic children and young adults
with grade 2/6 midsystolic murmurs and no other cardiac
physical findings need no further cardiac workup after the
initial history and physical examination (Figure 1). A particu-
larly important group is the large number of asymptomatic
elderly patients, many with systemic hypertension, who have
midsystolic murmurs related to sclerotic aortic valve leaflets;
flow into tortuous, noncompliant great vessels; or a combina-
tion of these. Such murmurs must be distinguished from those
caused by mild to severe valvular AS, which is prevalent in this
age group. The absence of LV hypertrophy on electrocardiog-
raphy is reassuring, and this test is considerably less costly than
routine echocardiography.
d. Electrocardiography and Chest Roentgenography. Al-
though echocardiography usually provides more specific and
often quantitative information about the significance of a heart
murmur and may be the only test needed, the electrocardio-
gram (ECG) and chest x-ray are readily available and may have
been obtained already. The absence of ventricular hypertro-
phy, atrial abnormality, arrhythmias, conduction abnormali-
ties, prior myocardial infarction, and evidence of active isch-
emia on the ECG provides useful negative information at a
relatively low cost. Abnormal findings on the ECG, such as
ventricular hypertrophy or a prior infarction, should lead to a
more extensive evaluation including 2-D and Doppler echo-
cardiography (Figure 1).
Table 2. Interventions Used to Alter the Intensity of
Cardiac Murmurs
Respiration
Right-sided murmurs generally increase with inspiration. Left-sided
murmurs usually are louder during expiration.
Valsalva maneuver
Most murmurs decrease in length and intensity. Two exceptions are the
systolic murmur of HCM, which usually becomes much louder, and that of
MVP, which becomes longer and often louder. Following release of the
Valsalva, right-sided murmurs tend to return to baseline intensity earlier
than left-sided murmurs.
Exercise
Murmurs caused by blood flow across normal or obstructed valves (eg, PS,
MS) become louder with both isotonic and submaximal isometric
(handgrip) exercise. Murmurs of MR, VSD, and AR also increase with
handgrip exercise. However, the murmur of HCM often decreases with
near-maximum handgrip exercise.
Positional changes
With standing, most murmurs diminish, 2 exceptions being the murmur of
HCM, which becomes louder, and that of MVP, which lengthens and often
is intensified. With prompt squatting, most murmurs become louder, but
those of HCM and MVP usually soften and may disappear. Passive leg
raising usually produces the same results as prompt squatting.
Postventricular premature beat or atrial fibrillation
Murmurs originating at normal or stenotic semilunar valves increase in
intensity during the cardiac cycle following a VPB or in the beat after a
long cycle length in AF. By contrast, systolic murmurs due to
atrioventricular valve regurgitation do not change, diminish (papillary
muscle dysfunction), or become shorter (MVP).
Pharmacological interventions
During the initial relative hypotension following amyl nitrite inhalation,
murmurs of MR, VSD, and AR decrease, while murmurs of AS increase
because of increased stroke volume. During the later tachycardia phase,
murmurs of MS and right-sided lesions also increase. This intervention may
thus distinguish the murmur of the Austin-Flint phenomenon from that of
MS. The response in MVP often is biphasic (softer then louder than
control).
Transient arterial occlusion
Transient external compression of both arms by bilateral cuff inflation to
20 mm Hg greater than peak systolic pressure augments the murmurs of
MR, VSD, and AR but not murmurs due to other causes.
Abbreviations: AF 5 atrial fibrillation, AR 5 aortic regurgitation, AS 5
aortic stenosis, HCM 5 hypertrophic cardiomyopathy, MR 5 mitral regurgita-
tion, MS 5 mitral stenosis, MVP 5 mitral valve prolapse, PS 5 pulmonic
stenosis, VPB 5 ventricular premature beat, VSD 5 ventricular septal defect.
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Posteroanterior and lateral chest roentgenograms often
yield qualitative information on cardiac chamber size, pulmo-
nary blood flow, pulmonary venous pressures, pulmonary
vascular redistribution, and cardiac calcification in patients
with cardiac murmurs. When abnormal findings are present on
chest x-ray, 2-D and Doppler echocardiography should be
performed (Figure 1). A normal chest x-ray and ECG are likely
in patients with insignificant midsystolic cardiac murmurs,
particularly in younger age groups and when the murmur is less
than grade 3 in intensity (15–17). Many asymptomatic patients
need neither an ECG nor a chest x-ray when a careful cardiac
examination indicates an insignificant vibratory midsystolic
heart murmur and no other abnormal findings.
e. Echocardiography. Echocardiography is an important
noninvasive method for assessing the significance of cardiac
murmurs by imaging cardiac structure and function and the
direction and velocity of blood flow through cardiac valves and
chambers. 2-D echocardiography may indicate abnormal val-
vular motion and morphology but usually does not indicate
the severity of valvular stenosis or regurgitation except in
MS. With Doppler echocardiography, a change or shift in
ultrasound frequency indicates the direction and velocity of
flow in relation to transducers. The direction of flow is
displayed as a spectral velocity profile of blood flowing
toward or away from the transducer. The velocity reflects
the pressure gradient across stenotic and regurgitant valves.
The presence of an abnormal regurgitant jet on color flow
imaging detects valvular regurgitation and provides semi-
quantitative information about its severity.
Although 2-D echocardiography and color flow Doppler
imaging can provide important information on patients with
Table 3. Factors That Differentiate the Various Causes of Left Ventricular Outflow Tract Obstruction
Valvular Supravalvular Discrete Subvalvular HOCM
Valve calcification Common after age 40 No No No
Dilated ascending aorta Common Rare Rare Rare
PP after VPB Increased Increased Increased Decreased
Valsalva effect on SM Decreased Decreased Decreased Increased
Murmur of AR Common Rare Sometimes No
Fourth heart sound (S4) If severe Uncommon Uncommon Common
Paradoxic splitting Sometimes* No No Rather common*
Ejection click Most (unless valve calcified) No No Uncommon or none
Maximal thrill and murmur 2nd RIS 1st RIS 2nd RIS 4th LIS
Carotid pulse Normal to anacrotic* (parvus et tardus) Unequal Normal to anacrotic Brisk, jerky, systolic rebound
*Depends on severity. Abbreviations: AR 5 aortic regurgitation, HOCM 5 hypertrophic obstructive cardiomyopathy, LIS 5 left intercostal space, PP 5 pulse
pressure, RIS 5 right intercostal space, SM 5 systolic murmur, VPB 5 ventricular premature beat. From Marriott HJL. Bedside Cardiac Diagnosis. Philadelphia, PA:
JB Lippincott Co; 1993:116. With permission.
Figure 1. Strategy for evaluating heart murmurs. *If an ECG or chest
x-ray has been obtained and is abnormal, an echocardiogram is
recommended.
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cardiac murmurs, these tests are not necessary for all
patients with cardiac murmurs and usually add little but
expense in the evaluation of asymptomatic patients with
short grade 1 to 2 midsystolic murmurs and otherwise
normal physical findings. Alternatively, if the diagnosis is
still questionable after transthoracic echocardiography, trans-
esophageal echocardiography or cardiac catheterization
may be appropriate.
It is important to consider that many recent studies indicate
that Doppler ultrasound devices are very sensitive and may
detect valvular regurgitation through the tricuspid and pul-
monic valves in a large percentage of young, healthy subjects
and through left-sided valves (particularly the mitral) in a
variable but lower percentage (18–22).
General recommendations for performing 2-D and Dopp-
ler echocardiography in asymptomatic and symptomatic pa-
tients with heart murmurs follow. Of course, individual excep-
tions to these indications may exist.
Recommendations for Echocardiography in Asymptomatic Patients
With Cardiac Murmurs
Indication Class
1. Diastolic or continuous murmurs. I
2. Holosystolic or late systolic murmurs. I
3. Grade 3 or midsystolic murmurs. I
4. Murmurs associated with abnormal physical findings
on cardiac palpation or auscultation.
IIa
5. Murmurs associated with an abnormal ECG or chest
x-ray.
IIa
6. Grade 2 or softer midsystolic murmur identified as
innocent or functional by an experienced observer.
III
7. To detect “silent” AR or MR in patients without
cardiac murmurs, then recommend endocarditis prophylaxis.
III
Recommendations for Echocardiography in Symptomatic Patients
With Cardiac Murmurs
Indication Class
1. Symptoms or signs of congestive heart failure, myocardial
ischemia, or syncope.
I
2. Symptoms or signs consistent with infective endocarditis or
thromboembolism.
I
3. Symptoms or signs likely due to noncardiac disease with
cardiac disease not excluded by standard cardiovascular
evaluation.
IIa
4. Symptoms or signs of noncardiac disease with an
isolated midsystolic “innocent” murmur.
III
f. Cardiac Catheterization. Cardiac catheterization can pro-
vide important information about the presence and severity of
valvular obstruction, valvular regurgitation, and intracardiac
shunting. It is not necessary in most patients with cardiac
murmurs and normal or diagnostic echocardiograms but pro-
vides additional information on some patients in whom there is
a discrepancy between echocardiographic and clinical findings.
Indications for cardiac catheterization for hemodynamic as-
sessment of specific valve lesions are given in sections III.A.
through III.F. of these guidelines. Specific indications for
coronary arteriography to assess the presence of coronary
disease are given in section VIII.
3. Approach to the Patient. The evaluation of the patient
with a heart murmur may vary greatly, depending on many of
the considerations discussed above (17,23). These include the
intensity of the cardiac murmur, its timing in the cardiac cycle,
its location and radiation, and its response to various physio-
logical maneuvers (Table 2). Also of importance is the pres-
ence or absence of cardiac and noncardiac symptoms and
whether other cardiac or noncardiac physical findings suggest
that the cardiac murmur is clinically significant (Figure 1).
Patients with definite diastolic heart murmurs or continu-
ous murmurs not due to a cervical venous hum or a mammary
souffle´ during pregnancy are candidates for 2-D and Doppler
echocardiography. If the results of echocardiography indi-
cate significant heart disease, further evaluation may be
indicated. An echocardiographic examination is also recom-
mended for most patients with apical or left sternal edge
holosystolic or late systolic murmurs, for patients with
midsystolic murmurs of grade 3 or greater intensity, and for
patients with softer systolic murmurs in whom dynamic
cardiac auscultation suggests a definite cardiac diagnosis
(eg, hypertrophic cardiomyopathy).
More specifically, further evaluation including echocardiog-
raphy is recommended for patients in whom the intensity of a
systolic murmur increases during the Valsalva maneuver,
becomes louder when the patient assumes the upright position,
and decreases in intensity when the patient squats. These
responses suggest the diagnosis of either hypertrophic cardio-
myopathy or mitral valve prolapse (MVP). Additionally, fur-
ther assessment is indicated when a systolic murmur increases
in intensity during transient arterial occlusion, becomes louder
during sustained handgrip exercise, or does not increase in
intensity either in the cardiac cycle following a premature
ventricular contraction or after a long R-R interval in patients
with atrial fibrillation. The diagnosis of MR or ventricular
septal defect is likely.
In many patients with grade 1 to 2 midsystolic murmurs, an
extensive workup is not necessary. This is particularly true for
children and young adults who are asymptomatic, have an
otherwise normal cardiac examination, and have no other
physical findings associated with cardiac disease.
However, echocardiography is indicated in certain patients
with grade 1 to 2 midsystolic murmurs, including patients with
symptoms or signs consistent with infective endocarditis or
thromboembolism and those with symptoms or signs consis-
tent with congestive heart failure, myocardial ischemia, or
syncope. Echocardiography also usually provides an accu-
rate diagnosis in patients with other abnormal physical
findings on cardiac palpation or auscultation, the latter
including widely split second heart sounds, systolic ejection
sounds, and specific changes in intensity of the systolic
murmur during certain physiological maneuvers as de-
scribed in Table 2.
Although 2-D and Doppler echocardiography is an impor-
tant test for those with a moderate to high likelihood of a
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clinically important cardiac murmur, it must be reemphasized
that trivial, minimal, or physiological valvular regurgitation,
especially affecting the mitral, tricuspid, or pulmonic valves, is
detected by color flow imaging techniques in many otherwise
normal patients and includes many patients who have no heart
murmur at all (18–22). This must be considered when the
results of echocardiography are used to guide decisions con-
cerning asymptomatic patients in whom echocardiography was
used to assess the clinical significance of an isolated murmur.
Very few data address the cost-effectiveness of various
approaches to the patient undergoing medical evaluation of a
cardiac murmur. Optimal auscultation by well-trained ex-
aminers who can recognize an insignificant midsystolic
murmur with confidence (by dynamic cardiac auscultation as
indicated) results in less frequent use of expensive addi-
tional testing to define murmurs that do not indicate cardiac
pathology.
Many murmurs in asymptomatic adults are innocent and
have no functional significance. Such murmurs have the fol-
lowing characteristics: (1) grade 1 to 2 intensity at the left
sternal border; (2) a systolic ejection pattern; (3) normal
intensity and splitting of the second heart sound; (4) no other
abnormal sounds or murmurs; and (5) no evidence of ventric-
ular hypertrophy or dilatation and the absence of increased
murmur intensity with the Valsalva maneuver (10). Such
murmurs are especially common in high-output states such as
pregnancy (24,25). When the characteristic features of individ-
ual murmurs are considered together with information ob-
tained from the history and physical examination, the correct
diagnosis can usually be established (17). In patients with
ambiguous clinical findings, the echocardiogram can often
provide a definite diagnosis, rendering a chest x-ray and/or
ECG unnecessary.
In the evaluation of heart murmurs, the purposes of echo-
cardiography are to (1) define the primary lesion in terms of
etiology and severity; (2) define hemodynamics; (3) define
coexisting abnormalities; (4) detect secondary lesions; (5)
evaluate cardiac chamber size and function; (6) establish a
reference point for future comparisons; and (7) reevaluate the
patient after an intervention.
As valuable as echocardiography may be, the basic cardio-
vascular physical examination is still the most appropriate
method of screening for cardiac disease and will establish many
clinical diagnoses. Echocardiography should not replace the
cardiovascular examination but can be useful in determining
the etiology and severity of lesions, particularly in elderly
patients.
B. Endocarditis and Rheumatic Fever Prophylaxis
1. Endocarditis Prophylaxis. Endocarditis is a serious ill-
ness associated with significant mortality. Its prevention by
appropriate administration of antibiotics before procedures
expected to produce bacteremia merits serious consideration.
Experimental studies suggest that endothelial damage leads to
Recommendations for Endocarditis Prophylaxis
Indication Class
High-Risk Category I
z Prosthetic heart valves, including bioprosthetic homograft and
allograft valves.
z Previous bacterial endocarditis.
z Complex cyanotic congenital heart disease, (eg, single
ventricle states, transposition of the great arteries, tetralogy of
Fallot).
z Surgically constructed systemic-pulmonary shunts or conduits.
Moderate-Risk Category I
z Most other congenital cardiac malformations (other than
above or below).
z Acquired valvular dysfunction (eg, rheumatic heart disease).
z Hypertrophic cardiomyopathy.*
z MVP with auscultatory evidence of valvular regurgitation and/
or thickened leaflets.†
Low- or Negligible-Risk Category III
z Isolated secundum atrial septal defect.
z Surgical repair of atrial septal defect, ventricular septal
defect, or patent ductus arteriosus (without residua >6 mo).
z Previous coronary artery bypass graft surgery.
z MVP without valvular regurgitation.†
z Physiological, functional, or innocent heart murmurs.‡
z Previous Kawasaki disease without valvular dysfunction.
z Cardiac pacemakers and implanted defibrillators.
Adapted from Dajani et al (36) with permission.
*This committee recommends prophylaxis in hypertrophic cardiomyopathy
only when there is latent or resting obstruction.
†Patients with MVP without regurgitation require additional clinical judg-
ment. Indications for antibiotic prophylaxis in MVP are discussed in section
III.D.2. of these guidelines. Patients who do not have MR but do have
echocardiographic evidence of thickening and/or redundancy of the valve leaflets
and especially men >245 years may be at increased risk for bacterial endocarditis
(36). Additionally, approximately one third of patients with MVP without MR at
rest may have exercise-induced MR (37). Some patients may exhibit MR at rest
on 1 occasion and not on others. There are no data available to address this latter
issue, and at present, the decision must be left to clinical judgment, taking into
account the nature of the invasive procedure, the previous history of endocarditis,
and the presence or absence of valve thickening and/or redundancy.
‡In patients with echocardiographic evidence of physiological MR in the
absence of a murmur and with structurally normal valves, prophylaxis is not
recommended. The committee also does NOT recommend prophylaxis for
physiological tricuspid and pulmonary regurgitation detected by Doppler in the
absence of a murmur, as such findings occur in a large number of normal
individuals and the risk of endocarditis is extremely low. Recommendations
regarding Doppler echocardiography for purposes of antibiotic prophylaxis in
patients who have received anorectic drugs are given in section III.H. of these
guidelines.
platelet and fibrin deposition and thus a nonbacterial throm-
botic endocardial lesion. In the presence of bacteremia, the
organisms adhere to these lesions and multiply within the
platelet-fibrin complex, leading to an infective vegetation
(26,27). Valvular and congenital abnormalities, especially
those that result in abnormal high-velocity jet streams, can
damage the endothelial lining and predispose to platelet
aggregation and fibrin deposition at those sites, which are thus
at higher risk for bacterial colonization.
Several issues must be considered in generating recommen-
dations for endocarditis prophylaxis (28). Evidence supporting
prophylaxis consists of the following:
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1. Clinical experience documents endocarditis following bac-
teremia.
2. Bacteremia by organisms known to produce endocarditis
follows various procedures such as dental procedures, en-
doscopy, cystoscopy, etc.
3. Antibiotics to which known offending organisms are sensi-
tive are available.
4. In laboratory animal models of endocarditis, antibiotic
prophylaxis has been shown to be effective.
5. Small clinical studies in humans appear to show benefit
from prophylaxis against endocarditis (29,30).
The following evidence raises questions about the value of
prophylaxis:
1. Lack of any sufficiently large, controlled clinical trials to
support the application of the results of laboratory animal
studies to humans.
2. Clinical reports of failure of antibiotic prophylaxis against
endocarditis (28,31) or studies that appear to show that
prophylaxis is not protective (32).
3. The evidence that dental and other procedures cause
endocarditis is circumstantial. With the incidence of bacte-
remia (positive blood culture) varying from 8% (urethral
catheterization) to as high as 88% (periodontal surgery)
(33), the actual incidence of endocarditis is low (10 to 60
cases/1 million persons per year) (28).
4. In specific circumstances, such as prophylaxis for all cases of
MVP, the risk of death from penicillin prophylaxis is
estimated to be greater than the risk for infective endocar-
ditis (34,35).
In view of these issues, it has been suggested that the risk of
endocarditis in patients with preexisting cardiac disorders be
classified as relatively high, moderate, and low or negligible, as
determined by the cardiac disorder. Guidelines for the preven-
tion of endocarditis have been issued by the American Heart
Association (36), and the recommendations made here are
based on those guidelines.
Various dental and/or surgical procedures are associated
with varying degrees and frequencies of bacteremia. The
frequency of bacteremia is highest with dental and oral proce-
Table 4. Endocarditis Prophylaxis for Dental Procedures (36)
A. Endocarditis prophylaxis recommended
z Dental extractions
z Periodontal procedures, including surgery, scaling and root planing,
probing, recall maintenance
z Dental implant placement and reimplantation of avulsed teeth
z Endodontic (root canal) instrumentation or surgery only beyond the apex
z Subgingival placement of antibiotic fibers/strips
z Initial placement of orthodontic bands but not brackets
z Intraligamentary local anesthetic injections*
z Prophylactic cleaning of teeth or implants where bleeding is anticipated
B. Endocarditis prophylaxis not recommended
z Restorative dentistry† (operative and prosthodontic) with/without
retraction cord
z Local anesthetic injections (nonintraligamentary)*
z Intracanal endodontic treatment; postplacement and buildup
z Placement of rubber dams
z Postoperative suture removal
z Placement of removable prosthodontic/orthodontic appliances
z Taking of oral impressions
z Fluoride treatments
z Taking of oral radiographs
z Orthodontic appliance adjustment
z Shedding of primary teeth
*Intraligamentary injections are directed between the root and bone to
deliver anesthetic agents to the periosteum of the bone.
†Includes filling cavities and replacement of missing teeth. In selected
circumstances, especially with significant bleeding, antibiotic use may be indi-
cated. From Dajani et al (36) with permission.
Table 5. Endocarditis Prophylaxis for Nondental Procedures (36)
A. Endocarditis prophylaxis recommended
Respiratory tract
z Tonsillectomy/adenoidectomy
z Surgical operations involving respiratory mucosa
z Bronchoscopy with rigid bronchoscope
Gastrointestinal tract (prophylaxis for high-risk patients; optimal for
moderate risk)
z Sclerotherapy for esophageal varices
z Esophageal stricture dilation
z Endoscopic retrograde cholangiography with biliary obstruction
z Biliary tract surgery
z Surgical operations involving intestinal mucosa
Genitourinary tract
z Prostatic surgery
z Cystoscopy
z Urethral dilation
B. Endocarditis prophylaxis not recommended
Respiratory tract
z Endotracheal intubation
z Bronchoscopy with a flexible bronchoscope, with or without biopsy*
z Tympanostomy tube insertion
Gastrointestinal tract
z Transesophageal echocardiography*
z Endoscopy with or without gastrointestinal biopsy*
Genitourinary tract
z Vaginal hysterectomy*
z Vaginal delivery*
z Caesarean section
z In uninfected tissue:
Urethral catheterization
Uterine dilation and curettage
Therapeutic abortion
Sterilization procedures
Insertion or removal of intrauterine devices
Other
z Cardiac catheterization, including balloon angioplasty
z Implantation of cardiac pacemakers, implantable defibrillators, and
coronary stents
z Incision or biopsy of surgically scrubbed skin
z Circumcision
*Prophylaxis is optional for high-risk patients. From Dajani et al (36) with
permission.
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Table 6. Endocarditis Prophylaxis Regimens for Dental, Oral, Respiratory Tract, or Esophageal Procedures (36)
Situation Agent Regimen*
Standard general prophylaxis Amoxicillin Adults: 2.0 g; children: 50 mg/kg PO 1 h before procedure.
Unable to take oral medication Ampicillin Adults: 2.0 g IM or IV; children: 50 mg/kg IM or IV
within 30 min before procedure.
Penicillin-allergic Clindamycin or Adults: 600 mg; children: 20 mg/kg PO 1 h before
procedure.
Cephalexin† or cephadroxil† or Adults: 2.0 g; children 50 mg/kg PO 1 h before procedure.
Azithromycin or clarithromycin Adults: 500 mg; children 15 mg/kg PO 1 h before
procedure.
Penicillin-allergic and unable to take oral medications Clindamycin or Adults: 600 mg; children 20 mg/kg IV within 30 min
before procedure.
Cefazolin† Adults: 1.0 g; children: 25 mg/kg IM or IV within 30 min
before procedure.
*Total children’s dose should not exceed adult dose.
†Cephalosporins should not be used in individuals with immediate-type hypersensitivity reaction (urticaria, angioedema, or anaphylaxis) to penicillins. From Dajani
et al (36) with permission.
Table 7. Endocarditis Prophylaxis Regimens for Genitourinary/Gastrointestinal (Excluding Esophageal) Procedures (36)
Situation Agent(s)* Regimen†
High-risk patients Ampicillin plus gentamicin Adults: ampicillin 2.0 g IM/IV plus gentamicin 1.5 mg/kg (not to exceed 120 mg) within 30 min
of starting the procedure. Six hours later, ampicillin 1 g IM/IV or amoxicillin 1 g PO.
Children: ampicillin 50 mg/kg IM or IV (not to exceed 2.0 g) plus gentamicin 1.5 mg/kg within
30 min of starting the procedure. Six hours later, ampicillin 25 mg/kg IM/IV or amoxicillin
25 mg/kg PO.
High-risk patients allergic to
ampicillin/amoxicillin
Vancomycin plus gentamicin Adults: vancomycin 1.0 g IV over 1–2 h plus gentamicin 1.5 mg/kg IV/IM (not to exceed
120 mg). Complete injection/infusion within 30 min of starting the procedure.
Children: vancomycin 20 mg/kg IV over 1–2 h plus gentamicin 1.5 mg/kg IV/IM. Complete
injection/infusion within 30 min of starting the procedure.
Moderate-risk patients Amoxicillin or ampicillin Adults: amoxicillin 2.0 g PO 1 h before procedure, or ampicillin 2.0 g IM/IV within 30 min of
starting the procedure.
Children: amoxicillin 50 mg/kg PO 1 h before procedure, or ampicillin 50 mg/kg IM/IV within
30 min of starting the procedure.
Moderate-risk patients allergic to
ampicillin/amoxicillin
Vancomycin Adults: vancomycin 1.0 g IV over 1–2 h. Complete infusion within 30 min of starting the
procedure.
Children: vancomycin 20 mg/kg IV over 1–2 h. Complete infusion within 30 min of starting the
procedure.
*No second dose of vancomycin or gentamicin is recommended.
†Total children’s dose should not exceed adult dose. From Dajani et al (36) with permission.
Table 8. Primary Prevention of Rheumatic Fever (40)
Agent Dose Mode Duration
Benzathine 600,000 U for patients ,227 kg (60 lb) Intramuscular Once
Penicillin G 1,200,000 U for patients .27 kg (60 lb)
or
Penicillin V (phenoxymethyl penicillin) Children: 250 mg 2–3 times daily Oral 10 d
Adolescents and adults: 500 mg 2–3 times daily
For individuals allergic to penicillin:
Erythromycin 20–40 mg/kg/d Oral 10 d
Estolate 2–4 times daily (maximum 1 g/d)
Ethylsuccinate 40 mg/kg/d Oral 10 d
2–4 times daily (maximum 1 g/d)
Azithromycin 500 mg on first day Oral 5 d
250 mg/d for the next 4 d
From Dajani et al (40) with permission.
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dures, intermediate with procedures involving the genitouri-
nary tract, and lowest with gastrointestinal diagnostic proce-
dures (28). Recommendations for endocarditis prophylaxis, as
determined by dental, surgical, and other procedures, are
listed in Tables 4 through 7.
The procedure—thus the portal of entry—is a determinant
of the type of organism involved in the resulting bacteremia.
This is usually the determinant of the antibiotic chosen for
prophylaxis. Because streptococci are normal inhabitants of
the oral cavity, the antibiotic prophylaxis regimen for dental
and oral procedures is directed against these organisms. For
genitourinary and lower gastrointestinal procedures, the anti-
biotic prophylactic regimen is designed to cover enterococci
and other gram-negative organisms.
2. Rheumatic Fever Prophylaxis. a. General Considerations.
Rheumatic fever is an important cause of valvular heart
disease. In the United States (and Western Europe), cases of
acute rheumatic fever have been uncommon since the 1970s.
However, starting in 1987, an increase in cases has been
observed (38,39). With the enhanced understanding of the
causative organism, group A streptococcus, their rheumatoge-
nicity is attributed to the prevalence of M protein serotypes in
the offending organism. This has resulted in the development
of kits that allow rapid detection of group A streptococci with
specificity .295% and more rapid identification of their pres-
ence in upper respiratory infection. Because the test has a low
sensitivity, the negative test requires a throat culture confir-
mation (39). Prompt recognition and treatment represent
primary rheumatic fever prevention. For patients who have
had a previous episode of rheumatic fever, continuous anti-
streptococcal prophylaxis results in secondary prevention.
b. Primary Prevention. Rheumatic fever prevention treat-
ment guidelines have been established by the American Heart
Association (40) (Table 8).
c. Secondary Prevention. Patients who have had an episode
of rheumatic fever are at high risk of developing recurrent
episodes of acute rheumatic fever. Patients who develop
carditis are especially prone to similar episodes with subse-
quent attacks. Secondary prevention of rheumatic fever recur-
rence is thus of great importance. Continuous antimicrobial
prophylaxis has been shown to be effective. Anyone who has
had rheumatic fever with or without carditis (including MS)
should have prophylaxis for recurrent rheumatic fever. The
AHA guidelines for secondary prevention are shown in Table
9. The AHA guidelines for duration of secondary prevention
are shown in Table 10.
III. Specific Valve Lesions
A. Aortic Stenosis
1. Introduction. The most common cause of AS in adults is
a degenerative-calcific process that produces an immobiliza-
tion of the aortic valve cusps. This calcific disease progresses
from the base of the cusps to the leaflets, eventually causing a
reduction in the effective valve area; true commissural fusion
may not occur. A congenital malformation of the valve may
also result in stenosis and is the more common cause in young
adults. The management of congenital AS in adolescents and
young adults is discussed in section VI.A. of these guidelines.
Over several decades, progressive fibrosis and calcification of
the congenitally abnormal valve (often bicuspid) produce a
deformity that resembles the degenerative-calcific lesion.
Rheumatic fever results in AS due to fusion of the commis-
sures with scarring and eventual calcification of the cusps.
Thus, calcification is a common feature of AS in older adults
regardless of the primary cause (41–43).
An ejection systolic murmur may be heard in the presence
of a normal valve, one that is thickened and minimally
calcified, and one that is stenotic (41,44). The 3 conditions
must be distinguished.
a. Grading the Degree of Stenosis. The aortic valve area
must be reduced to one fourth its normal size before significant
changes in the circulation occur. Because the orifice area of the
normal adult valve is '3.0 to 4.0 cm2, an area .0.75 to 1.0 cm2
is usually not considered severe AS (44,45). Historically, the
definition of severe AS is based on the hydraulic orifice-area
formulae developed by Gorlin and Gorlin, which indicate that
large pressure gradients accompany only modest increments in
flow when the valve area is ,0.75 cm2 (46). However, in large
Table 9. Secondary Prevention of Rheumatic Fever (40)
Agent Dose Mode
Benzathine 1,200,000 U every 4 wk Intramuscular
Penicillin G (every 3 wk for high-risk* pts such as
those with residual carditis)
Penicillin V 250 mg twice daily Oral
or
Sulfadiazine 0.5 g once daily for pts ,227 kg (60 lb) Oral
1.0 g once daily for pts .27 kg (60 lb)
For individuals allergic
to penicillin and
sulfadiazine:
Erythromycin 250 mg twice daily Oral
Abbreviations: Pts 5 patients. *High-risk patients include patients with
residual rheumatic carditis as well as patients from economically disadvantaged
populations. From Dajani et al (40) with permission.
Table 10. Duration of Secondary Rheumatic Fever Prophylaxis (40)
Category Duration
Rheumatic fever with carditis and
residual heart disease
(persistent valvular disease)
.210 y since last episode and at least
until age 40 y, sometimes lifelong
prophylaxis*
Rheumatic fever with carditis but
no residual heart disease (no
valvular disease)
10 y or well into adulthood, whichever is
longer
Rheumatic fever without carditis 5 y or until age 21 y, whichever is longer
*The committee’s interpretation of “lifelong” prophylaxis refers to patients
who are at high risk and likely to come in contact with populations with a high
prevalence of streptococcal infection, ie, teachers, day-care workers. From
Dajani et al (40) with permission.
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patients, a valve area of 1.0 cm2 may be severely stenotic,
whereas a valve area of 0.7 cm2 may be adequate for a smaller
patient.
On the basis of a variety of hemodynamic and natural
history data, in these guidelines we graded the degree of AS as
mild (area .1.5 cm2), moderate (area .1.0 to 1.5 cm2), or
severe (area ,21.0 cm
2) (46a). When stenosis is severe and
cardiac output is normal, the mean transvalvular pressure
gradient is generally .50 mm Hg. Some patients with severe
AS remain asymptomatic, whereas others with only moderate
stenosis develop symptoms. Therapeutic decisions, particularly
those related to corrective surgery, are based largely on the
presence or absence of symptoms. Thus, the absolute valve
area (or transvalvular pressure gradient) is not usually the
primary determinant of the need for aortic valve replacement
(AVR).
2. Pathophysiology. In adults with AS, the obstruction
develops gradually—usually over decades. During this time,
the left ventricle adapts to the systolic pressure overload
through a hypertrophic process that results in increased LV
wall thickness while a normal chamber volume is maintained
(47–49). The resulting increase in relative wall thickness is
usually enough to counter the high intracavitary systolic pres-
sure, and as a result, LV systolic wall stress (afterload) remains
within the range of normal. The inverse relation between
systolic wall stress and ejection fraction is maintained; as long
as wall stress is normal, the ejection fraction is preserved (50).
However, if the hypertrophic process is inadequate and rela-
tive wall thickness does not increase in proportion to pressure,
wall stress increases and the high afterload causes a decrease in
ejection fraction (50–52). The depressed contractile state of
the myocardium may also be responsible for a low ejection
fraction, but a combination of excessive afterload and de-
pressed contractility contributes to a low ejection fraction in
many patients (53). When low ejection fraction is caused by
depressed contractility, corrective surgery will be less beneficial
than in patients with a low ejection fraction caused by high
afterload (54).
As a result of increased wall thickness, low volume/mass
ratio, and diminished compliance of the chamber, LV end-
diastolic pressure increases without chamber dilatation (55–
58). Thus, increased end-diastolic pressure usually reflects
diastolic dysfunction rather than systolic dysfunction or failure
(59). A forceful atrial contraction that contributes to an
elevated end-diastolic pressure plays an important role in
ventricular filling without increasing mean left atrial or pulmo-
nary venous pressure (60). Loss of atrial contraction such as
that which occurs with atrial fibrillation is often followed by
serious clinical deterioration.
The development of concentric hypertrophy appears to be
an appropriate and beneficial adaptation to compensate for
high intracavitary pressures. Unfortunately, this adaptation
often carries adverse consequences. The hypertrophied heart
may have reduced coronary blood flow per gram of muscle and
also exhibit a limited coronary vasodilator reserve, even in the
absence of epicardial CAD (61,62). The hemodynamic stress of
exercise or tachycardia can produce a maldistribution of
coronary blood flow and subendocardial ischemia, which can
contribute to systolic or diastolic dysfunction of the left
ventricle. Hypertrophied hearts also exhibit an increased sen-
sitivity to ischemic injury, with larger infarcts and higher
mortalities than are seen in the absence of hypertrophy
(63–65). Another problem that is particularly common in
elderly patients, especially women, is an excessive or inappro-
priate degree of hypertrophy; wall thickness is greater than
necessary to counterbalance the high intracavitary pressures
(66–69). As a result, systolic wall stress is low, ejection fraction
is high, and the ventricle resembles that seen in patients with
hypertensive hypertrophic cardiomyopathy of the elderly (70).
Such inappropriate LV hypertrophy has been associated with
high perioperative morbidity and mortality (66,68).
3. Natural History. The natural history of AS in the adult
consists of a prolonged latent period during which morbidity
and mortality are very low. The rate of progression of the
stenotic lesion has been estimated in a variety of hemodynamic
studies performed largely in patients with moderate AS (71).
Cardiac catheterization studies indicate that some patients
have a decrease in valve area of 0.1 to 0.3 cm2 per year; the
systolic pressure gradient across the valve may increase by as
much as 10 to 15 mm Hg per year (72–78). However, more
than half of the reported patients show little or no progression
over a 3- to 9-year period. Doppler echocardiographic data
obtained over several years are consistent with those obtained
with cardiac catheterization. Some patients exhibit a significant
increase in transvalvular pressure gradient ('15 to 19 mm Hg
per year) and a decrease in valve area; others show little or no
change (79–83). The average rate of change is '0.12 cm2 per
year (84). Although it appears that the progression of AS can
be more rapid in patients with degenerative calcific disease
than in those with congenital or rheumatic disease (41,73), it is
not possible to predict the rate of progression in an individual
patient. For this reason, careful clinical follow-up is mandatory
in all patients with moderate to severe AS.
Eventually, symptoms of angina, syncope, or heart failure
develop after a long latent period, and the outlook changes
dramatically. After the onset of symptoms, average survival is
less than 2 to 3 years (85–90). Thus, the development of
symptoms identifies a critical point in the natural history of AS.
Management decisions are based largely on these natural
history data; many clinicians treat asymptomatic patients con-
servatively, whereas corrective surgery is generally recom-
mended in patients with symptoms thought to be due to AS.
Sudden death is known to occur in patients with severe AS
and rarely has been documented to occur without prior
symptoms (85,88,91). These older retrospective studies empha-
size the possibility of sudden death in asymptomatic patients.
However, prospective echocardiographic studies provide im-
portant data on the rarity of sudden death in asymptomatic
patients (Table 11). In one report, 51 asymptomatic patients
with severe AS were followed for an average of 17 months. In
this study, 2 patients died; symptoms preceded death in both
cases (90). In another report of 113 patients followed for 20
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months, there were no cases of sudden death without preced-
ing symptoms; in this study, survival was no different from that
of an age- and sex-matched control group (92). In this latter
study, all patients had Doppler velocities across the aortic valve
.24 m/s. However, only one third had aortic valve velocities
.25 m/s, and a number of patients were not included in the
follow-up analysis because they underwent AVR at the discre-
tion of the clinician. In a third report of 123 patients followed
for an average of 30 months, there were no cases of sudden
death (84). These findings were similar in 2 smaller studies
(77,81). Therefore, although sudden death occasionally does
occur in the absence of preceding symptoms in patients with
AS (85,88,93), it must be an uncommon event—probably ,1%
per year.
4. Management of the Asymptomatic Patient. Many
asymptomatic patients with severe AS develop symptoms
within a few years and require surgery. In one series, the
incidence of angina, dyspnea, or syncope in 113 asymptomatic
patients with Doppler outflow velocities .24 m/s was 14% after
1 year and 38% after 2 years (92). In another report of 123
asymptomatic patients, the rate of symptom development was
38% at 3 years for the total group but 79% at 3 years in
patients with Doppler outflow velocity .24 m/s (84). Therefore,
patients with severe AS require careful monitoring for devel-
opment of symptoms and progressive disease.
a. Initial Evaluation. The diagnosis of severe AS can usually
be made on the basis of the systolic outflow murmur, delayed
and diminished carotid upstrokes, sustained LV impulse, and
reduced intensity of the aortic component of the second heart
sound. Paradoxical splitting of the second sound may be
present. In the elderly, the pulsus tardus and parvus may be
absent because of the effects of aging on the vasculature.
Patients presenting with the physical findings of AS should
undergo selected laboratory examinations, including an ECG,
a chest x-ray, and an echocardiogram. The 2-D echocardio-
gram is valuable for confirming the presence of aortic valve
disease and determining the LV response to pressure overload.
In most patients, the severity of the stenotic lesion can be
defined with Doppler echocardiographic measurements of a
mean transvalvular pressure gradient and a derived valve area,
as discussed in the ACC/AHA Guidelines for the Clinical
Application of Echocardiography (2). The mean pressure
gradient may be underestimated if the Doppler beam is not
parallel to the velocity jet; however, it may occasionally
overestimate the transvalvular gradient, especially in the pa-
tient with a small aortic root and/or high cardiac output. Thus,
the pressure gradient and derived valve area require meticu-
lous attention to measurement of LV outflow tract area and
velocity. Echocardiography is also used to assess LV size and
function, degree of hypertrophy, and presence of other asso-
ciated valvular disease.
Recommendations for Echocardiography in Aortic Stenosis
Indication Class
1. Diagnosis and assessment of severity of AS. I
2. Assessment of LV size, function, and/or hemodynamics. I
3. Reevaluation of patients with known AS with changing symptoms
or signs.
I
4. Assessment of changes in hemodynamic severity and ventricular
function in patients with known AS during pregnancy.
I
5. Reevaluation of asymptomatic patients with severe AS. I
6. Reevaluation of asymptomatic patients with mild to moderate AS
and evidence of LV dysfunction or hypertrophy.
IIa
7. Routine reevaluation of asymptomatic adult patients with mild
AS having stable physical signs and normal LV size and function.
III
From the ACC/AHA Guidelines for the Clinical Application of
Echocardiography (2).
In some patients, it may be necessary to proceed with
cardiac catheterization and coronary angiography at the time
of initial evaluation. For example, this is appropriate if there is
a discrepancy between clinical and echocardiographic exami-
nations or if the patient is symptomatic and AVR is planned.
Exercise testing in adults with AS has been discouraged
largely because of concerns about safety. Furthermore, when
used to assess the presence or absence of CAD, the test has
limited diagnostic accuracy. Presumably, this is due to the
presence of an abnormal baseline ECG, LV hypertrophy, and
limited coronary flow reserve. Certainly, exercise testing
should not be performed in symptomatic patients. However, in
asymptomatic patients, exercise testing is safe and may provide
information that is not uncovered during the initial clinical
Table 11. Studies of the Natural History of Asymptomatic Patients With Aortic Stenosis
Study, y
Number
of patients
Mean
follow-up,
year
Severity of aortic
stenosis
Sudden death
without symptoms
(number of patients) Comments
Chizner et al 1980 (91) 8 5.7 AVA ,1.1 cm2 0 retrospective study
Turina et al 1987 (77) 17 2.0 AVA ,0.9 cm2 0 retrospective study
Horstkotte and Loogen 1988 (88) 35 “years” AVA 5 0.4–0.8 cm2 3 retrospective study
Kelly et al 1988 (90) 51 1.5 PV 5 3.5–5.8 m/s 0 prospective study
Pellikka et al 1990 (92) 113 1.7 PV .4.0 m/s 0 prospective study
Faggiano et al 1992 (81) 37 2.0 AVA 5 0.85 6 0.15 cm2 0 prospective study
Otto et al 1997 (84) 114 2.5 PV 5 3.6 6 0.6 m/s 0 prospective study
Total 375 2.1 3 average risk of sudden death '0.4%/y
Abbreviations: AVA 5 aortic valve area; PV 5 peak instantaneous velocity
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evaluation (94–97). Exercise testing in asymptomatic patients
should be performed only under the supervision of an experi-
enced physician with close monitoring of blood pressure and
the ECG. Such testing can identify patients with a limited
exercise capacity or even exercise-induced symptoms despite a
negative medical history. Although the prognostic significance
of electrocardiographic ST depression is unknown, an abnor-
mal hemodynamic response (eg, hypotension) in a patient with
severe AS is sufficient reason to consider AVR. Finally, in
selected patients, the observations made during exercise may
provide a basis for advice about physical activity.
The frequency of follow-up visits to the physician depends
on the severity of the valvular stenosis and in part on the
presence of comorbid conditions. Recognizing that an optimal
schedule for repeated medical examinations has not been
defined, many physicians perform an annual history and phys-
ical examination on patients with mild AS. Those with moder-
ate and severe AS should be examined more frequently.
Patients should be advised to promptly report the development
of any exertional chest discomfort, dyspnea, lightheadedness,
or syncope.
b. Serial Testing. Echocardiographic studies can be an
important part of an integrated approach that includes a
detailed history, physical examination, and in some patients a
carefully monitored exercise test. Recognizing that the rate of
progression varies considerably, clinicians often perform an
annual echocardiogram on patients known to have moderate
to severe AS. However, current understanding of the natural
history of AS and indications for surgical intervention do not
support the use of annual echocardiographic studies to assess
changes in valve area as such. However, serial echocardio-
grams are helpful for assessing changes in LV hypertrophy and
function. Therefore, in patients with severe AS, an echocar-
diogram every year may be appropriate. In patients with
moderate AS, serial studies performed every 2 years or so are
satisfactory, and in patients with mild AS, serial studies can be
performed every 5 years. Echocardiograms should be per-
formed more frequently if there is a change in clinical findings.
In patients with echocardiograms of suboptimal quality, car-
diac magnetic resonance imaging may be used to assess LV
volume, wall thickness, mass, and systolic function (98–102) as
well as severity of AS (103,104). In centers with specific
expertise in cardiac magnetic resonance imaging, serial mag-
netic resonance imaging may be performed in place of serial
echocardiograms.
c. Medical Therapy. Antibiotic prophylaxis is indicated for
prevention of infective endocarditis and, in those with rheu-
matic AS, recurrent episodes of rheumatic fever. Patients with
associated systemic arterial hypertension should be treated
cautiously with appropriate antihypertensive agents. With
these exceptions, there is no specific medical therapy for
patients who have not yet developed symptoms, and patients
who develop symptoms require surgery, not medical therapy.
Most asymptomatic patients lead a normal life, although
restriction of physical activity should be advised in most
patients with moderate or severe AS.
d. Physical Activity and Exercise. Recommendations for
physical activity are based on the clinical examination, with
special emphasis on the hemodynamic severity of the stenotic
lesion. The severity can usually be judged by Doppler echocar-
diography, but in borderline cases, diagnostic cardiac catheter-
ization may be necessary to accurately define the degree of
stenosis.
Recommendations on participation in competitive sports
have been published by the Task Force on Acquired Valvular
Heart Disease of the 26th Bethesda Conference (105). Physical
activity is not restricted in asymptomatic patients with mild AS;
these patients can participate in competitive sports. Patients
with moderate AS should avoid competitive sports that involve
high dynamic and static muscular demands. Other forms of
exercise can be performed safely, but it is advisable to evaluate
such patients with an exercise test before they begin an exercise
or athletic program. Patients with severe AS should be advised
to limit their activity to relatively low levels.
5. Indications for Cardiac Catheterization. In patients with
AS, the indications for cardiac catheterization and angiogra-
phy are essentially the same as in other conditions, namely to
assess the coronary circulation and confirm or clarify the
clinical diagnosis. In preparation for AVR, coronary angiog-
raphy is indicated in patients suspected of having CAD, as
discussed in detail in section VIII of these guidelines. If the
clinical and echocardiographic data are typical of severe
isolated AS, coronary angiography may be all that is needed
before AVR. A complete left- and right-heart catheterization
may be necessary to assess the hemodynamic severity of the AS
if there is a discrepancy between clinical and echocardio-
graphic data or there is evidence of associated valvular or
congenital disease or pulmonary hypertension.
Recommendations for Cardiac Catheterization in Aortic Stenosis
Indication Class
1. Coronary angiography before AVR in patients at risk for CAD
(see section VIII.B. of these guidelines).
I
2. Assessment of severity of AS in symptomatic patients when AVR
is planned or when noninvasive tests are inconclusive or there
is a discrepancy with clinical findings regarding severity of AS
or need for surgery.
I
3. Assessment of severity of AS before AVR when noninvasive tests
are adequate and concordant with clinical findings and
coronary angiography is not needed.
IIb
4. Assessment of LV function and severity of AS in asymptomatic
patients when noninvasive tests are adequate.
III
The pressure gradient across a stenotic valve is related to
the valve orifice area and the transvalvular flow (106). Thus, in
the presence of depressed cardiac output, relatively low pres-
sure gradients are frequently obtained in patients with severe
AS. On the other hand, during exercise or other high flow
states, systolic gradients can be measured in minimally stenotic
valves. For these reasons, complete assessment of AS requires
(1) measurement of transvalvular flow, (2) determination of
the transvalvular pressure gradient, and (3) calculation of the
effective valve area. Careful attention to detail with accurate
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measurements of pressure and flow is important, especially in
patients with low cardiac output or a low transvalvular pressure
gradient.
a. Low-Gradient Aortic Stenosis. Patients with severe AS
and low cardiac output often present with only modest trans-
valvular pressure gradients (ie, ,30 mm Hg). Such patients can
be difficult to distinguish from those with low cardiac output
and only mild to moderate AS. In the former (true anatomi-
cally severe AS), the stenotic lesion contributes to an elevated
afterload, decreased ejection fraction, and low stroke volume.
In the latter, primary contractile dysfunction is responsible for
the decreased ejection fraction and low stroke volume; the
problem is further complicated by reduced valve opening
forces that contribute to limited valve mobility and apparent
stenosis. In both situations, the low-flow state and low-pressure
gradient contribute to a calculated effective valve area that can
meet criteria for severe AS. The standard valve area formula is
less accurate and is known to underestimate the valve area in
low-flow states, and under such conditions, it should be
interpreted with caution. In theory, Doppler-derived valve
areas should be less susceptible to low flow, but this does not
appear to be borne out in clinical practice. It has been
suggested that valve resistance might provide a better separa-
tion between critical and noncritical AS, particularly in pa-
tients with low transvalvular pressure gradients (107,108).
Although valve resistance is less sensitive to flow than valve
area, the resistance calculations have not been proved to be
substantially better than valve area calculations.
In patients with low-gradient stenosis and what appears to
be moderate to severe AS, it may be useful to determine the
transvalvular pressure gradient and to calculate valve area and
resistance during a baseline state and again during exercise or
pharmacological (ie, dobutamine infusion) stress (97,109–
111). This approach is based on the notion that patients who
do not have true, anatomically severe stenosis exhibit an
increase in the valve area during an increase in cardiac output
(109,110). Thus, if a dobutamine infusion produces an incre-
ment in stroke volume, an increase in valve area, and a
decrease in valve resistance, it is likely that the baseline
calculations overestimated the severity of the stenosis. In
patients with severe AS, these changes may result in a calcu-
lated valve area that is higher than the baseline calculation but
one that remains in the severe range, whereas in patients
without severe AS, the calculated valve area with dobutamine
will fall outside the severe range and indicate that severe AS is
not present.
6. Indications for Aortic Valve Replacement. In the vast
majority of adults, AVR is the only effective treatment for
severe AS. However, younger patients may be candidates for
valvotomy (see section VI.A. of these guidelines). Although
there is some lack of agreement about the optimal timing of
surgery, particularly in asymptomatic patients, it is possible to
develop rational guidelines for most patients. Particular con-
sideration should be given to the natural history of symptom-
atic and asymptomatic patients and to operative risks and
outcomes after surgery.
a. Symptomatic Patients. Patients with angina, dyspnea, or
syncope exhibit symptomatic improvement and an increase in
survival after AVR (86,112–116). These salutary results of
surgery are partly dependent on the state of LV function. The
outcome is similar in patients with normal LV function and in
those with moderate depression of contractile function. The
depressed ejection fraction in many of the patients in this latter
group is caused by excessive afterload (afterload mismatch
[52]), and LV function improves after AVR in such patients. If
LV dysfunction is not caused by afterload mismatch, then
improvement in LV function and resolution of symptoms may
not be complete after valve replacement (116). Survival is still
improved in this setting (112), with the possible exception of
patients with severe LV dysfunction caused by CAD (116).
Therefore, in the absence of serious comorbid conditions,
AVR is indicated in virtually all symptomatic patients with
severe AS. However, patients with severe LV dysfunction,
particularly those with so-called low gradient AS, create a
difficult management decision (117) (see above). AVR should
not be performed in such patients if they do not have anatom-
ically severe AS. In patients who do have severe AS, even those
with a low transvalvular pressure gradient, AVR results in
hemodynamic improvement and better functional status.
b. Asymptomatic Patients. Many clinicians are reluctant to
proceed with AVR in an asymptomatic patient (118), whereas
others are concerned about following a patient with severe AS.
Although insertion of a prosthetic aortic valve is associated
with low perioperative morbidity and mortality, long-term
morbidity and mortality can be appreciable for mechanical and
bioprosthetic valves. Significant complications occur at the rate
of at least 2% to 3% per year, and death due directly to the
prosthesis occurs at the rate of '1% per year (119–124). Thus,
even if surgical mortality can be minimized, the combined risk
of surgery and the late complications of a prosthesis exceed the
possibility of preventing sudden death and prolonging survival
in all asymptomatic patients, as discussed previously. Despite
these considerations, some difference of opinion persists
among clinicians regarding the indications for corrective sur-
gery in asymptomatic patients. Some argue that irreversible
myocardial depression and/or fibrosis may develop during a
prolonged asymptomatic stage and that this may preclude an
optimal outcome. Such irreversibility has not been proved, but
this concept has been used to support early surgery (114,125).
Still others attempt to identify patients who may be at espe-
cially high risk of sudden death without surgery, although data
supporting this approach are limited. Patients in this subgroup
include those who have an abnormal response to exercise (eg,
hypotension), those with LV systolic dysfunction or marked/
excessive LV hypertrophy, or those with evidence of very
severe AS. However, it should be recognized that such “high-
risk” patients are rarely asymptomatic.
c. Patients Undergoing Coronary Artery Bypass Surgery. Pa-
tients with severe AS, with or without symptoms, who are
undergoing coronary artery bypass surgery should undergo
AVR at the time of the revascularization procedure. Similarly,
patients with severe AS undergoing surgery on other valves
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(such as mitral valve repair) or the aortic root should also
undergo AVR as part of the surgical procedure, and it is
generally accepted practice to perform AVR in patients with
moderate AS (for example, gradient .230 mm Hg) who are
undergoing mitral valve or aortic root surgery, as discussed in
sections III.F.6. and III.F.7. of these guidelines. Such patients
with moderate AS may also warrant AVR at the time of
coronary artery bypass surgery, but there are limited data to
support this policy. Greater controversy persists regarding the
indications for concomitant AVR at the time of coronary
artery bypass surgery in patients with milder forms of AS, as
discussed in section VIII.D. of these guidelines.
Recommendations for Aortic Valve Replacement in Aortic Stenosis
Indication Class
1. Symptomatic patients with severe AS. I
2. Patients with severe AS undergoing coronary artery bypass surgery. I
3. Patients with severe AS undergoing surgery on the aorta or other
heart valves.
I
4. Patients with moderate AS undergoing coronary artery bypass
surgery or surgery on the aorta or other heart valves (see sections
III.F.6., III.F.7., and VIII.D. of these guidelines).
IIa
5. Asymptomatic patients with severe AS and
z LV systolic dysfunction IIa
z Abnormal response to exercise (eg, hypotension) IIa
z Ventricular tachycardia IIb
z Marked or excessive LV hypertrophy (>215 mm) IIb
z Valve area <0.6 cm2 IIb
6. Prevention of sudden death in asymptomatic patients with none of
the findings listed under indication 5.
III
7. Aortic Balloon Valvotomy. Percutaneous balloon aortic
valvotomy is a procedure in which one or more balloons are
placed across a stenotic valve and inflated to decrease the
severity of stenosis (126–128). This procedure has an impor-
tant role in treating adolescents and young adults with AS (see
section VI.A.) but a very limited role in older adults. The
mechanism underlying relief of the stenotic lesion in older
adults is fracture of calcific deposits within the valve leaflets
and to some degree stretching of the annulus and separation of
the calcified or fused commissures (129–131). Immediate
hemodynamic results include a moderate reduction in the
transvalvular pressure gradient, but the postvalvotomy valve
area rarely exceeds 1.0 cm2. Despite the modest change in
valve area, an early symptomatic improvement is usually seen.
However, serious complications occur with a frequency .10%
(132–138); restenosis and clinical deterioration occur within 6
to 12 months in most patients (133,138–141). Therefore, in
adults with AS, balloon valvotomy is not a substitute for AVR
(141–144).
Despite the procedural morbidity and mortality and limited
long-term results, balloon valvotomy can have a temporary role
in the management of some symptomatic patients who are not
initially candidates for AVR (144). For example, patients with
severe AS and refractory pulmonary edema or cardiogenic
shock may benefit from aortic valvuloplasty as a “bridge” to
surgery; an improved hemodynamic state may reduce the risks
of surgery. The indications for palliative valvotomy in patients
with serious comorbid conditions are less well established, but
most patients can expect temporary relief of symptoms despite
a very limited life expectancy. Asymptomatic patients with
severe AS who require urgent noncardiac surgery may be
candidates for valvotomy, but most such patients can be
successfully treated with more conservative measures
(145,146).
Recommendations for Aortic Balloon Valvotomy in Adults With
Aortic Stenosis*
Indication Class
1. A “bridge” to surgery in hemodynamically unstable patients who
are at high risk for AVR.
IIa
2. Palliation in patients with serious comorbid conditions. IIb
3. Patients who require urgent noncardiac surgery. IIb
4. An alternative to AVR. III
*Recommendations for aortic balloon valvotomy in adolescents and young
adults with AS are provided in section VI.A. of these guidelines.
8. Medical Therapy for the Inoperable Patient. Comorbid
conditions (eg, malignancy) or, on occasion, patient prefer-
ences may preclude corrective surgery. Under such circum-
stances, limited medical therapies are available to control
symptoms. Patients with evidence of pulmonary congestion can
benefit from treatment with digitalis, diuretics, and angiotensin
converting enzyme (ACE) inhibitors. Indeed, a cautious reduc-
tion in central blood volume and LV preload can be efficacious
in some patients with heart failure symptoms. It should be
recognized, however, that excessive preload reduction can
depress cardiac output and reduce systemic arterial pressure;
patients with severe AS are especially subject to this untoward
effect. Digitalis should be reserved for patients with depressed
systolic function or atrial fibrillation. Atrial fibrillation and
other atrial arrhythmias have an adverse effect on atrial pump
function and ventricular rate; if prompt cardioversion is un-
successful, pharmacological control of the ventricular rate with
digitalis or perhaps amiodarone is essential. Efforts should be
made to prevent atrial fibrillation, especially development of a
rapid ventricular response. b-Adrenergic receptor blocking
agents as well as other drugs with negative inotropic effects
should not be used in patients with heart failure caused by AS.
If angina is the predominant symptom, cautious use of nitrates
and b-blockers can provide relief. There is no specific medical
therapy for syncope unless it is caused by a bradyarrhythmia or
tachyarrhythmia.
9. Evaluation After Aortic Valve Replacement. AVR
should be considered a form of palliative therapy in that a
prosthetic valve with its attendant complications is substituted
for a diseased native valve (119–124). Patients with prosthetic
heart valves therefore require periodic clinical and selected
laboratory examinations. A complete history and physical
examination should be performed at least once a year. Indica-
tions for echocardiography are discussed in section VII.C.3. of
these guidelines.
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10. Special Considerations in the Elderly. Because there is
no effective medical therapy and balloon valvotomy is not an
acceptable alternative to surgery, AVR must be considered in
all elderly patients who have symptoms caused by AS. Valve
replacement is technically possible at any age (147), but the
decision to proceed with such surgery depends on many
factors, including the patient’s wishes and expectations. Older
patients with symptoms due to severe AS, normal coronary
arteries, and preserved LV function can expect a better
outcome than those with coronary disease or ventricular
dysfunction (87). Certainly advanced cancer and permanent
neurological defects as a result of stroke make cardiac surgery
inappropriate. Deconditioned and debilitated patients often
do not return to an active existence, and the presence of the
other comorbid disorders may have a major impact on out-
come.
In addition to the confounding effects of CAD and the
potential for stroke, other considerations are peculiar to older
patients. For example, a narrow LV outflow tract and a small
aortic annulus sometimes present in elderly women may
require enlargement of the annulus. Heavy calcification of the
valve, annulus, and aortic root may require debridement.
Occasionally, a composite valve-aortic graft is needed. Like-
wise, excessive or inappropriate hypertrophy associated with
valvular stenosis can be a marker for perioperative morbidity
and mortality (66,68). Preoperative recognition of elderly
patients with marked LV hypertrophy followed by appropriate
perioperative management may substantially reduce this mor-
bidity and mortality. There is no perfect method for weighing
all of the relevant factors and identifying specifically high- and
low-risk elderly patients (148). The decision to proceed with
valve replacement depends on an imprecise analysis that
considers the balance between the potential for improved
symptoms and survival and the morbidity and mortality of
surgery.
B. Aortic Regurgitation
1. Etiology. There are a number of common causes of AR.
These include idiopathic dilatation, congenital abnormalities
of the aortic valve (most notably bicuspid valves), calcific
degeneration, rheumatic disease, infective endocarditis, sys-
temic hypertension, myxomatous proliferation, dissection of
the ascending aorta, and Marfan syndrome. Less common
etiologies include traumatic injuries to the aortic valve, anky-
losing spondylitis, syphilitic aortitis, rheumatoid arthritis, os-
teogenesis imperfecta, giant cell aortitis, Ehlers-Danlos syn-
drome, Reiter’s syndrome, discrete subaortic stenosis, and
ventricular septal defects with prolapse of an aortic cusp.
Recently, anorectic drugs have also been reported to cause AR
(see section III.H. of these guidelines). The majority of these
lesions produce chronic AR with slow, insidious LV dilatation
and a prolonged asymptomatic phase. Other lesions, in partic-
ular infective endocarditis, aortic dissection, and trauma, more
often produce acute severe AR, which can result in sudden
catastrophic elevation of LV filling pressures and reduction in
cardiac output.
2. Acute Aortic Regurgitation
a. Pathophysiology. In acute severe AR, the sudden large
regurgitant volume is imposed on a left ventricle of normal size
that has not had time to accommodate the volume overload.
With an abrupt increase in end-diastolic volume, the ventricle
operates on the steep portion of a normal diastolic pressure-
volume relationship, and LV end-diastolic and left atrial
pressures may increase rapidly and dramatically. The Frank-
Starling mechanism is used, but the inability of the ventricle to
develop compensatory chamber dilatation acutely results in a
decrease in forward stroke volume. Although tachycardia
develops as a compensatory mechanism to maintain cardiac
output, this is often insufficient. Hence, patients frequently
present with pulmonary edema and/or cardiogenic shock.
Acute AR creates especially marked hemodynamic changes in
patients with preexisting pressure overload hypertrophy, in
whom the small, noncompliant LV cavity is set on an even
steeper diastolic pressure-volume relationship and has reduced
preload reserve. Examples of this latter situation include aortic
dissection in patients with systemic hypertension, infective
endocarditis in patients with preexisting AS, and acute regur-
gitation after balloon valvotomy or surgical commissurotomy
for congenital AS.
b. Diagnosis. Many of the characteristic physical findings of
chronic AR are modified or absent when valvular regurgitation
is acute, which may lead to underestimation of its severity. LV
size may be normal on physical examination and cardiomegaly
may be absent on chest x-ray. Pulse pressure may not be
increased because systolic pressure is reduced and the aortic
diastolic pressure equilibrates with the elevated LV diastolic
pressure. Because this diastolic pressure equilibration between
aorta and ventricle may occur before the end of diastole, the
diastolic murmur may be short and/or soft and therefore
poorly heard. The elevated LV diastolic pressure may close the
mitral valve prematurely, reducing the intensity of the first
heart sound. An apical diastolic rumble may be present, but it
is usually brief and without presystolic accentuation. Tachycar-
dia is invariably present.
Echocardiography is indispensable in confirming the pres-
ence and severity of the valvular regurgitation, in determining
its etiology, in estimating the degree of pulmonary hyperten-
sion (if TR is present), and in determining whether there is
rapid equilibration of aortic and LV diastolic pressure. Evi-
dence for rapid pressure equilibration includes a short AR
diastolic half-time (,300 ms), a short mitral deceleration time
(,150 ms), or premature closure of the mitral valve.
Acute AR caused by aortic root dissection is a surgical
emergency that requires particularly prompt identification and
management. Transesophageal echocardiography is indicated
when aortic dissection is suspected (149–151). If the diagnosis
remains uncertain, cardiac catheterization and aortography
should be performed. Coronary angiography is an important
component of the evaluation of aortic dissection and acute AR
and should be performed, provided that it does not delay
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urgent surgery. In some patients, other diagnostic imaging
methods, such as computed tomographic imaging or magnetic
resonance imaging, may be required if echocardiography does
not provide the diagnosis and angiography is not planned
(149,150,152).
c. Treatment. Death from pulmonary edema, ventricular
arrhythmias, electromechanical dissociation, or circulatory col-
lapse is common in acute severe AR, even with intensive
medical management. Early surgical intervention is recom-
mended. Nitroprusside and possibly inotropic agents such as
dopamine or dobutamine to augment forward flow and reduce
LV end-diastolic pressure may be helpful to manage the
patient temporarily before operation. Intra-aortic balloon
counterpulsation is contraindicated. Although b-blockers are
often used in treating aortic dissection, these agents should be
used very cautiously if at all in the setting of acute AR because
they will block the compensatory tachycardia. In patients with
acute severe AR resulting from infective endocarditis, surgery
should not be delayed, especially if there is hypotension,
pulmonary edema, or evidence of low output. In patients with
mild acute AR, antibiotic treatment may be all that is necessary
if the patient is hemodynamically stable. Exceptions to this
latter recommendation are discussed in section IV.E. of these
guidelines.
3. Chronic Aortic Regurgitation
a. Pathophysiology. The left ventricle responds to the vol-
ume load of chronic AR with a series of compensatory
mechanisms, including an increase in end-diastolic volume, an
increase in chamber compliance that accommodates the in-
creased volume without an increase in filling pressures, and a
combination of eccentric and concentric hypertrophy. The
greater diastolic volume permits the ventricle to eject a large
total stroke volume to maintain forward stroke volume in the
normal range. This is accomplished through rearrangement of
myocardial fibers with the addition of new sarcomeres and
development of eccentric LV hypertrophy (153). As a result,
preload at the sarcomere level remains normal or near-normal,
and the ventricle retains its preload reserve. The enhanced
total stroke volume is achieved through normal performance
of each contractile unit along the enlarged circumference
(154). Thus, LV ejection performance is normal, and ejection
phase indexes such as ejection fraction and fractional shorten-
ing remain in the normal range. However, the enlarged
chamber size, with the associated increase in systolic wall
stress, also results in an increase in LV afterload and is a
stimulus for further concentric hypertrophy (153,155). Thus,
AR represents a condition of combined volume overload and
pressure overload (156). As the disease progresses, recruit-
ment of preload reserve and compensatory hypertrophy
permit the ventricle to maintain normal ejection perfor-
mance despite the elevated afterload (157,158). The major-
ity of patients remain asymptomatic throughout this com-
pensated phase, which may last for decades. Vasodilator
therapy has the potential to reduce the hemodynamic
burden in such patients.
For purposes of the subsequent discussion, patients with
normal LV systolic function will be defined as those with
normal LV ejection fraction at rest. It is recognized that overall
LV function is usually not “normal” in chronic severe AR and
that the hemodynamic abnormalities noted above may be
considerable. It is also recognized that the transition to LV
systolic dysfunction represents a continuum and that there is
no single hemodynamic measurement that represents the
absolute boundary between normal LV systolic function and
LV systolic dysfunction.
In a large subset of patients, the balance between afterload
excess, preload reserve, and hypertrophy cannot be maintained
indefinitely. Preload reserve may be exhausted (158) and/or
the hypertrophic response may be inadequate (48), so that
further increases in afterload result in a reduction in ejection
fraction, first into the low normal range and then below
normal. Impaired myocardial contractility may also contribute
to this process. Patients often develop dyspnea at this point in
the natural history, which is related to declining systolic
function or elevated filling pressures. In addition, diminished
coronary flow reserve in the hypertrophied myocardium may
result in exertional angina (159). However, this transition
may be much more insidious, and it is possible for patients
to remain asymptomatic until severe LV dysfunction has
developed.
LV systolic dysfunction (defined as an ejection fraction
below normal at rest) is initially a reversible phenomenon
related predominantly to afterload excess, and full recovery of
LV size and function is possible with AVR (160–171). With
time, during which the ventricle develops progressive chamber
enlargement and a more spherical geometry, depressed
myocardial contractility predominates over excessive load-
ing as the cause of progressive systolic dysfunction. This can
progress to the extent that the full benefit of surgical
correction of the regurgitant lesion, in terms of recovery of
LV function and improved survival, can no longer be
achieved (169,172–181).
A large number of studies have identified LV systolic
function and end-systolic size as the most important deter-
minants of survival and postoperative LV function in pa-
tients undergoing AVR for chronic AR (160 –170,172–189).
Studies of predictors of surgical outcome are listed in Table
12.
Among patients undergoing valve replacement for chronic
AR with preoperative LV systolic dysfunction (defined as an
ejection fraction below normal at rest), several factors are
associated with worse functional and survival results after
operation. These are listed in Table 13.
b. Natural History. (1) ASYMPTOMATIC PATIENTS WITH NOR-
MAL LV FUNCTION. There are no truly large-scale studies eval-
uating the natural history of asymptomatic patients in whom
LV systolic function was known to be normal as determined by
invasive or noninvasive testing. The current recommendations
are derived from 7 published series (190–197) involving a total
of 490 such patients (range, 27 to 104 patients/series) with a
mean follow-up period of 6.4 years (Table 14). This analysis is
subject to the usual limitations of comparing different clinical
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series with different patient selection factors and different end
points. For example, 1 series (192) represents patients receiv-
ing placebo in a randomized drug trial (198) that included
some patients with “early” New York Heart Association
(NYHA) functional Class II symptoms (although none had
“limiting” symptoms), and another (196) represents patients
receiving digoxin in a long-term study comparing the effects of
nifedipine with digoxin. In another study (197), 20% of pa-
tients were not asymptomatic but had “early” NYHA func-
tional Class II symptoms, and the presence of these symptoms
was a significant predictor of death, LV dysfunction, or devel-
opment of more severe symptoms. Some patients in this latter
series had evidence of LV systolic dysfunction (fractional
shortening as low as 18%).
The results of these 7 studies are summarized in Tables 14
and 15. The rate of progression to symptoms and/or LV
systolic dysfunction averaged 4.3% per year. Sudden death
occurred in 6 of the 490 patients, an average mortality rate of
,0.2% per year. Six of the 7 studies reported the rate of
development of asymptomatic LV dysfunction (191–
194,196,197); 36 of a total of 463 patients developed depressed
systolic function at rest without symptoms during a mean
5.9-year follow-up period, a rate of 1.3% per year.
Despite the low likelihood of patients developing asymp-
tomatic LV dysfunction, it should also be emphasized that
more than one fourth of patients who die or develop systolic
dysfunction do so before the onset of warning symptoms
(191–194,196). Thus, careful questioning of patients regarding
symptomatic status is not sufficient in the serial evaluation of
Table 12. Preoperative Predictors of Surgical Outcome in Aortic Regurgitation
Study, year Study design
Number
of patients Outcome assessed Findings
Forman et al 1980 (175) Retrospective 90 Survival High-risk group identified by preoperative angiographic LV EF ,0.50.
Henry et al 1980 (182) Prospective 50 Survival High-risk group identified by preoperative echocardiographic LV FS ,0.25 and/
or ESD .55 mm.
Cunha et al 1980 (176) Retrospective 86 Survival High-risk group identified by preoperative echocardiographic LV FS ,0.30.
Mortality also significantly associated with preoperative ESD. Among patients
with FS ,0.30, mortality higher in NYHA FC III–IV than in FC I–II.
Greves et al 1981 (177) Retrospective 45 Survival High-risk group identified by preoperative angiographic LV EF ,0.45 and/or CI
,2.5 L/min. Among patients with EF ,0.45, mortality higher in NYHA FC
III–IV than in FC I–II.
Kumpuris et al 1982 (183) Prospective 43 Survival, heart failure,
LV function
Persistent LV dilatation after AVR predicted by preoperative echocardiographic
LV ESD, radius/thickness mean and end-systolic wall stress. All deaths
occurred in patients with persistent LV dilatation.
Gaasch et al 1983 (178) Prospective 32 Symptoms, LV
function
Persistent LV dilatation after AVR predicted by echocardiographic LV ESD
.2.6 cm/m2, EDD .3.8 cm/m2 and radius/thickness ratio .3.8. Trend toward
worse survival in patients with persistent LV dilatation.
Fioretti et al 1983 (184) Retrospective 47 LV function Persistent LV dysfunction predicted by preoperative EDD .275 mm and/or ESD
.255 mm.
Stone et al 1984 (185) Prospective 113 LV function Normal LV function after AVR predicted by preoperative LV FS .0.26, ESD
,55 mm, and EDD ,80 mm. No preoperative variable predicted
postoperative LV function.
Bonow et al 1985, 1988
(179, 170)
Prospective 80 Survival, LV function Postoperative survival and LV function predicted by preoperative LV EF, FS,
ESD. High-risk group identified by subnormal EF at rest. Among patients
with subnormal EF, poor exercise tolerance and prolonged duration of LV
dysfunction identified the highest-risk group.
Daniel et al 1985 (186) Retrospective 84 Survival, symptoms,
LV function
Outcome after AVR predicted by preoperative LV FS and ESD. Survival at 2.5 y
was 90.5% with FS .0.25 and ESD ,255 mm but only 70% with ESD
.55 mm and FS ,225%.
Cormier et al 1986 (187) Prospective 73 Survival High-risk group identified by preoperative LV EF ,0.40 and ESD .255 mm.
Sheiban et al 1986 (188) Retrospective 84 Survival High-risk group identified by preoperative LV EF ,0.50 and ESD .55 mm.
Carabello et al 1987 (168) Retrospective 14 LV function Postoperative LV EF predicted by preoperative ESD, FS, EDD, radius/thickness
ratio.
Taniguchi et al 1987 (169) Retrospective 62 Survival High-risk group identified by preoperative ESV .200 mL/m2 and/or EF ,0.40.
Michel et al 1995 (181) Retrospective 286 LV function Postoperative LV dysfunction predicted by preoperative LV EF, FS, ESD, EDD.
Klodas et al 1996 (189) Retrospective 219 Survival High-risk group identified by preoperative EF ,0.50.
Abbreviations: EDD 5 end-diastolic dimension, EF 5 ejection fraction, ESD 5 end-systolic dimension, ESV 5 end-systolic volume, FC 5 functional class, FS 5
fractional shortening, LV 5 left ventricular, NYHA 5 New York Heart Association.
Table 13. Factors Predictive of Reduced Postoperative Survival and
Recovery of Left Ventricular Function in Patients With Aortic
Regurgitation and Preoperative Left Ventricular
Systolic Dysfunction
Severity of preoperative symptoms or reduced exercise tolerance
Severity of depression of LV ejection fraction
Duration of preoperative LV systolic dysfunction
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asymptomatic patients, and quantitative evaluation of LV
function is also indispensable. Moreover, patients at risk of
future symptoms, death, or LV dysfunction can also be iden-
tified on the basis of noninvasive testing. Three of the natural
history studies provide concordant information on the vari-
ables associated with higher risk (192–194). These are age, LV
end-systolic dimension (or volume), and LV end-diastolic
dimension (or volume). The LV ejection fraction during
exercise, which is also identified in these studies, may not be an
independent risk factor as the direction and magnitude of
change in ejection fraction from rest to exercise is related not
only to myocardial contractility (199) but also severity of
volume overload (193,200–202) and exercise-induced changes
in preload and peripheral resistance (203). In a multivariate
analysis (193), only age and end-systolic dimension on initial
study were independent predictors of outcome, as were the
rate of increase in end-systolic dimension and decrease in
resting ejection fraction during serial longitudinal studies.
During a mean follow-up period of 8 years, patients with
initial end-systolic dimensions .50 mm had a likelihood of
death, symptoms, and/or LV dysfunction of 19% per year. In
those with end-systolic dimensions of 40 to 50 mm, the likelihood
was 6% per year, and when the dimension was ,40 mm, it was
zero (193).
Table 14. Studies of the Natural History of Asymptomatic Patients With Aortic Regurgitation
Study, year
Number of
patients
Mean
follow-up, y
Progression to
symptoms, death,
or LV dysfunction,
rate/y
Progression to
asymptomatic
LV
dysfunction
Mortality
(no. of patients) Comments(n) (rate/y)
Bonow et al 1983, 1991
(190, 193)
104 8.0 3.8% 4 0.5% 2 Outcome predicted by LV ESD, EDD,
change in EF with exercise, and rate
of change in ESD and EF at rest
with time
Scognamiglio et al 1986
(191)*
30 4.7 2.1% 3 2.1% 0 3 patients developing asymptomatic
LV dysfunction initially had lower
PAP/ESV ratios and trend toward
higher LV ESD and EDD and
lower FS
Siemienczuk et al 1989
(192)
50 3.7 4.0% 1 0.5% 0 Patients included those receiving
placebo and medical dropouts in a
randomized drug trial; included
some patients with NYHA FC II
symptoms; outcome predicted by
LV ESV, EDV, change in EF with
exercise, and end-systolic wall stress
Tornos et al 1995 (194) 101 4.6 3.0% 6 1.3% 0 Outcome predicted by pulse pressure,
LV ESD, EDD, and EF at rest
Ishii et al 1996 (195) 27 14.2 3.6% — — 0 Development of symptoms predicted
by systolic BP, LV ESD, EDD, mass
index, and wall thickness
Scognamiglio et al 1994
(196)*
74 6.0 5.7% 15 3.4% 0 All patients received digoxin in a
randomized drug trial
Borer et al 1998 (197) 104 7.3 6.2% 7 0.9% 4 20% of patients in NYHA FC II;
outcome predicted by initial FC II
symptoms, change in LV EF with
exercise, LV ESD, and LV FS
Average 490 6.4 4.3% 36 1.3% (0.19%/y)
Average in
asymptomatic series
336 6.5 3.7% 28 1.6% (0.09%/y) Excludes series of Borer et al and
Siemienczuk et al
Abbreviations: BP 5 blood pressure, EDD 5 end-diastolic dimension, EDV 5 end-diastolic volume, EF 5 ejection fraction, ESD 5 end-systolic dimension, ESV 5
end-systolic volume, FC 5 functional class, FS 5 fractional shortening, LV 5 left ventricular, NYHA 5 New York Heart Association, PAP 5 pulmonary artery
pressure. *Two studies by same authors involved separate patient groups.
Table 15. Natural History of Aortic Regurgitation
Asymptomatic patients with normal LV systolic function (190–197):
z Progression to symptoms and/or LV dysfunction ,6%/y
z Progression to asymptomatic LV dysfunction ,3.5%/y
z Sudden death ,0.2%/y
Asymptomatic patients with LV systolic dysfunction (204–206):
z Progression to cardiac symptoms .25%/y
Symptomatic patients (207–209):
z Mortality rate .10%/y
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(2) ASYMPTOMATIC PATIENTS WITH DEPRESSED SYSTOLIC FUNC-
TION. The limited data in asymptomatic patients with de-
pressed LV ejection fraction indicate that the majority develop
symptoms warranting operation within 2 to 3 years (204–206).
The average rate of symptom onset in such patients is .25%
per year (Table 15).
(3) SYMPTOMATIC PATIENTS. There are no recent large-scale
studies of the natural history of symptomatic patients with
chronic AR because the onset of angina or significant dyspnea
is usually an indication for valve replacement. The data
developed in the presurgical era indicate that patients with
dyspnea, angina, or overt heart failure have a poor outcome
with medical therapy, analogous to that of patients with
symptomatic AS. Mortality rates of .10% per year have been
reported in patients with angina pectoris and .20% per year in
those with heart failure (207–209). LV function was not
measured in these patients, so it is unclear whether symptom-
atic patients with normal ejection fractions have the same
adverse outcome as symptomatic patients with LV dysfunction.
However, more recent data indicate a poor outcome of symp-
tomatic patients with medical therapy, even among those with
preserved LV systolic function (195,210).
c. Diagnosis and Initial Evaluation of the Asymptomatic
Patient. The diagnosis of chronic severe AR can usually be
made on the basis of the diastolic murmur, displaced LV
impulse, wide pulse pressure, and the characteristic peripheral
findings reflecting wide pulse pressure. A third heart sound is
often heard as a manifestation of the volume load and is not
necessarily an indication of heart failure. An Austin-Flint
rumble is a specific finding for severe AR (211,212). In many
patients with more mild to moderate AR, the physical exami-
nation will identify the regurgitant lesion but will be less
2accurate in determining its severity. When the diastolic murmur
of AR is louder in the third and fourth right intercostal spaces
compared with the third and fourth left intercostal spaces, the AR
likely results from aortic root dilatation rather than from a
deformity of the leaflets alone (213). The chest x-ray and ECG
are helpful in evaluating overall heart size and rhythm, evidence
of LV hypertrophy, and evidence of conduction disorders.
Echocardiography is indicated to confirm the diagnosis of
AR if there is an equivocal diagnosis based on physical
examination; assess the cause of AR as well as valve morphol-
ogy; provide a semiquantitative estimate of the severity of
regurgitation; assess LV dimension, mass, and systolic func-
tion; and assess aortic root size. In asymptomatic patients with
preserved systolic function, these initial measurements repre-
sent the baseline information with which future serial measure-
ments can be compared. Quantitative measurements of LV
cavity size and systolic function from 2-D–guided M-mode
tracings are more reproducible than and hence preferable to
quantitative measurements made directly from 2-D images. In
addition to semiquantitative assessment of the severity of
regurgitation by color flow jet area and width by Doppler
echocardiography, indirect measures of severity of regurgi-
tation are helpful, using the rate of decline in regurgitant
gradient measured by the slope of diastolic flow velocity, the
degree of reversal in pulse wave velocity in the descending
aorta, and the magnitude of LV outflow tract velocity
(2,214,215). Comparison of stroke volumes at the aortic
valve compared with another uninvolved valve may provide a
quantitative measurement of regurgitant fraction (216), but this
measurement should be made only in experienced laboratories.
LV wall stress may also be estimated from blood pressure
and echocardiographic measurements. However, such wall
stress measurements are difficult to reproduce, have method-
ological and conceptual problems, and should not be used
for diagnosis or management decision making in clinical
practice.
For purposes of the subsequent discussion of management
of patients with AR, severe AR is defined as clinical and Doppler
evidence of severe regurgitation (with the semiquantitative meth-
ods noted above) in addition to LV cavity dilatation.
Recommendations for Echocardiography in Aortic Regurgitation
Indication Class
1. Confirm presence and severity of acute AR. I
2. Diagnosis of chronic AR in patients with equivocal physical
findings.
I
3. Assessment of etiology of regurgitation (including valve
morphology and aortic root size and morphology).
I
4. Assessment of LV hypertrophy, dimension (or volume), and
systolic function.
I
5. Semiquantitative estimate of severity of AR. I
6. Reevaluation of patients with mild, moderate, or severe
regurgitation with new or changing symptoms.
I
7. Reevaluation of LV size and function in asymptomatic
patients with severe regurgitation (recommended timing of
reevaluation is given in Figure 2).
I
8. Reevaluation of asymptomatic patients with mild, moderate,
or severe regurgitation and enlarged aortic root.
I
9. Yearly reevaluation of asymptomatic patients with mild to
moderate regurgitation with stable physical signs and normal
or near-normal LV chamber size.
III
If the patient is asymptomatic and leads an active lifestyle
and the echocardiogram is of good quality, no other testing
is necessary. If the patient has severe AR and is sedentary or
has equivocal symptoms, exercise testing is helpful to assess
functional capacity, symptomatic responses, and hemo-
dynamic effects of exercise (Figure 2). If the echocardio-
gram is of insufficient quality to assess LV function, radio-
nuclide angiography should be used in asymptomatic
patients to measure LV ejection fraction at rest and esti-
mate LV volumes. In patients who are symptomatic on
initial evaluation, it is reasonable to proceed directly to
cardiac catheterization and angiography if the echocardio-
gram is of insufficient quality to assess LV function or
severity of AR.
The exercise ejection fraction and the change in ejection
fraction from rest to exercise are often abnormal, even in
asymptomatic patients (190,192–194,197,200 –202,206,217–
222). However, these have not been proved to have indepen-
dent diagnostic or prognostic value when LV function at rest
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and severity of LV volume overload by echocardiography are
already known. One study that did identify the LV ejection
fraction response to exercise as a predictor of symptomatic
deterioration or LV dysfunction (197) included many patients
with NYHA functional Class II symptoms, LV systolic dysfunc-
tion (fractional shortening as low as 18%), and severe LV
dilatation (end-diastolic and end-systolic dimensions as high as
87 mm and 65 mm, respectively). Hence, the predictive nature
of this response in asymptomatic patients with normal LV
systolic function and without severe LV dilatation has not been
demonstrated.
Recommendations for Exercise Testing in Chronic
Aortic Regurgitation*
Indication Class
1. Assessment of functional capacity and symptomatic responses in
patients with a history of equivocal symptoms.
I
2. Evaluation of symptoms and functional capacity before
participation in athletic activities.
IIa
3. Prognostic assessment before AVR in patients with LV dysfunction. IIa
4. Exercise hemodynamic measurements to determine the effect of AR
on LV function.
IIb
5. Exercise radionuclide angiography for assessing LV function in
asymptomatic or symptomatic patients.
IIb
6. Exercise echocardiography or dobutamine stress echocardiography
for assessing LV function in asymptomatic or symptomatic
patients.
III
*These recommendations differ from the ACC/AHA Guidelines for Exercise
Testing (3). The committee believes that indications 1, 2, and 3 above warrant a
higher recommendation than IIb.
Recommendations for Radionuclide Angiography in
Aortic Regurgitation
Indication Class
1. Initial and serial assessment of LV volume and function at rest
in patients with suboptimal echocardiograms or equivocal
echocardiographic data.*
I
2. Serial assessment of LV volume and function at rest when serial
echocardiograms are not used.*
I
3. Assessment of LV volume and function in asymptomatic patients
with moderate to severe regurgitation when echocardiographic
evidence of declining LV function is suggestive but not
definitive.*
I
4. Confirmation of subnormal LV ejection fraction before
recommending surgery in an asymptomatic patient with
borderline echocardiographic evidence of LV dysfunction.*
I
5. Assessment of LV volume and function in patients with
moderate to severe regurgitation when clinical assessment and
echocardiographic data are discordant.*
I
6. Routine assessment of exercise ejection fraction. IIb
7. Quantification of AR in patients with unsatisfactory
echocardiograms.
IIb
8. Quantification of AR in patients with satisfactory
echocardiograms.
III
9. Initial and serial assessment of LV volume and function at rest
in addition to echocardiography.
III
*In centers with expertise in cardiac magnetic resonance imaging (MRI),
cardiac MRI may be used in place of radionuclide angiography for these
indications.
d. Medical Therapy. Therapy with vasodilating agents is
designed to improve forward stroke volume and reduce regur-
gitant volume. These effects should translate into reductions in
LV end-diastolic volume, wall stress, and afterload, resulting in
preservation of LV systolic function and reduction in LV mass.
The acute administration of sodium nitroprusside, hydralazine,
or nifedipine reduces peripheral vascular resistance and results
in an immediate augmentation in forward cardiac output and a
decrease in regurgitant volume (223–231). With nitroprusside
and hydralazine, these acute hemodynamic changes lead to a
consistent reduction in end-diastolic volume and an increase in
ejection fraction (223–226). This is an inconsistent finding with
a single oral dose of nifedipine (228–231). Reduced end-
diastolic volume and increased ejection fraction have also been
observed in small numbers of patients receiving long-term
oral therapy with hydralazine and nifedipine for periods of
1 to 2 years (198,232); with nifedipine, these effects are
associated with a reduction in LV mass (196,232). Less
consistent results have been reported with ACE inhibitors,
depending on the degree of reduction in arterial pressure
and end-diastolic volume (233–235). Reduced blood pres-
sure with enalapril and quinapril has been associated with
decreases in end-diastolic volume and mass but no change in
ejection fraction (234,235).
There are 3 potential uses of vasodilating agents in chronic
AR. It should be emphasized that these criteria apply only to
patients with severe AR. The first is long-term treatment of
patients with severe AR who have symptoms and/or LV
dysfunction who are considered poor candidates for surgery
because of additional cardiac or noncardiac factors. The
second is improvement in the hemodynamic profile of
patients with severe heart failure symptoms and severe LV
dysfunction with short-term vasodilator therapy before pro-
ceeding with AVR. In such patients, vasodilating agents with
negative inotropic effects should be avoided. The third is
prolongation of the compensated phase of asymptomatic
patients who have volume-loaded left ventricles but normal
systolic function.
Only 1 study, which compared long-acting nifedipine with
digoxin therapy in a total of 143 patients followed for 6 years,
has evaluated whether vasodilating therapy alters the long-
term natural history of chronic asymptomatic AR in a favor-
able manner (196). Patients receiving nifedipine had a more
gradual rate of attrition due to onset of symptoms and/or
LV dysfunction; long-acting nifedipine reduced the need for
valve replacement over 6 years from 34% to 15%. Moreover,
when patients receiving nifedipine did undergo AVR be-
cause of symptoms or impaired systolic function, all survived
surgery, and LV size and function improved considerably in
all patients (196). Thus, nifedipine does not appear to
obscure the development of important signs and symptoms
that precede the development of irreversible LV dys-
function. Whether ACE inhibitors would provide similar
long-term results is unclear because plasma renin and
peripheral ACE activity may not be increased in asymptom-
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atic patients with uncomplicated chronic AR with normal
LV function.
The goal of vasodilator therapy is to reduce systolic blood
pressure, and drug dosage should be increased until there is a
measurable decrease in systolic blood pressure or the patient
develops side effects. It is rarely possible to decrease systolic
blood pressure to normal because of the increased LV stroke
volume, and drug dosage should not be increased excessively in
an attempt to achieve this goal. Vasodilator therapy is of
unknown benefit and is not indicated in patients with normal
blood pressure and/or normal LV cavity size.
Vasodilator therapy is not recommended for asymptomatic
patients with mild AR and normal LV function in the absence
of systemic hypertension, as these patients have an excellent
outcome with no therapy. In patients with severe AR, vasodi-
lator therapy is not an alternative to surgery in asymptomatic
or symptomatic patients with LV systolic dysfunction; such
patients should be considered surgical candidates rather
than candidates for long-term medical therapy unless AVR
is not recommended because of additional cardiac or non-
cardiac factors. Whether symptomatic patients who have
preserved systolic function can be treated safely with aggres-
sive medical management and whether aggressive medical
management is as good or better than AVR have not been
determined. It is recommended that symptomatic patients
undergo surgery rather than long-term medical therapy.
Recommendations for Vasodilator Therapy for Chronic
Aortic Regurgitation
Indication Class
1. Chronic therapy in patients with severe regurgitation who have
symptoms and/or LV dysfunction when surgery is not
recommended because of additional cardiac or noncardiac
factors.
I
2. Long-term therapy in asymptomatic patients with severe
regurgitation who have LV dilatation but normal systolic
function.
I
3. Long-term therapy in asymptomatic patients with hypertension
and any degree of regurgitation.
I
4. Long-term ACE inhibitor therapy in patients with persistent LV
systolic dysfunction after AVR.
I
5. Short-term therapy to improve the hemodynamic profile of
patients with severe heart failure symptoms and severe LV
dysfunction before proceeding with AVR.
I
6. Long-term therapy in asymptomatic patients with mild to
moderate AR and normal LV systolic function.
III
Figure 2. Management strategy for patients
with chronic severe aortic regurgitation. Pre-
operative coronary angiography should be
performed routinely as determined by age,
symptoms, and coronary risk factors. Cardiac
catheterization and angiography may also
be helpful when there is discordance be-
tween clinical findings and echocardiogra-
phy. In some centers, serial follow-up may
be performed with RVG or MRI rather
than echocardiography to assess LV vol-
ume and systolic function. Abbreviations:
DD 5 end-diastolic dimension, RVG 5
radionuclide ventriculography, SD 5 end-
systolic dimension.
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7. Long-term therapy in asymptomatic patients with LV systolic
dysfunction who are otherwise candidates for valve replacement.
III
8. Long-term therapy in symptomatic patients with either normal
LV function or mild to moderate LV systolic dysfunction who are
otherwise candidates for valve replacement.
III
There is scant information about long-term therapy with
drugs other than vasodilators in asymptomatic patients with
severe AR and normal LV function. Thus, there are no data to
support the long-term use of digoxin, diuretics, nitrates, or
positive inotropic agents in asymptomatic patients.
e. Physical Activity and Exercise. There are no data suggest-
ing that exercise, in particular strenuous periodic exercise, will
contribute to or accelerate the progression of LV dysfunction
in AR. Asymptomatic patients with normal LV systolic func-
tion may participate in all forms of normal daily physical
activity, including mild forms of exercise and in some cases
competitive athletics. Isometric exercise should be avoided.
Recommendations regarding participation in competitive
athletics were published by the Task Force on Acquired
Valvular Heart Disease of the 26th Bethesda Conference
(105). Before participation in athletics, exercise testing to at
least the level of exercise required by the proposed activity
is recommended so that the patient’s tolerance for this
degree of exercise can be evaluated. This does not neces-
sarily evaluate the long-term effects of strenuous exercise,
which are unknown.
f. Serial Testing. The aim of serial evaluation of asymptom-
atic patients with chronic AR is to detect the onset of
symptoms and objectively assess changes in LV size and
function that can occur in the absence of symptoms. In general,
the stability and chronicity of the regurgitant lesion and the LV
response to volume load need to be established when the
patient first presents to the physician, especially if AR is
moderate to severe. If the chronic nature of the lesion is
uncertain and the patient does not present initially with one of
the indications for surgery, repeat physical examination and
echocardiography should be performed within 2 to 3 months
after the initial evaluation to ensure that a subacute process
with rapid progression is not under way. Once the chronicity
and stability of the process has been established, the frequency
of clinical reevaluation and repeat noninvasive testing depends
on the severity of the valvular regurgitation, the degree of LV
dilatation, the level of systolic function, and whether previous
serial studies have revealed progressive changes in LV size or
function (Figure 2). In most patients, serial testing during the
long-term follow-up period should include a detailed history,
physical examination, and echocardiography. Serial chest
x-rays and ECGs have less value but are helpful in selected
patients.
Asymptomatic patients with mild AR, little or no LV
dilatation, and normal LV systolic function can be seen on a
yearly basis with instructions to alert the physician if symptoms
develop in the interim. Yearly echocardiography is not neces-
sary unless there is clinical evidence that regurgitation has
worsened. Routine echocardiography can be performed every
2 to 3 years in such patients.
Asymptomatic patients with normal systolic function but
severe AR and significant LV dilatation (end-diastolic dimen-
sion .60 mm) require more frequent and careful reevaluation,
with a history and physical examination every 6 months and
echocardiography every 6 to 12 months, depending on the
severity of dilatation and stability of measurements. If stable,
echocardiographic measurements are not required more fre-
quently than every 12 months. In patients with more advanced
LV dilatation (end-diastolic dimension .70 mm or end-
systolic dimension .50 mm), for whom the risk of developing
symptoms or LV dysfunction ranges between 10% and 20%
per year (193,194), it is reasonable to perform serial echocar-
diograms as frequently as every 4 to 6 months. Serial chest
x-rays and ECGs have less value but are helpful in selected
patients.
Chronic AR may develop from disease processes involving
the proximal ascending aorta. In patients with aortic root
dilatation, serial echocardiograms are indicated to evaluate
aortic root size as well as LV size and function. This is
discussed in section III.B.4. of these guidelines.
Repeat echocardiograms are also recommended when the
patient has onset of symptoms, there is an equivocal history of
changing symptoms or exercise tolerance, or there are clinical
findings suggesting worsening regurgitation or progressive LV
dilatation. Patients with echocardiographic evidence of pro-
gressive ventricular dilatation or declining systolic function
have a greater likelihood of developing symptoms or LV
dysfunction (193) and should have more frequent follow-up
examinations (every 6 months) than those with stable LV
function.
In some centers with expertise in nuclear cardiology, serial
radionuclide ventriculograms to assess LV volume and func-
tion at rest may be an accurate and cost-effective alternative to
serial echocardiograms. However, there is no justification for
routine serial testing with both an echocardiogram and a
radionuclide ventriculogram. Serial radionuclide ventriculo-
grams are also recommended in patients with suboptimal
echocardiograms, patients with suggestive but not definite
echocardiographic evidence of LV systolic dysfunction, and
patients for whom there is discordance between clinical assess-
ment and echocardiographic data. In centers with specific
expertise in cardiac magnetic resonance imaging, serial mag-
netic resonance imaging may be performed in place of radio-
nuclide angiography for the indications listed above. In addi-
tion to accurate assessment of LV volume, mass, wall
thickness, and systolic function (98–102), cardiac magnetic
resonance imaging may also be used to quantify the severity of
valvular regurgitation (236–240).
Serial exercise testing is also not recommended routinely in
asymptomatic patients with preserved systolic function. How-
ever, exercise testing may be invaluable to assess functional
capacity and symptomatic responses in patients with equivocal
changes in symptomatic status. Serial exercise imaging studies
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to assess LV functional reserve are not indicated in asymptom-
atic patients or those in whom symptoms develop.
g. Indications for Cardiac Catheterization. Cardiac catheter-
ization is not required in patients with chronic AR unless there
are questions about the severity of AR, hemodynamic abnor-
malities, or LV systolic dysfunction that persist despite physical
examination and noninvasive testing or unless AVR is contem-
plated and there is a need to assess coronary anatomy. The
indications for coronary arteriography are discussed in section
VIII of these guidelines. In some patients undergoing left-
heart catheterization for coronary angiography, additional
aortic root angiography and hemodynamic measurements may
provide useful supplementary data.
Recommendations for Cardiac Catheterization in Chronic
Aortic Regurgitation
Indication Class
1. Coronary angiography before AVR in patients at risk for CAD
(see section VIII.B. of these guidelines).
I
2. Assessing severity of regurgitation when noninvasive tests are
inconclusive or discordant with clinical findings regarding
severity of regurgitation or need for surgery.
I
3. Assessing LV function when noninvasive tests are inconclusive
or discordant with clinical findings regarding LV dysfunction
and need for surgery in patients with severe AR.
I
4. Assessment of LV function and severity of regurgitation before
AVR when noninvasive tests are adequate and concordant with
clinical findings and coronary angiography is not needed.
IIb
5. Assessment of LV function and severity of regurgitation in
asymptomatic patients when noninvasive tests are adequate.
III
Hemodynamic and angiographic assessment of severity of
AR and LV function may be necessary in some patients being
considered for surgery when there are conflicting data between
clinical assessment and noninvasive tests. Less commonly,
other asymptomatic patient subgroups may also require inva-
sive measurement of hemodynamics and/or determination of
severity of AR for occupational purposes or for providing
recommendations for physical activity and exercise when this
information cannot be obtained accurately from noninvasive
tests.
Hemodynamic measurements during exercise are occasion-
ally helpful for determining the effect of AR on LV function or
making decisions regarding medical or surgical therapy. In
selected patients with severe AR, borderline or normal LV
systolic function, and LV chamber enlargement that is ap-
proaching the threshold for operation (defined below), mea-
surement of cardiac output and LV filling pressures at rest and
during exercise with a right-heart catheter may be valuable for
identifying patients with severe hemodynamic abnormalities in
whom surgery is warranted.
h. Indications for Aortic Valve Replacement. In patients with
pure, chronic AR, AVR should be considered only if AR is
severe. Patients with only mild AR are not candidates for valve
replacement, and if such patients have symptoms or LV
dysfunction, other etiologies should be considered, such as
CAD, hypertension, or cardiomyopathic processes. If the
severity of AR is uncertain after a review of clinical and
echocardiographic data, additional information may be
needed, such as invasive hemodynamic and angiographic data.
The following discussion applies only to those patients with
pure, severe AR.
(1) SYMPTOMATIC PATIENTS WITH NORMAL LV SYSTOLIC FUNC-
TION. AVR is indicated in patients with normal systolic func-
tion (defined as ejection fraction .20.50 at rest) who have
NYHA functional Class III or IV symptoms. Patients with
Canadian Heart Association functional Class II to IV angina
pectoris should also be considered for surgery. In many
patients with NYHA functional Class II dyspnea, the etiology
of symptoms is often unclear, and clinical judgment is required.
Patients with well-compensated AR often have chronic mild
dyspnea or fatigue, and it may be difficult to differentiate the
effects of deconditioning or aging from true cardiac symptoms.
In such patients, exercise testing may be valuable. If the
etiology of these mild symptoms is uncertain and they are
not severe enough to interfere with the patient’s lifestyle, a
period of observation may be reasonable. However, new
onset of mild dyspnea has different implications in severe
AR, especially in patients with increasing LV chamber size
or evidence of declining LV systolic function into the low
normal range. Thus, even if patients have not achieved the
threshold values of LV size and function recommended for
surgery in asymptomatic patients, development of mild
symptoms is an indication for operation in a patient who is
nearing these values.
(2) SYMPTOMATIC PATIENTS WITH LV DYSFUNCTION. Patients
with NYHA functional Class II, III, or IV symptoms and with
mild to moderate LV systolic dysfunction (ejection fraction
0.25 to 0.49) should undergo AVR. Patients with functional
Class IV symptoms have worse postoperative survival rates and
lower likelihood of recovery of systolic function compared with
patients with less severe symptoms (170,176,177,179), but
AVR will improve ventricular loading conditions and expedite
subsequent management of LV dysfunction (163).
Symptomatic patients with advanced LV dysfunction (ejec-
tion fraction ,0.25 and/or end-systolic dimension .60 mm)
present difficult management issues. Some patients will mani-
fest meaningful recovery of LV function after operation, but
many will have developed irreversible myocardial changes. The
mortality associated with valve replacement approaches 10%,
and postoperative mortality over the subsequent few years is
high. Valve replacement should be considered more strongly in
patients with NYHA functional Class II and III symptoms,
especially if (1) symptoms and evidence of LV dysfunction are
of recent onset and (2) intensive short-term therapy with
vasodilators, diuretics, and/or intravenous positive inotropic
agents results in substantial improvement in hemodynamics or
systolic function. However, even in patients with NYHA
functional Class IV symptoms and ejection fraction ,0.25, the
high risks associated with AVR and subsequent medical man-
agement of LV dysfunction are usually a better alternative
than the higher risks of long-term medical management alone
(241).
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(3) ASYMPTOMATIC PATIENTS. AVR in asymptomatic pa-
tients remains a controversial topic, but it is generally agreed
(158,242–246) that valve replacement is indicated in patients
with LV systolic dysfunction. As noted previously, for the
purposes of these guidelines, LV systolic dysfunction is defined
as an ejection fraction below normal at rest. The lower limit of
normal will be assumed to be 0.50, realizing that this lower
limit is technique dependent and may vary among institutions.
The committee also realizes that there may be variability in
any given measured LV dimension or ejection fraction.
Therefore, the committee recommends that 2 consecutive
measurements be obtained before proceeding with a deci-
sion to recommend surgery in the asymptomatic patient.
These consecutive measurements could be obtained with the
same test repeated in a short time period (for example, a
second echocardiogram after an initial echocardiogram) or
with a separate independent test (for example, a radionu-
clide ventriculogram or a contrast left ventriculogram after
an initial echocardiogram).
Valve replacement is also recommended in patients with
severe LV dilatation (end-diastolic dimension .75 mm or
end-systolic dimension .55 mm), even if ejection fraction is
normal. The majority of patients with this degree of dilatation
will have already developed systolic dysfunction because of
afterload mismatch and will thus be candidates for valve
replacement on the basis of the depressed ejection fraction.
The elevated end-systolic dimension in this regard is often a
surrogate for systolic dysfunction. The relatively small number
of asymptomatic patients with preserved systolic function
despite severe increases in end-systolic and end-diastolic
chamber size should be considered for surgery, as they
appear to represent a high risk group with an increased
incidence of sudden death (193,247), and the results of valve
replacement in such patients have thus far been excellent
(189). In contrast, postoperative mortality is considerable
once patients with severe LV dilatation develop symptoms
and/or LV systolic dysfunction (189). The data regarding the
risk of sudden death and postoperative outcome with severe
LV dilatation have been developed with an LV end-diastolic
dimension .280 mm, but the committee recommends surgery
before the left ventricle achieves this degree of dilatation
and recommends AVR for patients with LV end-diastolic
dimension .75 mm.
Patients with severe AR in whom the degree of dilatation
has not reached but is approaching these threshold values (for
example, LV end-diastolic dimension of 70 to 75 mm or
end-systolic dimension of 50 to 55 mm) should be followed
carefully with frequent echocardiograms every 4 to 6 months,
as noted previously (Figure 2). In addition, it is reasonable to
recommend AVR in such patients if there is evidence of
declining exercise tolerance or abnormal hemodynamic re-
sponses to exercise, for example, an increase in pulmonary
artery wedge pressure $25 mm Hg with exercise.
Several patient subgroups develop LV systolic dysfunction
with less marked LV dilatation than observed in the majority of
patients with uncomplicated AR. These include patients with
long-standing hypertension in whom the pressure-overloaded
ventricle has reduced compliance and a limited potential to
increase its chamber size; patients with concomitant CAD, in
whom myocardial ischemia may develop with increasing myo-
cardial wall stress, resulting in ventricular dysfunction; and
patients with concomitant MS, in whom the left ventricle will
not dilate to the same extent as in patients with pure AR (248).
In such patients, it is particularly important that systolic
function and not merely systolic dimension be monitored.
Women also tend to develop symptoms and/or LV dysfunc-
tion with less LV dilatation than men (249); this appears to
be related to body size as these differences are not apparent
when LV dimensions are corrected for body surface area.
Hence, LV dimensions alone may be misleading in small
patients of either gender, and the threshold values of
end-diastolic and end-systolic dimension recommended
above for AVR in asymptomatic patients (75 mm and
55 mm, respectively) may need to be reduced in such
patients. There are no data with which to derive guidelines
for LV dimensions corrected for body size, and clinical
judgment is required.
A decrease in ejection fraction during exercise should not
be used as an indication for AVR in asymptomatic patients
with normal systolic function at rest, because the exercise
ejection fraction response is multifactorial and the strength of
evidence is limited. The ejection fraction response to exercise
has not proved to have independent prognostic value in
patients undergoing surgery (179). The change in ejection
fraction with exercise is a relatively nonspecific response
related to both severity of volume load (193,200–202) and
exercise-induced changes in preload and peripheral resistance
(203) that develop early in the natural history of AR. Valve
replacement should also not be recommended in asymptom-
atic patients with normal systolic function merely because of
evidence of LV dilatation as long as the dilatation is not severe
(end-diastolic dimension ,75 mm or end-systolic dimension
,55 mm).
Patients who demonstrate progression of LV dilatation or
progressive decline in ejection fraction on serial studies
represent a higher-risk group who require careful monitor-
ing (193), but such patients often reach a new steady state
and may do well for extended periods of time. Hence, valve
replacement is not recommended until the threshold values
noted above are reached or symptoms or LV systolic
dysfunction develop.
The surgical options for treating AR are expanding, with
growing experience in aortic homografts, pulmonary au-
tografts, unstented tissue valves, and aortic valve repair. If
these techniques are ultimately shown to improve long-term
survival or reduce postoperative valve complications, it is
conceivable that the thresholds for recommending operation
may be reduced. Until such data are available, the indications
for operation for AR should not vary with the operative
technique to be used.
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Recommendations for Aortic Valve Replacement in Chronic Severe
Aortic Regurgitation
Indication Class
1. Patients with NYHA functional Class III or IV symptoms and
preserved LV systolic function, defined as normal ejection
fraction at rest (ejection fraction >20.50).
I
2. Patients with NYHA functional class II symptoms and
preserved LV systolic function (ejection fraction >20.50 at
rest) but with progressive LV dilatation or declining ejection
fraction at rest on serial studies or declining effort tolerance
on exercise testing.
I
3. Patients with Canadian Heart Association functional Class II
or greater angina with or without CAD.
I
4. Asymptomatic or symptomatic patients with mild to moderate
LV dysfunction at rest (ejection fraction 0.25 to 0.49).
I
5. Patients undergoing coronary artery bypass surgery or
surgery on the aorta or other heart valves.
I
6. Patients with NYHA functional Class II symptoms and
preserved LV systolic function (ejection fraction >20.50 at
rest) with stable LV size and systolic function on serial
studies and stable exercise tolerance.
IIa
7. Asymptomatic patients with normal LV systolic function
(ejection fraction >0.50) but with severe LV dilatation (end-
diastolic dimension >75 mm or end-systolic dimension
>55 mm).*
IIa
8. Patients with severe LV dysfunction (ejection fraction <0.25). IIb
9. Asymptomatic patients with normal systolic function at rest
(ejection fraction >0.50) and progressive LV dilatation when
the degree of dilatation is moderately severe (end-diastolic
dimension 70 to 75 mm, end-systolic dimension 50 to 55 mm).
IIb
10. Asymptomatic patients with normal systolic function at rest
(ejection fraction >0.50) but with decline in ejection fraction
during
z Exercise radionuclide angiography IIb
z Stress echocardiography III
11. Asymptomatic patients with normal systolic function at rest
(ejection fraction >0.50) and LV dilatation when degree of
dilatation is not severe (end-diastolic dimension <70 mm,
end-systolic dimension <50 mm).
III
*Consider lower threshold values for patients of small stature of either
gender. Clinical judgment is required.
4. Concomitant Aortic Root Disease. In addition to causing
acute AR, diseases of the proximal aorta may also contribute
to chronic AR. The valvular regurgitation may be less impor-
tant in decision making than the primary disease of the aorta,
such as Marfan syndrome, dissection, or chronic dilatation of
the aortic root caused by hypertension. In such patients, if the
AR is mild and/or the left ventricle is only mildly dilated,
management should focus on treating the underlying aortic
root disease, which is beyond the scope of these guidelines. In
many patients, however, AR may be severe and associated with
severe LV dilatation and/or systolic dysfunction, in which case
decisions regarding medical therapy and timing of the opera-
tion must consider both conditions. In general, AVR and
aortic root reconstruction are indicated in patients with disease
of the proximal aorta and AR of any severity when the degree
of aortic root dilatation reaches or exceeds 50 mm by echocar-
diography (250).
5. Evaluation of Patients After Aortic Valve Replacement.
After AVR, careful follow-up is necessary during the early and
long-term postoperative course to evaluate prosthetic valve
function and assess LV function, as discussed in detail in
section VII.C.3. An echocardiogram should be performed soon
after surgery to assess the results of surgery on LV size and
function and to serve as a baseline against which subsequent
echocardiograms may be compared. This could be performed
either before hospital discharge or preferably at the first
outpatient reevaluation. Within the first few weeks of surgery,
there is little change in LV systolic function, and ejection
fraction may even deteriorate compared with preoperative
values because of the reduced preload (251), even though
ejection fraction may increase over the subsequent several
months. Thus, persistent or more severe systolic dysfunction
early after operation is a poor predictor of subsequent im-
provement in LV function in patients with preoperative LV
dysfunction. A better predictor of subsequent LV systolic
function is the reduction in LV end-diastolic dimension, which
declines significantly within the first week or two of operation
(165,170,252). This is an excellent marker of the functional
success of valve replacement because 80% of the overall
reduction in end-diastolic dimension observed during the
long-term postoperative course occurs within the first 10 to 14
days after AVR (165,170,252), and the magnitude of reduction
in end-diastolic dimension after surgery correlates with the
magnitude of increase in ejection fraction (170).
After the initial postoperative reevaluation, the patient
should be seen and examined again at 6 months and 12 months
and then on a yearly basis if the clinical course is uncompli-
cated. If the patient is asymptomatic and the early postopera-
tive echocardiogram demonstrates substantial reduction in LV
end-diastolic dimension and LV systolic function is normal,
serial postoperative echocardiograms after the initial early
postoperative study are usually not indicated. However, repeat
echocardiography is warranted at any point at which there is
evidence of a new murmur, questions of prosthetic valve
integrity, or concerns about LV function. Patients with persis-
tent LV dilatation on the initial postoperative echocardiogram
should be treated as any other patient with symptomatic or
asymptomatic LV dysfunction, including treatment with ACE
inhibitors. In such patients, repeat echocardiography to assess
LV size and systolic function is warranted at the 6- and
12-month reevaluations. If LV dysfunction persists beyond this
time frame, repeat echocardiograms should be performed as
clinically indicated. Management of patients after AVR is
discussed in greater detail in section VII.C.3. of these guide-
lines.
6. Special Considerations in the Elderly. The vast majority
of elderly patients with aortic valve disease have AS or
combined AS and AR, and pure AR is uncommon (253).
Elderly patients with AR generally fare less well than patients
in young or middle age. Patients older than 75 are more likely
to develop symptoms or LV dysfunction at earlier stages of LV
dilatation, have more persistent ventricular dysfunction and
heart failure symptoms after surgery, and have worse postop-
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erative survival rates than their younger counterparts. Many
such patients have concomitant CAD, which must be consid-
ered in the evaluation of symptoms, LV dysfunction, and
indications for surgery. Because the goal of therapy is to
improve the quality of life rather than longevity, symptoms are
the most important guide to determining whether or not AVR
should be performed. Nonetheless, asymptomatic or mildly
symptomatic patients who develop LV dysfunction (as defined
previously) should be considered for AVR if the risks of
surgery are balanced in otherwise healthy patients against the
expected improvement in long-term outcome.
C. Mitral Stenosis
1. Pathophysiology and Natural History. MS is an obstruc-
tion to LV inflow at the level of the mitral valve as a result of
a structural abnormality of the mitral valve apparatus, prevent-
ing proper opening during diastolic filling of the left ventricle.
The predominant cause of MS is rheumatic carditis. Isolated
MS occurs in 40% of all patients presenting with rheumatic
heart disease, and a history of rheumatic fever can be elicited
from '60% of patients presenting with pure MS (254,255).
The ratio of women to men presenting with isolated MS is 2:1
(254–256). Congenital malformation of the mitral valve occurs
rarely and is observed mainly in infants and children (257).
In patients with MS from rheumatic fever, the pathological
process causes leaflet thickening and calcification, commissural
fusion, chordal fusion, or a combination of these processes
(257,258). The result is a funnel-shaped mitral apparatus in
which the orifice of the mitral opening is decreased in size.
Interchordal fusion obliterates the secondary orifices and
commissural fusion narrows the principal orifice (257,258).
The normal mitral valve area is 4.0 to 5.0 cm2. Narrowing of
the valve area to ,2.5 cm2 must occur before the development
of symptoms (106). With a reduction in valve area by the
rheumatic process, blood can flow from the left atrium to the
left ventricle only if propelled by a pressure gradient. This
diastolic transmitral gradient is the fundamental expression of
MS (259) and results in elevation of left atrial pressure, which
is reflected back into the pulmonary venous circulation. In-
creased pressure and distension of the pulmonary veins and
capillaries can lead to pulmonary edema as pulmonary venous
pressure exceeds that of plasma oncotic pressure. The pulmo-
nary arterioles react with vasoconstriction, intimal hyperplasia,
and medial hypertrophy, which lead to pulmonary arterial
hypertension.
A mitral valve area .1.5 cm2 usually does not produce
symptoms at rest (260). However, if there is an increase in
transmitral flow or a decrease in the diastolic filling period,
there will be a rise in left atrial pressure and development of
symptoms. From hydraulic considerations, at any given orifice
size, the transmitral gradient is a function of the square of the
transvalvular flow rate and dependent on the diastolic filling
period (106). Thus, the first symptoms of dyspnea in patients
with mild MS are usually precipitated by exercise, emotional
stress, infection, pregnancy, or atrial fibrillation with a rapid
ventricular response (260). As the obstruction across the mitral
valve increases, there will be increasing symptoms of dyspnea
as the left atrial and pulmonary venous pressures increase.
Several other factors influence symptoms in patients with
MS. As the severity of stenosis increases, cardiac output
becomes subnormal at rest (260) and fails to increase during
exercise (261). The degree of pulmonary vascular disease is
also an important determinant of symptoms in patients with
MS (260,262,263). A second obstruction to flow develops from
increased pulmonary arteriolar resistance (262,263), which
may protect the lungs from pulmonary edema (262,263). In
some patients, an additional reversible obstruction develops at
the level of the pulmonary veins (264,265). The low cardiac
output and increased pulmonary arteriolar resistance, com-
bined with adaptation of the lungs (alveolar basement mem-
brane thickening, adaptation of neuroreceptors, and increased
lymphatic drainage), contribute to the ability of a patient with
severe MS to remain minimally symptomatic for prolonged
periods of time (260,262,263).
The natural history of patients with untreated MS has been
defined from studies in the 1950s and 1960s (254–256). MS is
a continuous, progressive, lifelong disease, usually consisting of
a slow, stable course in the early years followed by a progres-
sive acceleration later in life (254–256,266). In developed
countries, there is a long latent period of 20 to 40 years from
the occurrence of rheumatic fever to the onset of symptoms.
Once symptoms develop, there is another period of almost a
decade before symptoms become disabling (254). Overall, the
10-year survival of untreated patients presenting with MS is
50% to 60%, depending on symptoms at presentation
(255,256). In the asymptomatic or minimally symptomatic
patient, survival is .80% at 10 years, with 60% of patients
having no progression of symptoms (255,256,266). However,
once significant limiting symptoms occur, there is a dismal 0 to
15% 10-year survival (254–256,266,267). Once there is severe
pulmonary hypertension, mean survival drops to ,3 years
(268). The mortality of untreated patients with MS is due to
progressive heart failure in 60% to 70%, systemic embolism in
20% to 30%, pulmonary embolism in 10%, and infection in 1%
to 5% (256,257). In North America and Europe, this classic
history of MS has been replaced by an even milder delayed
course with the decline in incidence of rheumatic fever
(266,269). The mean age of presentation is now in the fifth to
sixth decade (266,269); more than one third of patients under-
going valvotomy are older than 65 years (270). In some
geographic areas, MS progresses more rapidly, presumably due
to either a more severe rheumatic insult or repeated episodes
of rheumatic carditis due to new streptococcal infections,
resulting in severe symptomatic MS in the late teens and early
twenties (266).
2. Evaluation and Management of the Asymptomatic Pa-
tient. a. Initial Workup. The diagnosis of MS should be made
on the basis of the history, physical examination, chest x-ray,
and ECG (Figure 3). Patients may present with no symptoms
but have an abnormal physical examination (266,269). Al-
though some patients may present with fatigue, dyspnea, or
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frank pulmonary edema, in others, the initial manifestation
of MS is the onset of atrial fibrillation or an embolic event
(254).
The diagnostic tool of choice in the evaluation of a patient
with MS is 2-D and Doppler echocardiography (271–276).
Echocardiography is able to identify restricted diastolic open-
ing of the mitral valve leaflets due to “doming” of the anterior
leaflet and immobility of the posterior leaflet (271–274). Other
entities that can simulate the clinical features of rheumatic MS,
such as left atrial myxoma, cor triatriatum, and a parachute
mitral valve can be readily identified by 2-D echocardiography.
Planimetry of the orifice area may be possible from the
short-axis view. 2-D echocardiography can be used to assess
the morphological appearance of the mitral valve apparatus,
including leaflet mobility, leaflet thickness, leaflet calcification,
subvalvular fusion, and the appearance of commissures (277–
280). These features may be important when considering the
timing and type of intervention to be performed (277–280).
Patients with mobile noncalcified leaflets, no commissural
calcification, and little subvalvular fusion may be candidates
for either balloon catheter or surgical commissurotomy/
valvotomy (277–280). Chamber size and function as well as
other structural valvular, myocardial, or pericardial abnor-
malities can be assessed with the 2-D echocardiographic
study.
Doppler echocardiography can be used to assess the hemo-
dynamic severity of the obstruction (275,276,281). The mean
transmitral gradient can be accurately and reproducibly mea-
sured from the continuous wave Doppler signal across the
mitral valve with the modified Bernoulli equation (275,276).
The mitral valve area can be noninvasively derived from
Doppler echocardiography with either the diastolic half-time
method (281–284) or the continuity equation (282). The
half-time may be inaccurate in patients with abnormalities of
left atrial or LV compliance, those with associated AR, and
those who have had mitral valvotomy (283,284). Doppler
echocardiography should also be used to estimate pulmonary
artery systolic pressure from the TR velocity signal (285) and
to assess severity of concomitant MR or AR. Formal hemody-
namic exercise testing can be done noninvasively with either a
Figure 3. Management strategy for patients with
mitral stenosis. Abbreviations: CXR 5 chest
x-ray, LA 5 left atrial, MVA 5 mitral valve area,
PMBV 5 percutaneous mitral balloon valvot-
omy, PAP 5 pulmonary artery pressure,
PAWP 5 pulmonary artery wedge pressure.
*The committee recognizes that there may be
variability in the measurement of MVA and that
the mean transmitral gradient, PAWP, and PAP
should also be taken into consideration. †There
is controversy as to whether patients with severe
MS (MVA ,1.0 cm2) and severe pulmonary
hypertension (PAP .60–80 mm Hg) should
undergo MVR to prevent right ventricular fail-
ure. ††Assuming no other cause for pulmonary
hypertension is present.
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supine bicycle or upright treadmill with Doppler recordings of
transmitral and tricuspid velocities (286–289). This allows
measurement of both the transmitral gradient (286–288) and
pulmonary artery systolic pressure (288,289) at rest and with
exercise. Dobutamine stress with Doppler recordings may also
be performed (290).
Recommendations for Echocardiography in Mitral Stenosis
Indication Class
1. Diagnosis of MS, assessment of hemodynamic severity (mean
gradient, mitral valve area, pulmonary artery pressure), and
assessment of right ventricular size and function.
I
2. Assessment of valve morphology to determine suitability for
percutaneous mitral balloon valvotomy.
I
3. Diagnosis and assessment of concomitant valvular lesions. I
4. Reevaluation of patients with known MS with changing
symptoms or signs.
I
5. Assessment of hemodynamic response of mean gradient and
pulmonary artery pressures by exercise Doppler
echocardiography in patients when there is a discrepancy
between resting hemodynamics and clinical findings.
IIa
6. Reevaluation of asymptomatic patients with moderate to
severe MS to assess pulmonary artery pressure.
IIb
7. Routine reevaluation of the asymptomatic patient with mild
MS and stable clinical findings.
III
Recommendations for Transesophageal Echocardiography in
Mitral Stenosis
Indication Class
1. Assess for presence or absence of left atrial thrombus in patients
being considered for percutaneous mitral balloon valvotomy or
cardioversion.
IIa
2. Evaluate mitral valve morphology and hemodynamics when
transthoracic echocardiography provides suboptimal data.
IIa
3. Routine evaluation of mitral valve morphology and hemodynamics
when complete transthoracic echocardiographic data are
satisfactory.
III
In the patient who presents with asymptomatic MS, an
initial clinical history, physical examination, ECG, and chest
x-ray should be performed. 2-D and Doppler echocardiogra-
phy should also be performed to confirm the diagnosis of MS
and rule out other concomitant problems that would require
further therapy, ie, myocardial or other valvular heart disease.
The morphology of the mitral valve apparatus should be
assessed. The severity of MS should be determined by using
both the mean transmitral gradient and valve area from the
Doppler echocardiogram, and pulmonary artery pressure
should be estimated when possible. A transesophageal echo-
cardiogram is not required unless a question about diagnosis
remains after transthoracic echocardiography.
In the asymptomatic patient who has documented mild MS
(valve area .1.5 cm2 and mean gradient ,5 mm Hg), no
further evaluation is needed on the initial workup (Figure 3).
These patients usually remain stable for years (255,256,266). If
there is more significant MS, a decision to proceed further
should be based on the suitability of the patient for mitral
valvotomy. In patients with pliable, noncalcified valves with no
or little subvalvular fusion and no calcification in the commis-
sures, percutaneous mitral valvotomy can be performed with a
low complication rate and may be indicated if symptoms
develop. Due to the slowly progressive course of MS, patients
may remain “asymptomatic” with severe stenosis merely by
readjusting their lifestyle to a more sedentary level. Elevated
pulmonary vascular resistance and/or low cardiac output may
also play an adaptive role in preventing symptoms from
occurring in patients with severe MS (260,262,263). Elevation
of pulmonary vascular resistance is an important physiological
event in MS (262), and the level of pulmonary pressure is an
indicator of the overall hemodynamic consequence. Patients
with moderate pulmonary hypertension at rest (pulmonary
artery systolic pressure .50 mm Hg) and pliable mitral valve
leaflets may be considered for percutaneous mitral valvotomy
even if they deny symptoms. In patients who lead a sedentary
lifestyle, a hemodynamic exercise test with Doppler echocar-
diography is useful (286–289). Objective limitation of exercise
tolerance with a rise in transmitral gradient .15 mm Hg and in
pulmonary artery systolic pressure .60 mm Hg may be an
indication for percutaneous valvotomy if the mitral valve
morphology is suitable. There is a subset of asymptomatic
patients with severe MS (valve area ,1.0 cm2) and severe
pulmonary hypertension (pulmonary artery systolic pressure
.75% of systemic pressure either at rest or with exercise). If
these patients do not have a valve morphology favorable for
percutaneous mitral balloon valvotomy or surgical valve repair,
it is controversial whether mitral valve replacement (MVR)
should be performed in the absence of symptoms to prevent
right ventricular failure, but surgery is generally recommended
in such patients.
b. Medical Therapy: General. In the patient with MS, the
major problem is mechanical obstruction to inflow at the level
of the mitral valve, and no medical therapy will specifically
relieve the fixed obstruction. The left ventricle is protected
from a volume or pressure overload, and thus no specific
medical therapy is required in the asymptomatic patient in
normal sinus rhythm who has mild MS. Because rheumatic
fever is the primary cause of MS, prophylaxis against rheu-
matic fever is recommended. Infective endocarditis is uncom-
mon but does occur in isolated MS (255,256), and appropriate
endocarditis prophylaxis is also recommended.
In the patient who has more than a mild degree of MS,
counseling on avoidance of unusual physical stresses is advised.
Increased flow and a shortening of the diastolic filling period
by tachycardia increase left atrial pressure against an ob-
structed mitral valve. Agents with negative chronotropic prop-
erties such as b-blockers or calcium channel blockers may be of
benefit in patients in sinus rhythm who have exertional symp-
toms if these symptoms occur with high heart rates (291,292).
Salt restriction and intermittent administration of a diuretic
are useful if there is evidence of pulmonary vascular conges-
tion. Digitalis does not benefit patients with MS in sinus
rhythm unless there is left and/or right ventricular dysfunction
(293).
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c. Medical Therapy: Atrial Fibrillation. Patients with MS are
prone to developing atrial arrhythmias, particularly atrial
fibrillation and atrial flutter. Thirty to forty percent of patients
with symptomatic MS develop atrial fibrillation (254,255).
Structural changes from the pressure and volume overload
alter the electrophysiological properties of the left atrium
(266), and the rheumatic process itself may lead to fibrosis of
the internodal tracts and damage to the sinoatrial node. There
may be significant hemodynamic consequences resulting from
the acute development of atrial fibrillation, with loss of atrial
contribution to LV filling, and from the rapid ventricular rate,
which shortens the diastolic filling period and causes elevation
of left atrial pressure. Atrial fibrillation occurs more commonly
in older patients (254) and is associated with a poorer prog-
nosis, with a 10-year survival rate of 25% compared with 46%
in patients who remain in sinus rhythm (256). The risk of
arterial embolization, especially stroke, is significantly in-
creased in patients with atrial fibrillation (254,255,294–296).
Treatment of an acute episode of rapid atrial fibrillation
consists of anticoagulation with heparin and control of the
heart rate response. Intravenous digoxin, calcium channel
blockers, or b-blockers should be used to control ventricular
response by slowing conduction through the atrioventricular
node. If there is hemodynamic instability, electrical cardiover-
sion should be undertaken urgently, with intravenous heparin
before, during, and after the procedure. Patients who have
been in atrial fibrillation longer than 24 to 48 hours without
anticoagulation are at an increased risk for embolic events
after cardioversion, but embolization may occur with ,24
hours of atrial fibrillation. The decision to proceed with
elective cardioversion is dependent on multiple factors, includ-
ing duration of atrial fibrillation, hemodynamic response to the
onset of atrial fibrillation, a documented history of prior
episodes of atrial fibrillation, and a history of prior embolic
events. If the decision has been made to proceed with elective
cardioversion in a patient who has had documented atrial
fibrillation for longer than 24 to 48 hours and who has not been
on long-term anticoagulation, 1 of 2 approaches is recom-
mended, based on data from patients with nonrheumatic atrial
fibrillation. The first is anticoagulation with warfarin for
.23 weeks, followed by elective cardioversion (297). The sec-
ond is anticoagulation with heparin and transesophageal echo-
cardiography to look for left atrial thrombus. In the absence of
left atrial thrombus, cardioversion is performed with intrave-
nous heparin before, during, and after the procedure (298). It
is important to continue anticoagulation after cardioversion to
prevent thrombus formation due to atrial mechanical inactiv-
ity and then continue long-term warfarin.
Recurrent paroxysmal atrial fibrillation may be treated with
antiarrhythmic drugs consisting of group IC agents, group IA
agents (in conjunction with a negative dromotropic agent), or
amiodarone to try to prevent further episodes. Eventually,
atrial fibrillation becomes resistant to prevention or cardiover-
sion (266), and control of ventricular response becomes the
mainstay of therapy. Digoxin slows the heart rate response in
patients with atrial fibrillation and MS (293). However, cal-
cium channel blockers or b-blockers are more effective for
preventing exercise-induced increases in heart rate. Patients
with either paroxysmal or sustained atrial fibrillation should be
treated with long-term anticoagulation with warfarin to pre-
vent embolic events if they do not have a strong contraindica-
tion to anticoagulation (295,299). It is controversial whether
percutaneous mitral valvotomy should be performed in pa-
tients with new-onset atrial fibrillation and moderate to severe
MS who are otherwise asymptomatic.
d. Medical Therapy: Prevention of Systemic Embolization.
Systemic embolization may occur in 10% to 20% of patients
with MS (254,255,294). The risk of embolization is related to
age and the presence of atrial fibrillation (254,255,294–296).
One third of embolic events occur within 1 month of the onset
of atrial fibrillation and two thirds occur within 1 year. The
frequency of embolic events does not seem to be related to the
severity of MS, cardiac output, size of the left atrium, or even
the presence or absence of heart failure symptoms
(254,295,300). An embolic event may thus be the initial
manifestation of MS (254). In patients who have experienced
an embolic event, the frequency of recurrence is as high as 15
to 40 events per 100 patient months (295,299).
There are no randomized trials examining the efficacy of
anticoagulation in preventing embolic events specifically in
patients with MS. Retrospective studies have shown a 4- to
15-fold decrease in the incidence of embolic events with
anticoagulation in these patients (295,299). This benefit ap-
plies to both systemic and pulmonary embolism. Most trials
involved patients who had .21 embolus before the onset of
anticoagulation therapy (299). However, large randomized
trials have demonstrated a significant reduction in embolic
events by treatment with anticoagulation in subsets of patients
with atrial fibrillation not associated with MS (301,302). In
these randomized trials, the subset of patients who benefited
most from anticoagulation were those with the highest risk of
embolic events (301,302). Patients with MS at the highest risk
for future embolic events are those with prior embolic events
and those with paroxysmal or persistent atrial fibrillation
(254,255,294–296,299). Paroxysmal atrial fibrillation may be
difficult to detect; ambulatory ECG monitoring is valuable in
patients with palpitations. There are no data to support the
concept that oral anticoagulation is beneficial in patients with
MS who have not had atrial fibrillation or an embolic event. It
is controversial whether patients without atrial fibrillation or
an embolic event who might be at higher risk for future
embolic events (ie, severe stenosis or an enlarged left atrium)
should be considered for long-term warfarin therapy (303,304).
Although embolic events are thought to originate from left
atrial thrombi (295,296), the presence or absence of a left atrial
thrombus does not seem to correlate with embolic events
(254,294). Left atrial thrombi are found during surgery in 15%
to 20% of patients with prior embolic events and a similar
number of patients without embolic events (254,294). Thus,
the decision to anticoagulate a patient with MS should not be
based solely on the echocardiographic demonstration of a left
atrial thrombus.
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It has been suggested that surgical commissurotomy re-
duces the incidence of future embolic events (267). There are
no randomized trial data to support this hypothesis, and the
retrospective studies that have been reported were performed
before the availability of standardized anticoagulation regi-
mens. Other retrospective studies have concluded that surgery
does not decrease the incidence of systemic emboli
(266,305,306).
Recommendations for Anticoagulation in Mitral Stenosis
Indication Class
1. Patients with atrial fibrillation, paroxysmal or chronic. I
2. Patients with a prior embolic event. I
3. Patients with severe MS and left atrial dimension >255 mm by
echocardiography.*
IIb
4. All other patients with MS. III
*Based on grade C recommendation given this indication by American
College of Chest Physicians Fourth Consensus Conference on Antithrombotic
Therapy (303). The Working Group of the European Society of Cardiology
recommended a lower threshold of left atrial dimension (>50 mm) for recom-
mending anticoagulation (304).
e. Recommendations Regarding Physical Activity and Exer-
cise. Many patients with mild MS will remain asymptomatic
even with strenuous exercise. In more severe MS, exercise can
cause sudden marked increases in pulmonary venous pressure
from the increase in heart rate and cardiac output, at times
resulting in pulmonary edema (261,263). The long-term effects
of repeated exertion-related increases in pulmonary venous
and pulmonary artery pressures on the lung or right ventricle
remain unknown (105). MS rarely causes sudden death (254–
256). These factors must be considered when recommending
physical activity and exercise for the patient with MS.
In the majority of patients with MS, recommendations for
exercise are symptom limited. Patients should be encouraged
to pursue a low-level aerobic exercise program for mainte-
nance of cardiovascular fitness. Exertional symptoms of dys-
pnea are the limiting factors in terms of exercise tolerance.
However, there is a subset of asymptomatic patients who wish
to participate in competitive athletics who may deny symptoms.
The 26th Bethesda Conference on Recommendations for
Determining Eligibility for Competition in Athletes with Car-
diovascular Abnormalities has published guidelines for pa-
tients with MS who wish to engage in competitive athletics
(105).
f. Serial Testing. Serial follow-up testing of a patient with
MS should be based on whether the results of a test will dictate
either a change in therapy or a recommendation for a proce-
dure. Patients with MS usually have years without symptoms
before the onset of deterioration (254,266). All patients should
be informed that any change in symptoms warrants reevalua-
tion. In the asymptomatic patient, yearly reevaluation is rec-
ommended (Figure 3). At the time of the yearly evaluation, a
history, physical examination, chest x-ray, and ECG should be
obtained. An echocardiogram is not recommended yearly
unless there is a change in clinical status. Ambulatory ECG
monitoring to detect paroxysmal atrial fibrillation is indicated
in patients with palpitations.
3. Evaluation of the Symptomatic Patient. a. Initial
Workup. Patients who develop symptoms should undergo
evaluation with a history, physical examination, ECG, chest
x-ray, and echocardiogram (Figures 4 and 5). 2-D and Doppler
echocardiography is indicated to evaluate mitral valve mor-
phology, mitral valve hemodynamics, and pulmonary artery
pressure. Patients with NYHA functional Class II symptoms
and moderate or severe stenosis (mitral valve area ,21.5 cm
2 or
mean gradient .25 mm Hg) may be considered for mitral
balloon valvotomy if they have suitable mitral valve morphol-
ogy. Patients who have NYHA functional Class III or IV
symptoms and evidence of severe MS have a poor prognosis if
left untreated (254–256) and should be considered for inter-
vention with either balloon valvotomy or surgery.
A subset of patients has significant limiting symptoms yet
resting hemodynamics that do not indicate moderate to severe
MS. If there is a discrepancy between symptoms and hemody-
namic data, formal exercise testing or dobutamine stress may
be useful to differentiate symptoms due to MS from other
causes of symptoms. Exercise tolerance, heart rate and blood
pressure response, transmitral gradient, and pulmonary artery
pressure can be obtained at rest and during exercise. This can
usually be accomplished with either supine bicycle or upright
exercise with Doppler recording of TR and transmitral veloc-
ities (286–289). Right- and left-heart catheterization with
exercise may also be helpful (307). Patients who are symptom-
atic with a significant elevation of pulmonary artery pressure
(.60 mm Hg), mean transmitral gradient (.15 mm Hg), or
pulmonary artery wedge pressure (.225 mm Hg) on exertion
(261,286–288,308) have hemodynamically significant MS and
should be considered for further intervention. Alternatively,
patients who do not manifest elevation in either pulmonary
artery, pulmonary artery wedge, or transmitral pressures coin-
cident with development of exertional symptoms most likely
would not benefit from intervention on the mitral valve.
b. Indications for Cardiac Catheterization. Cardiac catheter-
ization has been considered the standard for determining the
severity of MS. Direct measurements of left atrial and LV
pressure determine the transmitral gradient, which is the
fundamental expression of the severity of MS (259). Because
the severity of obstruction is dependent on both flow and
gradient (263), the hydraulic Gorlin equation has been used in
the catheterization laboratory to derive a calculated valve area
(106). Pulmonary artery pressures and resistance can be ob-
tained to examine the effect of MS on the pulmonary circula-
tion.
With the advent of Doppler echocardiography, cardiac
catheterization is no longer required for assessment of hemo-
dynamics in the majority of patients with isolated MS. Reliable
measurements of the transmitral gradient may be obtained
with the modified Bernoulli equation (275,276). The potential
problems of angle dependence, pressure recovery, proximal
acceleration, and inadequate velocity signals that occur in the
evaluation of other valve lesions are not present with MS.
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There is often overestimation of the transmitral gradient when
catheterization is performed with pulmonary artery wedge
pressure as a substitute for left atrial pressure, even after
correction for phase delay. Thus, the transmitral gradient
derived by Doppler echocardiography may be more accurate
than that obtained by cardiac catheterization with pulmonary
artery wedge pressure (309).
Mitral valve area is derived from either the half-time
method or continuity equation by Doppler echocardiography.
These measurements correlate well in most instances with
valve areas from cardiac catheterization (281,282). The Dopp-
ler half-time method may be inaccurate if there are changes in
compliance of the left atrium or left ventricle (282,283),
especially after mitral balloon valvotomy, or if there is con-
comitant AR. There are limitations to mitral valve area
calculations derived from catheter measurements, because the
Gorlin equation may not be valid under varying hemodynamic
conditions and the empirical coefficient of discharge may be
inaccurate with different orifice shapes (265,284). Calculation
of valve area by catheterization is also dependent on measure-
ment of transmitral gradient and cardiac output. Gradients
may be inaccurate when pulmonary artery wedge pressure is
used, as may cardiac output derived by the thermodilution
method. Thus, there may be inaccuracies with both Doppler
and catheter-derived valve areas, and a single valve area should
not be the sole measure of MS severity. Estimates of the
severity of MS should be based on all data, including transmi-
tral gradient, mitral valve area, pulmonary artery wedge pres-
sure, and pulmonary artery pressure.
In most instances Doppler measurements of transmitral
gradient, valve area, and pulmonary pressure will correlate
well with each other. Catheterization is indicated to assess
hemodynamics when there is a discrepancy between Doppler-
derived hemodynamics and the clinical status of a symptomatic
patient. Absolute left- and right-side pressure measurements
should be obtained by catheterization when there is elevation
of pulmonary artery pressure out of proportion to mean
gradient and valve area. Catheterization including left ven-
triculography (to evaluate severity of MR) is indicated when
there is a discrepancy between the Doppler-derived mean
gradient and valve area. Aortic root angiography may be
necessary to evaluate severity of AR. If symptoms appear to be
out of proportion to noninvasive assessment of resting hemo-
dynamics, right- and left-heart catheterization with exercise
may be useful. Transseptal catheterization may rarely be
required for direct measurement of left atrial pressure if there
is doubt about the accuracy of pulmonary artery wedge pres-
sure. Coronary angiography may be required in selected
patients who may need intervention (see section VIII of these
guidelines).
Figure 4. Management strategy for patients with mitral
stenosis and mild symptoms. Abbreviations: CXR 5 chest
x-ray, LA 5 left atrial, MVA 5 mitral valve area, PMBV 5
percutaneous mitral balloon valvotomy, PAP 5 pulmonary
artery pressure, PAWP 5 pulmonary artery wedge pressure.
*The committee recognizes that there may be variability in
the measurement of MVA and that the mean transmitral
gradient, PAWP, and PAP should also be taken into consid-
eration. †There is controversy as to whether patients with
severe MS (MVA ,1.0 cm2) and severe pulmonary hyper-
tension (PAP .60–80 mm Hg) should undergo MVR to
prevent right ventricular failure.
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Recommendations for Cardiac Catheterization in Mitral Stenosis
Indication Class
1. Perform percutaneous mitral balloon valvotomy in
properly selected patients.
I
2. Assess severity of MR in patients being considered for
percutaneous mitral balloon valvotomy when clinical and
echocardiographic data are discordant.
IIa
3. Assess pulmonary artery, left atrial, and LV diastolic
pressures when symptoms and/or estimated pulmonary
artery pressure are discordant with the severity of MS by
2-D and Doppler echocardiography.
IIa
4. Assess hemodynamic response of pulmonary artery and
left atrial pressures to stress when clinical symptoms and
resting hemodynamics are discordant.
IIa
5. Assess mitral valve hemodynamics when 2-D and Doppler
echocardiographic data are concordant with clinical
findings.
III
4. Indications for Surgical or Percutaneous Valvotomy.
The concept of mitral commissurotomy was first proposed by
Brunton in 1902, and the first successful surgical mitral com-
missurotomy was performed in the 1920s. By the late 1940s and
1950s, both transatrial and transventricular closed surgical
commissurotomy were accepted clinical procedures. With the
development of cardiopulmonary bypass in the 1960s, open
mitral commissurotomy and replacement of the mitral valve
became the surgical procedures of choice for the treatment of
MS. Percutaneous mitral balloon valvotomy emerged in the
mid 1980s. This procedure, in which one or more large
balloons is inflated across the mitral valve by a catheter-based
approach, has become an accepted alternative to surgical
approaches in selected patients.
The mechanism of improvement from surgical commissur-
otomy or percutaneous valvotomy is related to the successful
opening of commissures that were fused by the rheumatic
process. This results in a decrease in gradient and increase in
the calculated mitral valve area, with resulting improvement in
clinical symptomatology. The extent of hemodynamic and
clinical improvement is dependent on the underlying morphol-
ogy of the mitral valve apparatus. Patients with pliable, non-
calcified valves and minimal fusion of the subvalvular appara-
tus achieve the best immediate and long-term results.
Closed surgical commissurotomy with either a transatrial or
transventricular approach was popularized in the 1950s and
1960s. Early and long-term postoperative follow-up studies
showed that patients had a significant improvement in symp-
toms and survival compared with those treated medically
(310–312). Closed commissurotomy remains the surgical tech-
nique of choice in many developing countries. Open commis-
surotomy has now become the accepted surgical procedure in
Figure 5. Management strategy for patients
with mitral stenosis and moderate to severe
symptoms. Abbreviations: CXR 5 chest x-ray,
LA 5 left atrial, MV 5 mitral valve, MVA 5
mitral valve area, PMBV 5 percutaneous mi-
tral balloon valvotomy; PAP 5 pulmonary
artery pressure; PAWP 5 pulmonary artery
wedge pressure. *The committee recognizes
that there may be variability in the measure-
ment of MVA and that the mean transmitral
gradient, PAWP, and PAP should also be
taken into consideration. †It is controversial as
to which patients with less favorable valve
morphology should undergo PMBV rather
than mitral valve surgery (see text).
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most institutions in the United States (313–316), because it
allows direct inspection of the mitral valve apparatus and,
under direct vision, division of the commissures, splitting of
fused chordae tendineae and papillary muscles, and debride-
ment of calcium deposits. Amputation of the left atrial ap-
pendage is recommended to reduce the likelihood of postop-
erative thromboembolic events (317). The results of the
operation are dependent on the morphology of the mitral valve
apparatus and the surgeon’s skill and experience. In patients
with marked deformity of the mitral valve apparatus, a decision
for MVR can be made at the time of operation. The risk of
operation is between 1% and 3%, depending on the concom-
itant medical status of the patient (313–316). Although there is
an inherent bias in the large reported surgical series, the 5-year
reoperation rate is 4% to 7% and the 5-year complication-free
survival rate ranges from 80% to 90%.
Percutaneous mitral balloon valvotomy was first performed
in the mid 1980s and became a clinically approved technique in
1994. In the past decade, there have been major advances in
techniques and equipment as well as changes in patient
selection. A double balloon technique was the initial procedure
used by most investigators. Today, an hourglass-shaped single
balloon (Inoue balloon) is used by most centers performing the
technique. The procedure itself is technically challenging and
involves a steep learning curve. There is a higher success rate
and lower complication rate in experienced high-volume cen-
ters (318). Thus, the results of the procedure are highly
dependent on the experience of the operators involved, which
must be considered when making recommendations for pro-
ceeding with this technique.
The immediate results of percutaneous mitral valvotomy
are similar to those of mitral commissurotomy (318–323). The
mean valve area usually doubles (from 1.0 cm2 to 2.0 cm2), with
a 50% to 60% reduction in transmitral gradient. Overall, 80%
to 95% of patients may have a successful procedure, which is
defined as a mitral valve area .1.5 cm2 and a decrease in left
atrial pressure to ,218 mm Hg in the absence of complications.
The most common acute complications reported in large series
include severe MR, which occurs in 2% to 10%, and a residual
atrial septal defect. A large atrial septal defect (.1.5:1 left-to-
right shunt) occurs in ,212% of patients with the double
balloon technique and ,5% with the Inoue balloon technique.
Smaller atrial septal defects may be detected by transesopha-
geal echocardiography in larger numbers of patients. Less
frequent complications include perforation of the left ventricle
(0.5% to 4.0%), embolic events (0.5% to 3%), and myocardial
infarction (0.3% to 0.5%). The mortality of balloon valvotomy
in larger series has ranged from 1% to 2% (318–321); however,
with increasing experience with the procedure, percutaneous
mitral valvotomy can be done in selected patients with a
mortality of ,1% (322).
Follow-up information after percutaneous balloon valvot-
omy is limited. Event-free survival (freedom from death,
repeat valvotomy, or MVR) overall is 50% to 65% over 3 to 7
years, with an event-free survival of 80% to 90% in patients
with favorable mitral valve morphology (280,320,322–324).
More than 90% of patients free of events remain in NYHA
functional Class I or II after percutaneous mitral valvotomy.
Randomized trials have compared percutaneous balloon val-
votomy with both closed and open surgical commissurotomy
(325–329). These trials, summarized in Table 16, consisted of
younger patients (aged 10 to 30 years) with pliable mitral valve
leaflets. There was no significant difference in acute hemody-
namic results or complication rate between percutaneous
mitral valvotomy and surgery, and early follow-up data indicate
no difference in hemodynamics, clinical improvement, or ex-
ercise time. However, longer-term follow-up studies at 3 to 7
years (327,329) indicate more favorable hemodynamic and
symptomatic results with percutaneous balloon valvotomy than
with closed commissurotomy and results equivalent to those of
open commissurotomy.
The immediate results, acute complications, and follow-up
results of percutaneous balloon valvotomy are dependent on
multiple factors. It is of utmost importance that this procedure
be performed in centers with skilled and experienced opera-
tors. Other factors include age, NYHA functional class, steno-
sis severity, LV end-diastolic pressure, cardiac output, and
pulmonary artery wedge pressure (320,322,323). The underly-
ing mitral valve morphology is the factor of greatest impor-
tance in determining outcome (277–280,320,323,324,330), and
immediate post-valvotomy hemodynamics are predictive of
long-term clinical outcome (322). Patients with valvular calci-
fication, thickened fibrotic leaflets with decreased mobility,
and subvalvular fusion have a higher incidence of acute
complications and a higher rate of recurrent stenosis on
follow-up (Table 17). Because the success of the procedure
is dependent on the ability to split fused commissures, the
presence of marked fusion and severe calcification of com-
missures is associated with an increased complication rate
and higher incidence of recurrent symptoms (279,280).
Alternatively, in patients with noncalcified pliable valves
and no calcium in the commissures, the procedure can be
performed with a high success rate (.90%), low complica-
tion rate (,3%), and sustained improvement in 80% to 90%
over a 3- to 7-year follow-up period (280,320,322,324).
Relative contraindications to percutaneous balloon valvot-
omy include the presence of a left atrial thrombus and
significant (31 to 41) MR. Transesophageal echocardiogra-
phy is frequently performed before the procedure to determine
the presence of left atrial thrombus, specifically examining the
left atrial appendage. If a thrombus is found, 3 months of
anticoagulation with warfarin may result in resolution of the
thrombus.
In centers with skilled, experienced operators, percutane-
ous balloon valvotomy should be considered the initial proce-
dure of choice for symptomatic patients with moderate to
severe MS who have a favorable valve morphology in the
absence of significant MR or left atrial thrombus. In asymp-
tomatic patients with a favorable valve morphology, percuta-
neous mitral valvotomy may be considered if there is evidence
of a hemodynamic effect on left atrial pressure (new-onset
atrial fibrillation) or pulmonary circulation (pulmonary artery
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pressure .50 mm Hg at rest or .60 mm Hg with exercise);
the strength of evidence for this recommendation is low
because there are no data comparing the results of percu-
taneous balloon valvotomy and those of medical therapy in
such asymptomatic patients. It is controversial whether
severely symptomatic patients with less favorable valve
morphology should undergo this catheter-based procedure
(331) (see Figure 5). Although there is a higher acute
complication rate and a lower event-free survival rate
('50% at 5 years in these patients, compared with 80% to
90% in patients with favorable valve morphology), this must
be weighed against the risks and potential complications of
surgical MVR.
Patients who are being considered for an intervention
should undergo evaluation with a history, physical examina-
tion, and 2-D and Doppler echocardiographic examination.
The appearance and mobility of the mitral valve apparatus and
commissures should be evaluated by 2-D echocardiography,
and the transmitral gradient, mitral valve area, and pulmonary
artery pressure should be obtained from the Doppler exami-
nation. If there is a discrepancy between symptoms and
hemodynamics, a formal hemodynamic exercise test may be
performed. Patients thought to be candidates for percutaneous
mitral valvotomy should undergo transesophageal echocardi-
ography to rule out left atrial thrombus and to examine the
severity of MR. If a left atrial thrombus is present, a repeat
transesophageal echocardiogram can be performed after sev-
eral months of anticoagulation. Percutaneous mitral balloon
valvotomy may be safely performed if there has been resolu-
tion of the thrombus. If there is a suspicion that the severity of
MR is 31 or 41 based on the physical examination and/or
echocardiogram, a left ventriculogram should be performed.
Mitral balloon valvotomy should not be performed in patients
who have grade 31 or 41 MR. Percutaneous mitral balloon
valvotomy should be performed only by skilled operators at
institutions with extensive experience in performing the tech-
nique (318,321). Thus, the decision to proceed with percuta-
neous balloon valvotomy or surgical commissurotomy is de-
pendent on the experience of the operator and institution. Due
to the less invasive nature of percutaneous balloon valvotomy
compared with surgical intervention, appropriate patients
without symptoms or those with NYHA functional Class II
symptoms may be considered for catheter-based therapy (Fig-
ures 3 and 4).
Table 16. Randomized Trials of Percutaneous Mitral Balloon Valvotomy and Surgical Commissurotomy
Study, year
Mean
follow-up Procedure
Number of
patients Age
Average
score
Mitral gradient MVA
Restenosis
Freedom
from
reintervention
NYHA
FC IPre Post Pre Post
Patel et al 1991 (325) Immediate PMBV 23 30 6 11 6.0 12 6 4 4 6 3 0.8 6 0.3 2.1 6 0.7* — — 91%
CC 22 26 6 26 6.0 12 6 5 6 6 4 0.7 6 0.2 1.3 6 0.3 — — —
Turi et al 1991 (328) 7 mo PMBV 20 27 6 8 7.2 18 6 4 10 6 2 0.8 6 0.2 1.6 6 0.2 — — —
CC 20 28 6 1 8.4 20 6 6 12 6 2 0.9 6 0.4 1.7 6 0.2 — — —
Arora et al 1993 22 mo PMBV 100 19 6 5 — — — 0.8 6 0.3 2.3 6 0.1 5% — —
(326) CC 100 20 6 6 — — — 0.8 6 0.2 2.1 6 0.4 4%
Reyes et al 1994 3 y PMBV 30 30 6 9 6.7 — — 0.9 6 0.3 2.4 6 0.6* 10% — 72%
(327) OC 30 31 6 9 7.0 — — 0.9 6 0.3 1.8 6 0.4 13% — 57%
Ben Farhat et al 1998 7 y PMBV 30 29 6 12 6.0 — — 0.9 6 0.2 1.8 6 0.4 — 90% 87%
(329) OC 30 27 6 9 6.0 — — 0.9 6 0.2 1.8 6 0.3 — 93% 90%
CC 30 28 6 10 6.0 — — 0.9 6 0.2 1.3 6 0.3 — 50% 33%
Abbreviations: CC 5 closed commissurotomy, FC 5 functional class, MVA 5 mitral valve area, NYHA 5 New York Heart Association, OC 5 open
commissurotomy, PMBV 5 percutaneous mitral balloon valvotomy. *Significant difference (P , 0.05) in increased MVA by PMBV compared with surgical
commissurotomy.
Table 17. Echocardiographic Prediction of Outcome of Percutaneous Mitral Balloon Valvotomy
Study, year
Mean
follow-up, mo
Echo
criteria
Number of
patients Age Survival
Survival free
of events Events
Cohen et al 1992 (320) 36 6 20 score ,28 84 — — 68% at 5 y Death, MVR, repeat PMBV
score .8 52 — — 28% at 5 y
Palacios et al 1995 (324) 20 6 12 score ,28 211 48 6 14 98% at 4 y 98% at 4 y Death, MVR, NYHA FC III–IV symptoms
score .8 116 64 6 11 72% at 4 y 39% at 4 y
Dean et al 1996 (323) 38 6 16 score ,8 272 49 6 13 95% at 4 y — Death
score 8–12 306 58 6 15 83% at 4 y —
score .12 24 58 6 15 24% at 4 y —
Cannan et al 1997 (280) 22 6 10 Com Ca2 120 — — 86% at 3 y Death, MVR, repeat PMBV
Com Ca1 29 — — 40% at 3 y
Abbreviations: Com Ca 5 commissural calcification, echo 5 echocardiographic, FC 5 functional class, MVR 5 mitral valve replacement, NYHA 5 New York
Heart Association, PMBV 5 percutaneous mitral balloon valvotomy.
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Recommendations for Percutaneous Mitral Balloon Valvotomy
Indication Class
1. Symptomatic patients (NYHA functional Class II, III, or
IV), moderate or severe MS (mitral valve area <21.5 cm
2),*
and valve morphology favorable for percutaneous balloon
valvotomy in the absence of left atrial thrombus or
moderate to severe MR.
I
2. Asymptomatic patients with moderate or severe MS (mitral
valve area <21.5 cm
2)* and valve morphology favorable for
percutaneous balloon valvotomy who have pulmonary
hypertension (pulmonary artery systolic pressure
>50 mm Hg at rest or 60 mm Hg with exercise) in the
absence of left atrial thrombus or moderate to severe MR.
IIa
3. Patients with NYHA functional Class III-IV symptoms,
moderate or severe MS (mitral valve area <21.5 cm
2),* and
a nonpliable calcified valve who are at high risk for surgery
in the absence of left atrial thrombus or moderate to severe
MR.
IIa
4. Asymptomatic patients, moderate or severe MS (mitral valve
area <21.5 cm
2)* and valve morphology favorable for
percutaneous balloon valvotomy who have new onset of
atrial fibrillation in the absence of left atrial thrombus or
moderate to severe MR.
IIb
5. Patients in NYHA functional Class III-IV, moderate or
severe MS (MVA <21.5 cm
2), and a nonpliable calcified valve
who are low-risk candidates for surgery.
IIb
6. Patients with mild MS. III
*The committee recognizes that there may be variability in the measurement
of mitral valve area and that the mean transmitral gradient, pulmonary artery
wedge pressure, and pulmonary artery pressure at rest or during exercise should
also be taken into consideration.
Recommendations for Mitral Valve Repair for Mitral Stenosis
Indication Class
1. Patients with NYHA functional Class III-IV symptoms,
moderate or severe MS (mitral valve area <21.5 cm
2),*
and valve morphology favorable for repair if
percutaneous mitral balloon valvotomy is not available.
I
2. Patients with NYHA functional Class III-IV symptoms,
moderate or severe MS (mitral valve area <21.5 cm
2),*
and valve morphology favorable for repair if a left
atrial thrombus is present despite anticoagulation.
I
3. Patients with NYHA functional Class III-IV symptoms,
moderate or severe MS (mitral valve area <21.5 cm
2),*
and a nonpliable or calcified valve with the decision to
proceed with either repair or replacement made at the
time of the operation.
I
4. Patients in NYHA functional Class I, moderate or
severe MS (mitral valve area <21.5 cm
2),* and valve
morphology favorable for repair who have had
recurrent episodes of embolic events on adequate
anticoagulation.
IIb
5. Patients with NYHA functional Class I-IV symptoms
and mild MS.
III
*The committee recognizes that there may be a variability in the measure-
ment of mitral valve area and that the mean transmitral gradient, pulmonary
artery wedge pressure, and pulmonary artery pressure at rest or during exercise
should also be considered.
5. Indications for Mitral Valve Replacement. MVR is an
accepted surgical procedure for patients with severe MS who
are not candidates for surgical commissurotomy or percutane-
ous mitral valvotomy. The risk of MVR is dependent on
multiple factors, including functional status, age, LV function,
cardiac output, concomitant medical problems, and concomi-
tant CAD. In the young, healthy person, MVR can be per-
formed with a risk of ,5%. However, in the older patient with
concomitant medical problems or pulmonary hypertension at
systemic levels, the risk of MVR may be as high as 10% to
20%. Complications of MVR include valve thrombosis, valve
dehiscence, valve infection, valve malfunction, and embolic
events. These are discussed in detail in section VII of these
guidelines. There is also the known risk of long-term antico-
agulation.
If there is significant calcification, fibrosis, and subvalvular
fusion of the mitral valve apparatus, commissurotomy or
percutaneous balloon valvotomy is less likely to be successful,
and MVR will be necessary. Given the risk of MVR and the
potential long-term complications of a prosthetic valve, there
are stricter indications for mitral valve operation in these
patients with calcified fibrotic valves. In the patient with
NYHA functional Class III symptoms due to severe MS or
combined MS/MR, MVR results in excellent symptomatic
improvement. Postponement of surgery until the patient
reaches the functional Class IV symptomatic state should be
avoided because operative mortality is high and long-term
outcome is suboptimal. However, if the patient presents in
NYHA functional Class IV heart failure, surgery should not be
denied because the outlook without surgical intervention is
grave. It is controversial whether asymptomatic or mildly
symptomatic patients with severe MS (valve area ,1 cm2) and
severe pulmonary hypertension (pulmonary artery systolic
pressure .60 to 80 mm Hg) should undergo MVR to prevent
right ventricular failure, but surgery is generally recommended
in such patients. It is recognized that patients with such severe
pulmonary hypertension are rarely asymptomatic.
Recommendations for Mitral Valve Replacement for Mitral Stenosis
Indication Class
1. Patients with moderate or severe MS (mitral valve area
<21.5 cm
2)* and NYHA functional Class III-IV symptoms
who are not considered candidates for percutaneous balloon
valvotomy or mitral valve repair.
I
2. Patients with severe MS (mitral valve area <21 cm
2)* and
severe pulmonary hypertension (pulmonary artery systolic
pressure >60 to 80 mm Hg) with NYHA functional Class
I-II symptoms who are not considered candidates for
percutaneous balloon valvotomy or mitral valve repair.
IIa
*The committee recognizes that there may be a variability in the measure-
ment of mitral valve area and that the mean transmitral gradient, pulmonary
artery wedge pressure, and pulmonary artery pressure should also be consid-
ered.
6. Management of Patients After Valvotomy or Commis-
surotomy. Symptomatic improvement occurs immediately af-
ter successful percutaneous balloon valvotomy or surgical
commissurotomy, although objective measurement of maxi-
mum oxygen consumption may continue to improve over
several months postoperatively due to slowly progressive im-
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provement in skeletal muscle metabolism (332). Hemody-
namic measurements before and after either percutaneous
valvotomy or surgical commissurotomy have confirmed a de-
crease in left atrial pressure, pulmonary artery pressure, and
pulmonary arteriolar resistance and an improvement in cardiac
output (333–336). Gradual regression of pulmonary hyperten-
sion over months has been demonstrated (333,334,336).
Recurrent symptoms after successful surgical commissurot-
omy have been reported to occur in as many as 60% of patients
after 9 years (285,310,337). However, recurrent stenosis ac-
counts for symptoms in ,20% of patients (337). In patients
with an adequate initial result, progressive MR and develop-
ment of other valvular or coronary problems are more fre-
quently responsible for recurrent symptoms (337). Thus, in
patients presenting with symptoms late after commissurotomy,
a comprehensive evaluation is required to look for other
causes. Patients undergoing percutaneous mitral valvotomy
have a higher incidence of recurrent symptoms at 1- to 2-year
follow-up if there was an unfavorable mitral valve morphology,
due to either an initial inadequate result or restenosis (338).
The management of patients after successful percutaneous
balloon valvotomy or surgical commissurotomy is similar to
that of the asymptomatic patient with MS. A baseline echo-
cardiogram should be performed after the procedure to obtain
a baseline measurement of postoperative hemodynamics as
well as to exclude significant complications such as MR, LV
dysfunction, or atrial septal defect (in the case of percutaneous
valvotomy). This echocardiogram should be performed at least
72 hours after the procedure because acute changes in atrial
and ventricular compliance immediately after the procedure
affect the reliability of the half-time in calculation of valve area
(282,283). Patients with severe MR or a large atrial septal
defect should be considered for early operation. However, the
majority of small left-to-right shunts at the atrial level will close
spontaneously over the course of 6 months. In patients with a
history of atrial fibrillation, warfarin should be restarted 1 to 2
days after the procedure.
A history, physical examination, chest x-ray, and ECG
should be obtained at yearly intervals in the patient who
remains asymptomatic or minimally symptomatic. Prophylaxis
against infective endocarditis and recurrence of rheumatic
fever should be followed. If the patient is in atrial fibrillation or
has a history of atrial fibrillation, anticoagulation is recom-
mended, as would be the case for all patients with MS. With
recurrent symptoms, extensive 2-D and Doppler echocardiog-
raphy should be performed to evaluate the mitral valve hemo-
dynamics and pulmonary artery pressure as well as to rule out
significant MR or a left-to-right shunt. As with all patients with
MS, exercise hemodynamics may be indicated in the patient
with a discrepancy in clinical and hemodynamic findings.
Repeat percutaneous balloon valvotomy can be performed
in the patient in whom there is restenosis after either a prior
surgical commissurotomy or balloon valvotomy (277,339). The
results of these procedures are less satisfactory than the overall
results of initial valvotomy because there is usually more valve
deformity, calcification, and fibrosis than with the initial pro-
cedure (277,339). MVR should be considered in those patients
with recurrent severe symptoms and severe deformity of the
mitral apparatus.
7. Special Considerations. a. Pregnant Patients. MS often
affects young women who are in their childbearing years. The
increased intravascular volume, increased cardiac output, and
tachycardia associated with pregnancy may raise complex
issues in the patient with MS and are reviewed in section V of
these guidelines.
b. Older Patients. An increasing number of older patients
now present with symptomatic MS, most likely due to a change
in the natural history of the disease (269,270). Older patients
are more likely to have heavy calcification and fibrosis of the
mitral valve leaflets, with significant subvalvular fusion. In
patients older than 65, the success rate of percutaneous
valvotomy is lower (,50%) than in prior reports of younger
patients. Procedural mortality is 3%, and there is an increased
risk of complications, including pericardial tamponade in 5%
and thromboembolism in 3%. However, in selected patients
with favorable valve morphology, the procedure may be done
safely with good intermediate-term results (270).
D. Mitral Valve Prolapse
1. Pathophysiology and Natural History. MVP refers to a
systolic billowing of one or both mitral leaflets into the left
atrium with or without MR. It is the most common form of
valvular heart disease and occurs in 2% to 6% of the popula-
tion. MVP often occurs as a clinical entity with little or no MR
but is also the most common cause of significant MR in the
United States. MR stemming from MVP is frequently associ-
ated with unique clinical characteristics when compared with
other causes of MR (340,341).
The mitral valve apparatus is a complex structure composed
of the mitral annulus; valve leaflets; chordae tendineae; pap-
illary muscles; and the supporting LV, left atrial, and aortic
walls (342). Disease processes involving any of these compo-
nents may result in dysfunction of the valve apparatus and
prolapse of the mitral leaflets toward the left atrium during
systole, when LV pressure exceeds left atrial pressure. A
classification of MVP is shown in Table 18 (343,344).
In primary MVP, there is interchordal hooding due to
leaflet redundancy that includes both the rough and clear
zones of the involved leaflets (345). The height of the inter-
chordal hooding is usually .4 mm and involves at least one
half of the anterior leaflet or two thirds of the posterior leaflet.
The basic microscopic feature of primary MVP is marked
proliferation of the spongiosa, the delicate myxomatous con-
nective tissue between the atrialis (a thick layer of collagen and
elastic tissue forming the atrial aspect of the leaflet) and the
fibrosa or ventricularis (dense layers of collagen that form the
basic support of the leaflet). In primary MVP, myxomatous
proliferation of the acid mucopolysaccharide-containing spon-
giosa tissue causes focal interruption of the fibrosa. Secondary
effects of the primary MVP syndrome include fibrosis of the
surfaces of the mitral valve leaflets, thinning and/or elongation
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of chordae tendineae, and ventricular friction lesions. Fibrin
deposits often form at the mitral valve–left atrial angle.
The primary form of MVP usually occurs as isolated cases
but may be familial and transmitted as an autosomal dominant
trait (346,347). It occurs with increased frequency in patients
with Marfan syndrome and in other connective tissue diseases
(345,348–350). It has been speculated that the primary MVP
syndrome represents a generalized disease of connective tis-
sue. Thoracic skeletal abnormalities such as a straight thoracic
spine and pectus excavatum are commonly associated with
MVP (351). The increased incidence of primary MVP in
patients with von Willebrand’s disease and other coagulopa-
thies, primary hypomastia, and various connective tissue dis-
eases has been used to support the concept that MVP is a
result of defective embryogenesis of cell lines of mesenchymal
origin (352).
Secondary forms of MVP occur in which myxomatous
proliferation of the spongiosa portion of the mitral valve leaflet
is absent. Serial studies in patients with known ischemic heart
disease have occasionally documented unequivocal MVP after
an acute coronary syndrome that was previously absent (353–
355). In most patients with CAD and MVP, however, the 2
entities are coincident but unrelated.
Several recent studies indicate that valvular regurgitation
caused by MVP may result from postinflammatory changes,
including those after rheumatic fever (356–358). In histologi-
cal studies of surgically excised valves, fibrosis with vascular-
ization and scattered infiltration of round cells including
lymphocytes and plasmacytes were found without myxomatous
proliferation of the spongiosa. With rheumatic carditis the
anterior mitral leaflet is more likely to prolapse.
MVP has been observed in patients with hypertrophic
cardiomyopathy in whom posterior MVP may result from a
disproportionally small LV cavity, altered papillary muscle
alignment, or a combination of factors (359). The mitral valve
leaflet is usually normal. MVP may occur secondary to rup-
tured chordae tendineae as a “flail” or partial flail mitral
leaflet, whether spontaneous or due to infective endocarditis.
Patients with primary and secondary MVP must be distin-
guished from normal variants by cardiac auscultation and/or
echocardiography; these variations can result in an incorrect
diagnosis of MVP, particularly in patients whose hearts are
hyperkinetic or who are dehydrated (360). Other auscultatory
findings may be misinterpreted as midsystolic clicks or late
systolic murmurs. Patients with mild to moderate billowing of
one or both nonthickened leaflet(s) toward the left atrium with
the leaflet coaptation point on the LV side of the mitral
annulus and with minimal or no MR by Doppler echocardiog-
raphy are probably normal (361). Unfortunately, many such
patients are overdiagnosed as having the MVP syndrome.
In patients with MVP, there may be left atrial dilatation and
LV enlargement, depending on the presence and severity of
MR. The supporting apparatus is often involved, and in
patients with connective tissue syndromes such as Marfan
syndrome, the mitral annulus is usually dilated and sometimes
calcified and does not decrease its circumference by the usual
30% during LV systole.
Many studies suggest autonomic nervous system dysfunc-
tion in many patients with primary MVP. In several studies,
measurements of serum and 24-hour urine epinephrine or
norepinephrine levels were increased in patients with symp-
tomatic MVP compared with age-matched controls (362–365).
Tricuspid valve prolapse with similar interchordal hooding
and histological evidence of mucopolysaccharide proliferation
and collagen dissolution occurs in '40% of patients with MVP
(346). Pulmonic valve prolapse and aortic valve prolapse occur
in '10% and 2% of patients with MVP, respectively (345).
There is an increased incidence of secundum atrial septal
defect in patients with MVP as well as an increased incidence
of left-sided atrioventricular bypass tracts and supraventricular
arrhythmias (345).
In most patient studies, the MVP syndrome is associated
with a benign prognosis (366,367). The age-adjusted survival
rate of both men and women with MVP is similar to that of
individuals without this common clinical entity (346). The
gradual progression of MR in patients with MVP may result in
the progressive dilatation of the left atrium and ventricle. Left
atrial dilatation may result in atrial fibrillation, and moderate
to severe MR may eventually result in LV dysfunction and
development of congestive heart failure (340). Pulmonary
hypertension may occur with associated right ventricular dys-
function. In some patients, after an initially prolonged asymp-
tomatic interval, the entire process may enter an accelerated
phase as a result of left atrial and LV dysfunction, atrial
fibrillation, and in certain instances ruptured mitral valve
chordae (340).
Several long-term prognostic studies suggest that complica-
Table 18. Classification of Mitral Valve Prolapse
Primary MVP
Familial
Nonfamilial
Marfan’s syndrome
Other connective tissue diseases
Secondary MVP
CAD
Rheumatic heart disease
Reduced LV dimensions*
Hypertrophic cardiomyopathy
Atrial septal defect
Pulmonary hypertension
Anorexia nervosa
Dehydration
Straight-back syndrome/pectus excavatum
“Flail” mitral valve leaflet(s)
Normal variant
Inaccurate auscultation
“Echocardiographic heart disease”
Adapted from O’Rourke RA (343). The mitral valve prolapse syndrome. In:
Chizner MA, ed. Classic Teachings in Clinical Cardiology: A Tribute to W Proctor
Harvey, M.D. New Jersey: Laennec Publ Co; 1996:1049–1070. *From Levine HJ,
Isner JM, Salem DN (344). Primary versus secondary mitral valve prolapse:
clinical features and implications. Clin Cardiol. 1982;5:371–375.
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tions occur most commonly in patients with a mitral systolic
murmur, those with thickened redundant mitral valve leaflets,
and those with increased LV or left atrial size, especially in
men older than 45 years (340,368–372).
Sudden death is a rare complication of MVP occurring in
,2% of known cases during long-term follow-up (366–373),
with annual mortality rates ,1% per year. The likely cause is
a ventricular tachyarrhythmia based on the finding of an
increased incidence of complex ventricular ectopy on ambula-
tory ECG recordings in patients with MVP who had sudden
cardiac death (374,375). Although infrequent, the highest
incidence of sudden death has been reported in the familial
form of MVP; some of these patients have also been noted to
have QT prolongation (340,376).
Infective endocarditis is a serious complication of MVP,
which is the leading predisposing cardiovascular diagnosis in
most series of patients reported with endocarditis
(340,350,377). Because the absolute incidence of endocarditis
is extremely low for the entire MVP population, there has been
much controversy about the risk of endocarditis in MVP (378).
As indicated above, progressive MR occurs frequently in
patients with long-standing MVP. Fibrin emboli are responsi-
ble in some patients for visual symptoms consistent with
involvement of the ophthalmic or posterior cerebral circulation
(379). Several studies have indicated an increased likelihood of
cerebrovascular accidents in patients under age 45 who have
MVP over what would have been expected in a similar
population without MVP (380).
2. Evaluation and Management of the Asymptomatic Pa-
tient. The diagnosis of MVP is most commonly made by
cardiac auscultation in asymptomatic patients or echocardiog-
raphy performed for another purpose. The patient may be
evaluated because of a family history of cardiac disease or
occasionally may be referred because of an abnormal resting
ECG.
The primary diagnostic evaluation of the patient with MVP
is a careful physical examination (340,381). The principal
cardiac auscultatory feature of this syndrome is the midsystolic
click, a high-pitched sound of short duration. One or more
clicks may vary considerably in intensity and timing in systole
according to LV loading conditions and contractility. Clicks
result from sudden tensing of the mitral valve apparatus as the
leaflets prolapse into the left atrium during systole. The
midsystolic click(s) is frequently followed by a late systolic
murmur, usually medium- to high-pitched and loudest at the
cardiac apex. Occasionally, the murmur has a musical or
honking quality. The character and intensity of the murmur
also vary under certain conditions, from brief and almost
inaudible to holosystolic and loud. Dynamic auscultation is
often useful for establishing the clinical diagnosis of the MVP
syndrome (381). Changes in LV end-diastolic volume result in
changes in the timing of the midsystolic click(s) and murmur.
When end-diastolic volume is decreased (such as with stand-
ing), the critical volume is achieved earlier in systole and the
click-murmur complex occurs shortly after the first heart
sound. By contrast, any maneuver that augments the volume of
blood in the ventricle (eg, squatting), reduces myocardial
contractility, or increases LV afterload lengthens the time from
onset of systole to initiation of MVP, and the systolic click
and/or murmur move toward the second heart sound.
Although the ECG may provide some information in
patients with MVP, it is most often normal. Nonspecific ST-T
wave changes, T-wave inversions, prominent U waves, and
prolongation of the QT interval also occur. Continuous ambu-
latory ECG recordings or event monitors may be useful for
documenting arrhythmias in patients with palpitations. They
are not indicated as a routine test for asymptomatic patients.
Most of the arrhythmias detected are not life-threatening, and
patients often complain of palpitations when the ambulatory
ECG recording shows no abnormalities.
Posterior-anterior and lateral chest roentgenograms usually
show normal cardiopulmonary findings. The skeletal abnor-
malities described above, such as pectus excavatum, are often
seen (351). When severe MR is present, both left atrial and LV
enlargement often result. Various degrees of pulmonary ve-
nous congestion are evident when left-heart failure results.
Calcification of the mitral annulus may be seen, particularly in
adults with Marfan syndrome (381). In asymptomatic patients
with MVP, a chest x-ray usually provides no additional infor-
mation.
2-D and Doppler echocardiography is the most useful
noninvasive test for defining MVP. The M-mode echocardio-
graphic definition of MVP includes .22 mm posterior displace-
ment of one or both leaflets or holosystolic posterior “ham-
mocking” .3 mm. On 2-D echocardiography, systolic
displacement of one or both mitral leaflets in the parasternal
long-axis view, particularly when they coapt on the atrial side
of the annular plane, indicates a high likelihood of MVP.
There is disagreement concerning the reliability of echocardio-
graphic diagnosis of MVP when observed in only the apical
4-chamber view (382,383). The diagnosis of MVP is even more
certain when the leaflet thickness is .5 mm. Leaflet redun-
dancy is often associated with an enlarged mitral annulus and
elongated chordae tendineae (340). On Doppler echocardiog-
raphy, the presence or absence of MR is an important consid-
eration, and MVP is more likely when MR is detected as a
high-velocity eccentric jet in late systole (361).
At present, there is no consensus on the 2-D echocardio-
graphic criteria for MVP. Because echocardiography is a
tomographic cross-sectional technique, no single view should
be considered diagnostic. The parasternal long-axis view per-
mits visualization of the medial aspect of the anterior mitral
leaflet and middle scallop of the posterior leaflet. If the
findings of prolapse are localized to the lateral scallop in the
posterior leaflet, they would be best visualized by the apical
4-chamber view. All available echocardiographic views should
be used with the provision that billowing of the anterior leaflet
alone in the 4-chamber apical view is not evidence of prolapse;
however, a displacement of the posterior leaflet or the coap-
tation point in any view, including the apical view, suggests the
diagnosis of prolapse. The echocardiographic criteria for MVP
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should include structural changes such as leaflet thickening,
redundancy, annular dilatation, and chordal elongation.
Patients with echocardiographic evidence for MVP but
without evidence of thickened/redundant leaflets or definite
MR are more difficult to classify. If such patients have clinical
auscultatory findings of MVP, then the echocardiogram usually
confirms the diagnosis.
Recommendations for Echocardiography in Mitral Valve Prolapse*
Indication Class
1. Diagnosis, assessment of hemodynamic severity of MR, leaflet
morphology, and ventricular compensation in patients with
physical signs of MVP.
I
2. To exclude MVP in patients who have been given the diagnosis
when there is no clinical evidence to support the diagnosis.
I
3. To exclude MVP in patients with first-degree relatives with
known myxomatous valve disease.
IIa
4. Risk stratification in patients with physical signs of MVP or
known MVP.
IIa
5. To exclude MVP in patients in the absence of physical findings
suggestive of MVP or a positive family history.
III
6. Routine repetition of echocardiography in patients with MVP
with mild or no regurgitation and no changes in clinical signs
or symptoms.
III
*From the ACC/AHA Guidelines for the Clinical Application of Echocardi-
ography (2).
Although the echocardiogram is a confirmatory test for
diagnosing MVP, it is not always abnormal. Nevertheless,
echocardiography is useful for defining left atrial size, LV size
and function, and the extent of mitral leaflet redundancy for
detecting patients at high risk for complications and for
detecting associated lesions such as secundum atrial septal
defect. Doppler echocardiography is helpful for detection and
semiquantitation of MR. Although there is controversy con-
cerning the need for echocardiography in patients with classic
auscultatory findings of MVP, the usefulness of echocardiog-
raphy for risk stratification in patients with MVP has been
demonstrated in .26 published studies (Table 19) (368,382,
384–387). All patients with MVP should have an initial
echocardiogram. Serial echocardiograms are not usually nec-
essary in the asymptomatic patient with MVP unless there are
clinical indications of severe or worsening MR.
The use of echocardiography as a screening test for MVP in
patients with and without symptoms who have no systolic click
or murmur on serial, carefully performed auscultatory exami-
nations is not recommended. The likelihood of finding a
prolapsing mitral valve in such patients is extremely low. Most
patients with or without symptoms who have a negative
dynamic cardiac auscultation and “mild MVP” by echocardi-
ography should not be diagnosed as having MVP.
Reassurance is a major part of the management of patients
with MVP, most of whom are asymptomatic or have no cardiac
symptoms and lack a high-risk profile. These patients with mild
or no symptoms and findings of milder forms of prolapse
should be reassured of the benign prognosis. A normal lifestyle
and regular exercise is encouraged (340,381).
Antibiotic prophylaxis for the prevention of infective endo-
carditis during procedures associated with bacteremia is rec-
ommended for most patients with a definite diagnosis of MVP
(388) as indicated in section II.B. of these guidelines. There
has been some disagreement concerning whether patients with
an isolated systolic click and no systolic murmur should
undergo endocarditis prophylaxis. Patients with only a systolic
click who have echocardiographic evidence of a higher-risk
profile for endocarditis, such as leaflet thickening, elongated
chordae, left atrial enlargement, or LV dilatation, should
receive endocarditis prophylaxis (368,382,384–387).
Recommendations for Antibiotic Endocarditis Prophylaxis for
Patients With Mitral Valve Prolapse Undergoing Procedures
Associated With Bacteremia*
Indication Class
1. Patients with characteristic systolic click-murmur complex. I
2. Patients with isolated systolic click and echocardiographic
evidence of MVP and MR.
I
3. Patients with isolated systolic click, echocardiographic
evidence of high-risk MVP.
IIa
4. Patients with isolated systolic click and equivocal or no
evidence of MVP.
III
*These procedures are listed in Tables 4 and 5.
3. Evaluation and Management of the Symptomatic Pa-
tient. Some patients consult their physicians about one or
more of the common symptoms that occur with this syndrome;
palpitations, often reported at a time when continuous ambu-
latory ECG recordings show no arrhythmias; atypical chest
pain that rarely resembles classic angina pectoris; dyspnea and
fatigue, when objective exercise testing often fails to show any
impairment in exercise tolerance; and neuropsychiatric com-
plaints, with many patients having panic attacks and similar
syndromes (340). Transient cerebral ischemic episodes occur
with increased incidence in patients with MVP, and some
patients develop stroke syndromes. Reports of amaurosis
fugax, homonymous field loss, and retinal artery occlusion have
been described; occasionally the visual loss persists (380,389–
391).
The roles of cardiac auscultation and echocardiography in
the assessment of symptomatic patients with MVP are the
same as for patients without symptoms. The indications for
antibiotic prophylaxis to prevent endocarditis are also un-
changed.
Patients with MVP and palpitations associated with mild
tachyarrhythmias or increased adrenergic symptoms and those
with chest pain, anxiety, or fatigue often respond to therapy
with b-blockers (392). In many cases, however, the cessation of
stimulants such as caffeine, alcohol, and cigarettes may be
sufficient to control symptoms. In patients with recurrent
palpitations, continuous or event-activated ambulatory ECG
recordings may reveal the presence or absence of arrhythmias
at the time of symptoms and indicate appropriate treatment of
existing arrhythmias. The indications for electrophysiological
testing are similar to those in the general population (eg,
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aborted sudden death, recurrent syncope of unknown cause,
and symptomatic or sustained ventricular tachycardia) (393).
Cardiac catheterization is not required for the diagnosis of
MVP. It is helpful in evaluating associated conditions (eg,
CAD and atrial septal defect) and may be needed to assess the
hemodynamic effects of severe MR (as well as coronary artery
anatomy) before consideration for valve repair or replacement.
Orthostatic symptoms due to postural hypotension and
tachycardia are best treated with volume expansion, preferably
by liberalizing fluid and salt intake. Mineralocorticoid therapy
or clonidine may be needed in severe cases, and wearing
support stockings may be beneficial.
Daily aspirin therapy (80 to 325 mg/d) is recommended for
MVP patients with documented focal neurological events who
are in sinus rhythm with no atrial thrombi. Such patients also
should avoid cigarettes and oral contraceptives. Long-term
anticoagulation therapy with warfarin is recommended for
post-stroke patients with MVP and MVP patients with recur-
rent transient ischemic attacks on aspirin therapy (INR 2 to 3).
In MVP patients with atrial fibrillation, warfarin therapy is
indicated in patients aged $65 years and those with MR,
hypertension, or a history of heart failure (INR 2 to 3). Aspirin
therapy is satisfactory in patients with atrial fibrillation who are
,65 years, have no MR, and have no history of hypertension or
heart failure (394,395). Daily aspirin therapy is often recom-
mended for patients with high-risk echocardiographic charac-
teristics.
Recommendations for Aspirin and Oral Anticoagulants in Mitral
Valve Prolapse
Indication Class
1. Aspirin therapy for cerebral transient ischemic attacks. I
2. Warfarin therapy for patients aged >265 years, in atrial
fibrillation with hypertension, MR murmur, or history of heart
failure.
I
3. Aspirin therapy for patients aged <65 years in atrial fibrillation
with no history of MR, hypertension, or heart failure.
I
4. Warfarin therapy for poststroke patients. I
5. Warfarin therapy for transient ischemic attacks despite aspirin
therapy.
IIa
6. Aspirin therapy for poststroke patients with contraindications to
anticoagulants.
IIa
7. Aspirin therapy for patients in sinus rhythm with
echocardiographic evidence of high-risk MVP.
IIb
A normal lifestyle and regular exercise are encouraged for
most patients with MVP, especially those who are asymptom-
atic (370,396). Restriction from competitive sports is recom-
mended when moderate LV enlargement, LV dysfunction,
uncontrolled tachyarrhythmias, long QT interval, unexplained
syncope, prior sudden death, or aortic root enlargement is
present individually or in combination (340). A familial occur-
rence of MVP should be explained to the patient and is
particularly important in those with associated disease who are
at greater risk for complications. There is no contraindication
to pregnancy based on the diagnosis of MVP alone.
Asymptomatic patients with MVP and no significant MR
can be evaluated clinically every 3 to 5 years. Serial echocar-
diography is not necessary in most patients and is obtained
only in patients who have high-risk characteristics on the initial
echocardiogram and those who develop symptoms consistent
with cardiovascular disease or have a change in physical
findings suggesting development of significant MR. Patients
who have high-risk characteristics, including those with mod-
erate to severe MR, should be followed once a year.
Patients with severe MR with symptoms and/or impaired
LV systolic function require cardiac catheterization and eval-
uation for mitral valve surgery. The thickened, redundant
mitral valve can often be repaired rather than replaced with a
low operative mortality and excellent short- and long-term
results (391–393,397,398). Follow-up studies also suggest lower
thrombotic and endocarditis risk with valve repair than with
prosthetic valves.
4. Surgical Considerations. Management of MVP may
require valve surgery, particularly in those patients who de-
velop a flail mitral leaflet due to rupture of chordae tendineae
Table 19. Use of Echocardiography for Risk Stratification in Mitral Valve Prolapse
Study, year
Number of
patients Features examined Outcome P value
Nishimura et al 1985 (368) 237 MV leaflet .25 mm 1 sum of sudden death, endocarditis, and cerebral embolus P , 0.02
LVID .260 mm 1 MVR (26% vs 3.1%) P , 0.001
Zuppiroli et al 1994 (384) 119 MV leaflet .5 mm 1 complex ventricular arrhythmia P , 0.001
Babuty et al 1994 (385) 58 undefined MV thickening no relation to complex ventricular arrhythmias NS
Takamoto et al 1991 (386) 142 MV leaflet .23 mm, redundant,
low echo density
1 ruptured chordae (48% vs 5%)
Marks et al 1989 (382) 456 MV leaflet .25 mm 1 endocarditis (3.5% vs 0%) P , 0.02
1 moderate-severe MR (11.9% vs 0%) P , 0.001
1 MVR (6.6% vs 0.7%) P , 0.02
1 stroke (7.5% vs 5.8%) NS
Chandraratna et al 1984 (387) 86 MV leaflets .5.1 mm 1 cardiovascular abnormalities (60% vs 6%) (Marfan
syndrome, TVP, MR, dilated ascending aorta)
P , 0.001
Abbreviations: MV 5 mitral valve, LVID 5 left ventricular internal diameter, MVR 5 mitral valve replacement, MR 5 mitral regurgitation, TVP 5 tricuspid valve
prolapse. From the ACC/AHA Guidelines for the Clinical Application of Echocardiography (2).
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or their marked elongation. Most such valves can be repaired
successfully by surgeons experienced in mitral valve repair,
especially when the posterior leaflet of the mitral valve is
predominantly affected. Symptoms of heart failure, severity of
MR, presence or absence of atrial fibrillation, LV systolic
function, LV end-diastolic and end-systolic volumes, and pul-
monary artery pressure (rest and exercise) all influence the
decision to recommend mitral valve surgery. Recommenda-
tions for surgery in patients with MVP and MR are the same
as for those with other forms of nonischemic severe MR, as
indicated in section III.E.4. of these guidelines.
E. Mitral Regurgitation
1. Etiology. The common etiologies for MR include MVP
syndrome, rheumatic heart disease, CAD, infective endocardi-
tis, and collagen vascular disease. Recently, anorectic drugs
have also been reported to cause MR (see section III.H. of
these guidelines). In some cases, such as ruptured chordae
tendineae or infective endocarditis, MR may be acute and
severe. Alternatively, MR may worsen gradually over a pro-
longed period of time. These 2 ends of the spectrum have quite
different clinical presentations.
2. Acute Severe Mitral Regurgitation.
a. Pathophysiology. In acute severe MR, a sudden volume
overload is imposed on the left ventricle. Acute volume
overload increases LV preload, allowing for a modest increase
in total LV stroke volume (399). However, in the absence of
compensatory eccentric hypertrophy (which has had no time to
develop), forward stroke volume and cardiac output are re-
duced. At the same time, the unprepared left atrium and left
ventricle cannot accommodate the regurgitant volume, result-
ing in pulmonary congestion. In this phase of the disease, the
patient has both reduced forward output (even shock) and
simultaneous pulmonary congestion. In severe MR, the hemo-
dynamic overload often cannot be tolerated, and mitral valve
repair or replacement must often be performed urgently.
b. Diagnosis. The patient with acute severe MR is almost
always symptomatic. Physical examination of the precordium
may be misleading because a normal-sized left ventricle does
not produce a hyperdynamic apical impulse. The systolic
murmur of MR, which may or may not be holosystolic, and a
third heart sound may be the only abnormal physical findings
present. A fourth heart sound is also common in acute MR
because the patient is usually still in sinus rhythm. Trans-
thoracic echocardiography may demonstrate the disruption of
the mitral valve and help provide semiquantitative information
on lesion severity. However, transthoracic echocardiography
may underestimate lesion severity by inadequate imaging of
the color flow jet. Because transesophageal echocardiography
can more accurately assess the color flow jet (400), transesoph-
ageal imaging should be performed if mitral valve morphology
and regurgitant severity are still in question after transthoracic
echocardiography. Transesophageal echocardiography is also
helpful in demonstrating the anatomic cause of MR and
directing successful surgical repair. Indeed, assessment of valve
anatomy is a major goal of transesophageal imaging.
If ischemia is not the cause of MR and there is no reason to
suspect CAD, mitral valve repair can usually be performed
without the need for cardiac catheterization. However, if CAD
is suspected or there are risk factors for CAD (see Section
VIII. B.), coronary arteriography is necessary before surgery
because myocardial revascularization should be performed
during mitral valve surgery in those patients with concomitant
CAD (401,402).
c. Medical Therapy. In acute severe MR, the goal of
nonsurgical therapy is to diminish the amount of MR, in turn
increasing forward output and reducing pulmonary congestion.
In the normotensive patient, administration of nitroprusside
may effectively accomplish all 3 goals. Nitroprusside increases
forward output not only by preferentially increasing aortic flow
but also by partially restoring mitral valve competence as LV
size diminishes (403,404). In the patient rendered hypotensive
because of a severe reduction in forward output, nitroprusside
should not be administered alone, but combination therapy
with an inotropic agent (such as dobutamine) and nitroprus-
side is of benefit in some patients. In such patients, aortic
balloon counterpulsation increases forward output and mean
arterial pressure while diminishing regurgitant volume and LV
filling pressure and can be used to stabilize the patient while
preparing for surgery. If infective endocarditis is the cause of
acute MR, identification and treatment of the infectious
organism are essential.
3. Chronic Asymptomatic Mitral Regurgitation.
a. Pathophysiology. In chronic severe MR, there has been
time for development of eccentric cardiac hypertrophy in
which new sarcomeres are laid down in series, increasing the
length of individual myocardial fibers (153,399). The resulting
increase in LV end-diastolic volume is compensatory because
it permits an increase in total stroke volume, allowing for
restoration of forward cardiac output (405). At the same time,
the increase in LV and left atrial size allows accommodation of
the regurgitant volume at a lower filling pressure, and the
symptoms of pulmonary congestion abate. In this phase of
compensated MR, the patient may be entirely asymptomatic,
even during vigorous exercise. It should be noted that in the
compensatory phase, augmented preload and reduced or nor-
mal afterload (provided by the unloading of the left ventricle
into the left atrium) facilitate LV ejection, resulting in a large
total stroke volume and a normal forward stroke volume.
The duration of the compensated phase of MR is variable
but may last for many years. However, the prolonged burden of
volume overload may eventually result in LV dysfunction. In
this phase, contractile dysfunction impairs ejection and end-
systolic volume increases. There may be further LV dilatation
and increased LV filling pressure. These hemodynamic events
result in reduced forward output and pulmonary congestion.
However, the still favorable loading conditions often maintain
ejection fraction in the low normal range (0.50 to 0.60) despite
the presence of significant muscle dysfunction (399,406,407).
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Correction of MR should occur before the advanced phases of
LV decompensation.
b. Diagnosis. In evaluating the patient with chronic MR, a
careful history is invaluable. A well-established estimation of
baseline exercise tolerance is important in gauging the subtle
onset of symptoms at subsequent evaluations. Physical exami-
nation should demonstrate displacement of the LV apical
impulse, which indicates that MR is severe and chronic,
producing cardiac enlargement. A third heart sound is usually
present and does not necessarily indicate heart failure. Find-
ings consistent with pulmonary hypertension are worrisome
because they indicate advanced disease with worsened prog-
nosis (408). An ECG and chest x-ray are useful in establishing
rhythm and heart size, respectively. An initial echocardiogram
including Doppler interrogation of the mitral valve is indis-
pensable in the management of the patient with MR. The
echocardiogram provides a baseline estimation of LV and left
atrial volume, an estimation of LV ejection fraction, and
approximation of the severity of regurgitation. Changes from
these baseline values are subsequently used to guide the timing
of mitral valve surgery. In addition, the echocardiogram can
often disclose the anatomic cause of the patient’s condition. In
the presence of even mild TR, interrogation of the tricuspid
valve yields an estimate of pulmonary artery pressure by
measurement of the gradient from the right ventricle to the
right atrium (409).
In some patients, Doppler studies show that MR worsens
with exercise, possibly reconciling exercise-induced symptoms
with resting echocardiograms that show only mild or moderate
regurgitation (410).
c. Serial Testing. The aim of serial follow-up of the patient
with MR is to subjectively assess changes in symptomatic status
and objectively assess changes in LV function and exercise
tolerance that can occur in the absence of symptoms. Asymp-
tomatic patients with mild MR and no evidence of LV
enlargement, LV dysfunction, or pulmonary hypertension can
be followed on a yearly basis with instructions to alert the
physician if symptoms develop in the interim. Yearly echocar-
diography is not necessary unless there is clinical evidence that
regurgitation has worsened. In patients with moderate MR,
clinical evaluations should be performed annually, and echo-
cardiograms are not necessary more than once per year.
Asymptomatic patients with severe MR should be followed
with history, physical examination, and echocardiography every
6 to 12 months to assess symptoms or transition to asymptom-
atic LV dysfunction. Serial chest x-rays and ECGs have less
value but are helpful in selected patients. Exercise stress
testing may be used to add objective evidence regarding
symptoms and changes in exercise tolerance. Exercise testing is
especially important if a good history of the patient’s exercise
capacity cannot be obtained.
Assessment of LV function in the patient with MR is made
difficult because the loading conditions present in MR facili-
tate ejection and increase ejection fraction, the standard guide
to LV function. Nonetheless, several studies indicated that the
preoperative ejection fraction is an important predictor of
postoperative survival in patients with chronic MR
(406,408,411,412). Ejection fraction in a patient with MR with
normal LV function is usually .20.60. Consistent with this
concept, postoperative survival is reduced in patients with a
preoperative ejection fraction ,0.60 compared with patients
with higher ejection fractions (412).
Alternatively or in concert, echocardiographic LV end-
systolic dimension (or volume) can be used in the timing of
mitral valve surgery. End-systolic dimension, which may be less
load-dependent than ejection fraction (413), should be
,45 mm preoperatively to ensure normal postoperative LV
function (405,413). If patients become symptomatic, they
should undergo mitral valve surgery even if LV function is
normal.
Recommendations for Transthoracic Echocardiography in
Mitral Regurgitation
Indication Class
1. For baseline evaluation to quantify severity of MR and LV
function in any patient suspected of having MR.
I
2. For delineation of mechanism of MR. I
3. For annual or semiannual surveillance of LV function
(estimated by ejection fraction and end-systolic
dimension) in asymptomatic severe MR.
I
4. To establish cardiac status after a change in symptoms. I
5. For evaluation after MVR or mitral valve repair to
establish baseline status.
I
6. Routine follow-up evaluation of mild MR with normal LV
size and systolic function.
III
Recommendations for Transesophageal Echocardiography in
Mitral Regurgitation
Indication Class
1. Intraoperative transesophageal echocardiography to establish the
anatomic basis for MR and to guide repair.
I
2. For evaluation of MR patients in whom transthoracic
echocardiography provides nondiagnostic images regarding
severity of MR, mechanism of MR, and/or status of LV function.
I
3. In routine follow-up or surveillance of patients with native valve
MR.
III
d. Guidelines for Physical Activity and Exercise. Recommen-
dations regarding participation in competitive athletics were
published by the Task Force on Acquired Valvular Heart
Disease of the 26th Bethesda Conference (105). Asymptomatic
patients with MR in sinus rhythm who have normal LV
volumes may exercise without restriction (105). For mildly
symptomatic patients, those with LV dilatation or atrial fibril-
lation, exercise should be limited to activities with low to
moderate dynamic and low to moderate static cardiovascular
demands (105).
e. Medical Therapy. In the asymptomatic patient with
chronic MR, there is no generally accepted medical therapy.
Although intuitively the use of vasodilators may appear to be
logical for the same reasons that they are effective in acute MR
and chronic AR, there are no large long-term studies to
indicate that they are beneficial. Furthermore, because MR
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with normal ejection fraction is a disease in which afterload is
not increased (155,405,414,415), drugs that reduce afterload
might produce a physiological state of chronic low afterload
with which there is very little experience. However, in patients
with MR resulting from increased preload (ie, CAD or dilated
cardiomyopathy), there is reason to believe that preload
reduction may be beneficial (223), and in a small series of
patients with chronic MR in NYHA functional Class I to III, 1
year of quinapril therapy reduced LV volumes and mass and
improved functional class (416). These data do not appear to
be applicable to asymptomatic patients. Thus, in the absence of
systemic hypertension, there is no known indication for the use
of vasodilating drugs in asymptomatic patients with preserved
LV function.
In patients with MR who develop symptoms but have
preserved LV function, surgery is the most appropriate ther-
apy. If atrial fibrillation develops, heart rate should be con-
trolled with digitalis, rate-lowering calcium channel blockers,
b-blockers, or, rarely, amiodarone. Although the risk of em-
bolism with the combination of MR and atrial fibrillation was
formerly considered similar to that of MS and atrial fibrilla-
tion, more recent studies suggest that embolic risk may be less
in MR (417,418). Although this suggests that the intensity of
anticoagulation in such patients can probably be reduced, firm
guidelines are not yet established, and it is recommended that
the INR be maintained at 2 to 3 in this population.
f. Indications for Cardiac Catheterization. Cardiac catheter-
ization, with or without exercise, is necessary when there is a
discrepancy between clinical and noninvasive findings. Cathe-
terization is also performed when surgery is contemplated in
cases where there is still some doubt about the severity of MR
after noninvasive testing or when there is a need to assess
extent and severity of CAD preoperatively. In patients with
MR who have risk factors for CAD (advanced age, hypercho-
lesterolemia, hypertension, etc) or when there is a suspicion
that MR is ischemic in etiology (either because of known
myocardial infarction or suspected ischemia), coronary angiog-
raphy should be performed before surgery. In cases in which
no reasonable suspicion of CAD exists, coronary angiography
can be avoided.
Obviously, patients should not undergo valve surgery unless
the valve lesion is severe. In cases of chronic MR, noninvasive
imaging should demonstrate anatomic disruption of the valve
or its apparatus, and color flow Doppler should indicate severe
MR. Both the left atrium and left ventricle should be enlarged.
Discordance between chamber enlargement and the presumed
severity of regurgitation (ie, supposedly chronic severe MR
without cardiac enlargement) raises questions about the accu-
racy of the diagnosis. Such questions should be resolved during
ventriculography at cardiac catheterization. Although the stan-
dard semiquantitative approach to determining the severity of
MR from ventriculography has its own limitations (419),
ventriculography does provide an additional method to assess
LV dilatation and function and gauge the severity of MR.
Exercise hemodynamics and quantitative angiography may
provide additional information helpful in decision making.
During the catheterization procedure, a right-heart cathe-
terization should be performed if the severity of MR is
uncertain to obtain right-sided pressures to quantify the in-
crease in left atrial pressure (pulmonary artery wedge pres-
sure) and pulmonary artery pressure. Although much has been
written about the presence of a large V wave in the pulmonary
artery wedge pressure tracing, the presence or absence of a
large V wave has little diagnostic impact when combined with
data from the rest of the catheterization (420).
Recommendations for Coronary Angiography in
Mitral Regurgitation
Indication Class
1. When mitral valve surgery is contemplated in patients
with angina or previous myocardial infarction.
I
2. When mitral valve surgery is contemplated in patients
with >21 risk factor for CAD (see section VIII.B. of these
guidelines).
I
3. When ischemia is suspected as an etiologic factor in MR. I
4. To confirm noninvasive tests in patients not suspected of
having CAD.
IIb
5. When mitral valve surgery is contemplated in patients
aged <35 years and there is no clinical suspicion of CAD.
III
Recommendations for Left Ventriculography and
Hemodynamic Measurements in Mitral Regurgitation
Indication Class
1. When noninvasive tests are inconclusive regarding severity of
MR, LV function, or the need for surgery.
I
2. When there is a discrepancy between clinical and noninvasive
findings regarding severity of MR.
I
3. In patients in whom valve surgery is not contemplated. III
4. Indications for Surgery. a. Types of Surgery. Three dif-
ferent mitral valve operations are currently used for correction
of MR: mitral valve repair, MVR with preservation of part or
all of the mitral apparatus, and MVR with removal of the
mitral apparatus. Each procedure has its advantages and
disadvantages, and therefore the indications for each proce-
dure are somewhat different. In most cases, mitral valve repair
is the operation of choice when the valve is suitable for repair
and appropriate surgical skill and expertise are available. This
procedure preserves the patient’s native valve without a pros-
thesis and therefore avoids the risk of chronic anticoagulation
(except in patients in atrial fibrillation) or prosthetic valve
failure late after surgery. Additionally, preservation of the
mitral apparatus leads to better postoperative LV function and
survival than in cases in which the apparatus is removed
(421–427). Improved postoperative function occurs with repair
because the mitral apparatus is an integral part of the left
ventricle that is essential for maintenance of normal shape,
volume, and function of the left ventricle (428). However, mitral
valve repair is technically more demanding than MVR, may
require longer extracorporeal circulation time, and may occasion-
ally fail. Valve calcification, rheumatic involvement, and anterior
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leaflet involvement decrease the likelihood of repair, whereas
uncalcified posterior leaflet disease is almost always reparable.
The advantage of MVR with preservation of the chordal
apparatus is that this operation ensures postoperative mitral
valve competence, preserves LV function, and enhances post-
operative survival compared with MVR in which the apparatus
is disrupted (423,429–432). The disadvantage is the use of a
prosthetic valve, with the risks of deterioration inherent in
tissue valves or the need for anticoagulation inherent in
mechanical valves.
MVR in which the mitral valve apparatus is destroyed
should almost never be performed. It should only be per-
formed in those circumstances in which the native valve and
apparatus are so distorted by the preoperative pathology
(rheumatic disease, for example) that the mitral apparatus
cannot be spared.
The advantages of mitral valve repair make it applicable in
the 2 extremes of the spectrum of MR. Valve repair might be
possible in patients with far-advanced symptomatic MR and
depressed LV function because it preserves LV function at the
preoperative level (425); MVR with disruption of the appara-
tus in such patients could lead to worsened or even fatal LV
dysfunction after surgery. At the other extreme, in the rela-
tively asymptomatic patient with well-preserved LV function,
repair of a severely regurgitant valve might be contemplated.
However, failed mitral valve repair would result in a prosthetic
valve; this would represent a clear complication, as it would
impose the risks of a prosthesis on a patient who did not
previously require it. Hence, most cardiologists would not
recommend “prophylactic” surgery in an asymptomatic patient
with MR and normal LV function.
b. Timing of Surgery for Symptomatic Patients With Normal
Left Ventricular Function. Patients with symptoms of conges-
tive heart failure despite normal LV function on echocardiog-
raphy (ejection fraction .0.60 and end-systolic dimension
,45 mm) require surgery. Surgery should be performed in
patients with mild symptoms and severe MR (Figure 6),
especially if it appears that mitral valve repair rather than
replacement can be performed. The feasibility of repair is
dependent on several factors, including valve anatomy and
surgical expertise. Successful surgical repair improves symp-
toms, preserves LV function, and avoids the problems of a
prosthetic valve. When repair is not feasible, MVR with
chordal preservation should relieve symptoms and maintain
LV function.
c. Timing of Surgery for Asymptomatic or Symptomatic
Patients With Left Ventricular Dysfunction. Preoperative vari-
ables that are predictive of postoperative survival, symptomatic
Figure 6. Management strategy for patients with chronic severe mitral
regurgitation. Abbreviations: AF 5 atrial fibrillation, EF 5 ejection
fraction, ESD 5 end-systolic diameter, FC 5 functional class, MV 5
mitral valve, NYHA 5 New York Heart Association, PHT 5 pulmo-
nary hypertension.
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improvement, and postoperative LV function are summarized
in Table 20. The timing of surgery for asymptomatic patients
was controversial, but most would now agree that mitral valve
surgery is indicated with the appearance of echocardiographic
indicators of LV dysfunction. These include LV ejection
fraction ,20.60 and/or LV end-systolic dimension .245 mm
(Figure 6). Surgery performed at this time will likely prevent
further deterioration in LV function and improve longevity.
This is true whether repair or replacement is performed (412),
although repair is clearly preferred. Although some recom-
mend a slightly lower threshold ejection fraction (0.55), it must
be emphasized that, unlike timing of AVR for AR, LV ejection
fraction should not be allowed to fall into the lower limit of the
normal range in patients with chronic MR (412,433–435). The
data regarding postoperative survival are much stronger with
LV ejection fraction than end-systolic dimension
(408,411,412), whereas both ejection fraction and end-systolic
dimension strongly influence postoperative LV function and
heart failure (405,406,408,413,436). Outcome is also influenced
by LV wall thickness–to–radius ratio (436,437).
Mitral valve surgery should also be recommended for
symptomatic patients with evidence of LV systolic dysfunction
(ejection fraction ,20.60, end-systolic dimension .245 mm).
Determining the surgical candidacy of the symptomatic
patient with MR and far-advanced LV dysfunction is a com-
mon clinical dilemma. The question that often arises is
whether the patient with MR has such advanced LV dysfunc-
tion that he or she is no longer a candidate for surgery. Often
such cases present difficulty in distinguishing primary cardio-
myopathy with secondary MR from primary MR with second-
ary myocardial dysfunction. In the latter case, if mitral valve
repair appears likely, surgery should still be contemplated,
provided ejection fraction is .20.30 (Figure 6). Even though
such a patient is likely to have persistent LV dysfunction,
surgery is likely to improve symptoms and prevent further
deterioration of LV function (241).
d. Asymptomatic Patients With Normal Left Ventricular
Function. As noted previously, repair of a severely regurgitant
valve may be contemplated in an asymptomatic patient with
normal LV function in order to preserve LV size and function
and prevent the sequelae of chronic MR. Although there are
no data with which to recommend this approach to all patients,
the committee recognizes that some experienced centers are
moving in this direction for patients for whom the likelihood of
successful repair is high (see below). This approach is often
recommended in hemodynamically stable patients with newly
acquired severe MR, such as might occur with ruptured
chordae. Surgery is also recommended in an asymptomatic
patient with chronic MR with recent onset of episodic or
chronic atrial fibrillation in whom there is a high likelihood of
successful valve repair (see below).
e. Atrial Fibrillation. Atrial fibrillation is a common, poten-
tially morbid arrhythmia associated with MR. Preoperative
atrial fibrillation is an independent predictor of reduced long-
term survival after mitral valve surgery for chronic MR (412).
The persistence of atrial fibrillation after mitral valve surgery
can lead to thromboembolism and partially nullifies an advan-
tage of mitral repair by requiring anticoagulation. Predictors of
the persistence of atrial fibrillation after successful valve
surgery are the presence of atrial fibrillation for .1 year and
left atrial size .50 mm (438). In one study, an even shorter
duration of preoperative atrial fibrillation (3 months) was a
predictor of persistent atrial fibrillation after mitral valve
repair (439); persistent atrial fibrillation after surgery occurred
in 80% of patients with preoperative atrial fibrillation .23
months but in no patient with preoperative atrial fibrillation
,3 months. Although patients who develop atrial fibrillation also
usually manifest other symptomatic or functional changes that
Table 20. Preoperative Predictors of Surgical Outcome in Mitral Regurgitation
Study, year Study design
Type of
surgery
Number of
patients Outcome assessed Findings
Schuler et al 1979 (406) retrospective MVR 20 LV function 12 patients with average LV EF 0.70 had normal postoperative
EF; 4 patients with average EF 0.58 had postoperative EF
0.25.
Phillips et al 1981 (411) retrospective MVR 105 survival EF ,0.50 predicted poor survival.
Zile et al 1984 (405) prospective MVR 16 heart failure, LV function LV ESD index .2.6 cm/m2 (45 mm) and LV FS ,0.32
predicted poor outcome.
Crawford et al 1990 (408) prospective MVR 48 survival, LV function LV EF ,0.50 predicted survival; ESV .50 mL/m2 predicted
persistent LV dilatation.
Reed et al 1991 (437) prospective MVR 176 survival LA area .7.0 cm2/m2, end-systolic LV thickness/radius ,0.4,
and PAWP .9 mm Hg predicted poor survival.
Wisenbaugh et al 1994 registry MVR 26 survival, LV function ESD, EDD, and FS predicted poor survival and LV function;
(413) MVR-CP 35 only ESD significant in multivariate analysis.
Enriquez-Sarano et al 1994 retrospective MVR 214 survival LV EF ,20.60 predicted poor survival whether MVR or CP
(412) repair 195 was performed; EF estimated by echo FS or visual analysis.
Enriquez-Sarano et al 1994 retrospective MVR 104 LV function EF, ESD, LV diameter/thickness ratio, and end-systolic wall
(436) repair 162 stress predicted outcome; EF estimated by echo FS or visual
analysis
Abbreviations: CP 5 chordal sparing procedure, EDD 5 end-diastolic dimension; EF 5 ejection fraction, ESD 5 end-systolic dimension, ESV 5 end-systolic
volume, FS 5 fractional shortening, LA 5 left atrial, LV 5 left ventricular, MVR 5 mitral valve replacement, PAWP 5 pulmonary artery wedge pressure.
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would warrant mitral valve repair or MVR, many clinicians would
consider the onset of episodic or chronic atrial fibrillation to be an
indication in and of itself for surgery (Figure 6) (432,439).
f. Feasibility of Repair Versus Replacement. As noted above,
in many cases the type of operation, repair versus MVR, is
important in timing surgery. In fact, although the type of
surgery to be performed is never actually established until the
operation, many situations lend themselves to preoperative
prediction of the operation that can be performed. This
prediction is based on the skill and experience of the surgeon
in performing repair and on the location and type of mitral
valve disease that caused MR. Nonrheumatic posterior leaflet
prolapse due to degenerative mitral valve disease or a ruptured
chordae tendineae can usually be repaired (440,441). Involve-
ment of the anterior leaflet diminishes the likelihood of repair,
and consequently the skill and experience of the surgeon are
probably the most important determinants of the eventual
operation that will be performed. In general, rheumatic and
ischemic involvement of the mitral valve and calcification of
the mitral valve leaflets or annulus diminish the likelihood of
repair even in experienced hands.
Recommendations for Mitral Valve Surgery in Nonischemic Severe
Mitral Regurgitation
Indication Class
1. Acute symptomatic MR in which repair is likely. I
2. Patients with NYHA functional Class II, III, or IV symptoms
with normal LV function defined as ejection fraction >0.60
and end-systolic dimension <45 mm.
I
3. Symptomatic or asymptomatic patients with mild LV
dysfunction, ejection fraction 0.50 to 0.60, and end-systolic
dimension 45 to 50 mm.
I
4. Symptomatic or asymptomatic patients with moderate LV
dysfunction, ejection fraction 0.30 to 0.50, and/or end-systolic
dimension 50 to 55 mm.
I
5. Asymptomatic patients with preserved LV function and
atrial fibrillation.
IIa
6. Asymptomatic patients with preserved LV function and
pulmonary hypertension (pulmonary artery systolic pressure
>50 mm Hg at rest or >60 mm Hg with exercise).
IIa
7. Asymptomatic patients with ejection fraction 0.50 to 0.60
and end-systolic dimension <45 mm and asymptomatic
patients with ejection fraction >0.60 and end-systolic
dimension 45 to 55 mm.
IIa
8. Patients with severe LV dysfunction (ejection fraction <0.30
and/or end-systolic dimension >55 mm) in whom chordal
preservation is highly likely.
IIa
9. Asymptomatic patients with chronic MR with preserved LV
function in whom mitral valve repair is highly likely.
IIb
10. Patients with MVP and preserved LV function who have
recurrent ventricular arrhythmias despite medical therapy.
IIb
11. Asymptomatic patients with preserved LV function in whom
significant doubt about the feasibility of repair exists.
III
5. Ischemic Mitral Regurgitation. The outlook for the
patient with ischemic MR is substantially worse than that for
regurgitation from other causes (402,442). A worse prognosis
accrues from the fact that ischemic MR is usually caused by LV
dysfunction resulting from myocardial infarction. Further-
more, the mitral valve itself is usually anatomically normal and
MR is secondary to papillary muscle dysfunction and/or dis-
placement that make repair of the valve more difficult. On the
other hand, coronary artery bypass graft surgery may improve
LV function and reduce ischemic MR. In many patients with
transient severe MR due to ischemia, myocardial revascular-
ization can eliminate episodes of severe MR.
In severe MR secondary to acute myocardial infarction,
hypotension and pulmonary edema often occur. Treatment is
aimed at hemodynamic stabilization, usually with insertion of
an intra-aortic balloon pump. Occasionally, revascularization
of the coronary artery supplying an ischemic papillary muscle
can lead to improvement in mitral valve competence. How-
ever, such improvement is rare, and correction of acute severe
ischemic MR usually requires valve surgery. Unlike nonisch-
emic MR, in which mitral repair is clearly the operation of
choice, the best operation for ischemic MR is controversial
(443,444). In one recent report, MVR had a better outcome
than repair, especially when annular dilatation rather than
chordal or papillary muscle rupture was the cause of MR (444).
6. Evaluation of Patients After Mitral Valve Replacement
or Repair. After mitral valve surgery, follow-up is necessary to
detect late surgical failure and assess LV function, as discussed
in detail in section VII.C.3. of these guidelines. For patients in
whom a bioprosthesis has been inserted, the specter of even-
tual deterioration is always present and must be anticipated. If
a mechanical valve has been inserted, anticoagulation is re-
quired, and chronic surveillance of prothrombin time and INR
is necessary. After valve repair, follow-up to assess the effec-
tiveness of the repair is indicated early, especially because most
repair failures are detected soon after surgery.
7. Special Considerations in the Elderly. Elderly patients
with MR fare more poorly with valve surgery than do their
counterparts with AS. In general, operative mortality increases
and survival is reduced in patients .75, especially if MVR
must be performed or if the patient has concomitant CAD
(427). In such patients, the goal of therapy is to improve the
quality of life rather than prolong it. Thus, surgery may be
performed in asymptomatic younger patients to preserve LV
function, but it is hard to argue this position in patients older
than 75. For such patients, symptoms are an important guide in
deciding whether or not surgery is necessary. Under most
circumstances, asymptomatic patients or patients with mild
symptoms should be treated medically.
F. Multiple Valve Disease
1. Introduction. Remarkably few data exist to objectively
guide the management of mixed valve disease. The large
number of combined hemodynamic disturbances (and their
varied severity) yield a large number of potential combinations
to consider, and few data exist for any specific category. Hence,
each case must be considered individually and management
based on understanding the potential derangements in hemo-
dynamics and LV function and the probable benefit of medical
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versus surgical therapy. The committee has developed no
specific recommendations in this section.
2. Mixed Single-Valve Disease. a. Pathophysiology. In
mixed mitral or aortic valve disease, one lesion usually pre-
dominates over the other, and the pathophysiology resembles
that of the pure dominant lesion. Thus, for the patient with
mixed AS and AR where stenosis predominates, the patho-
physiology and management resemble that of pure AS. The
left ventricle develops concentric hypertrophy rather than
dilatation. The timing of AVR is based on symptomatic status.
However, if the attendant regurgitation is more than mild, it
complicates the pathophysiology by placing the concentrically
hypertrophied and noncompliant left ventricle on a steeper
portion of its diastolic pressure-volume curve, in turn causing
pulmonary congestion. The effect is that neither lesion by itself
might be considered severe enough to warrant surgery, but both
together produce substantial hemodynamic compromise requir-
ing intervention.
In patients with severe AR and mild AS, the high total
stroke volume due to extensive regurgitation may produce a
substantial transvalvular gradient. Because the transvalvular
gradient varies with the square of the transvalvular flow (106),
a high gradient in predominant regurgitation may be predi-
cated primarily on excess transvalvular flow rather than on a
severely compromised orifice area.
In mixed mitral disease, predominant MS produces a left
ventricle of normal volume, whereas predominant MR cham-
ber dilatation occurs. A substantial transvalvular gradient may
exist in regurgitation-predominant disease because of high
transvalvular flow, but (as in mixed aortic valve disease with
predominant regurgitation) the gradient does not represent
severe orifice stenosis.
b. Diagnosis. (1) 2-D AND DOPPLER ECHOCARDIOGRAPHIC
STUDIES. As noted above, chamber geometry is important
in assessing the dominant lesion (stenotic versus regur-
gitant), which in turn is important in management. For
instance, a small left ventricle is inconsistent with
chronic severe regurgitation. Doppler interrogation of
the aortic and mitral valves with mixed disease should
provide a reliable estimate of the transvalvular mean
gradient. However, there may be a significant discrep-
ancy between the Doppler-derived maximum instanta-
neous gradient and catheter peak gradient with mixed
aortic valve disease. Exercise hemodynamics derived by
Doppler echocardiography have been helpful in man-
agement of mixed valve disease. Mitral valve area can be
measured accurately by the half-time method in mixed
MS/MR. Aortic valve area would be measured inaccu-
rately at the time of cardiac catheterization in mixed
AS/AR if cardiac output is measured by either thermodi-
lution or the Fick method. The valve area can be measured
more accurately by the continuity equation from Doppler
echocardiography in mixed AS/AR. However, the continu-
ity equation calculation of valve area may not be com-
pletely independent of flow (445). Although these valve
area measurements by Doppler echocardiography are
more accurate than those obtained at cardiac catheteriza-
tion, in general, the confusing nature of mixed valve disease
makes cardiac catheterization necessary to obtain addi-
tional hemodynamic information in most patients.
(2) CARDIAC CATHETERIZATION. Catheterization is often
necessary to fully assess hemodynamics. The diagnosis of
“moderate” mixed disease is frequently made on the basis of
noninvasive tests alone. This term suggests that the valve
disease is not severe enough to mandate surgery. However, as
noted previously, the nondominant lesion may exacerbate the
pathophysiology of the dominant lesion and produce symp-
toms. In this context, a complete hemodynamic evaluation
including exercise hemodynamics may be important. For ex-
ample, resting hemodynamics in mixed mitral disease might
show a transmitral gradient of 5 mm Hg, a valve area of 1.5
cm2, and 21 MR with a resting pulmonary artery wedge
pressure of 15 mm. However, with exercise, the wedge pressure
may increase dramatically, identifying a hemodynamic cause
for the patient’s symptoms and suggesting that mechanical
correction will be of benefit. Many cases of mixed valve disease
require hemodynamic exercise testing to delineate proper
assessment (446).
Hemodynamic estimation of valve area requires determina-
tion of total valve flow and transvalvular gradient. The pres-
ence of valvular regurgitation in a primarily stenotic valve
causes forward cardiac output to underestimate total valve
flow, which is the sum of forward plus regurgitant flow. Thus,
if standard measures of forward cardiac output (thermodilu-
tion, Fick, etc) are used to calculate valve area, the area will be
underestimated. One approach to this problem is to use total
stroke volume (angiographic end-diastolic volume–end systolic
volume) in place of forward stroke volume (Fick or thermodi-
lution cardiac output/heart rate) in the Gorlin formula. Al-
though this approach is logically valid, it has not been clinically
tested or vetted against a gold standard. Furthermore, angio-
graphic stroke volume is dependent on accurate calculation of
cardiac volumes, which may be difficult in the very large and/or
spherical left ventricles encountered in valvular regurgitation
(447). In general, the utility of this approach is limited.
Doppler pressure half-time may be very useful in this situation.
c. Management. Unlike the management of a severe pure
valve lesion, solid guidelines for mixed disease are difficult to
establish. The most logical approach is to surgically correct
disease that produces more than mild symptoms or, in the case
of AS-dominant aortic valve disease, to operate in the presence
of even mild symptoms. In regurgitant dominant lesions,
surgery can be delayed until symptoms develop or asymptom-
atic LV dysfunction (as gauged by markers used in pure
regurgitant disease) becomes apparent. The use of vasodilators
to forestall surgery in patients with asymptomatic mixed dis-
ease is untested. Anticoagulants should be used in mixed mitral
disease if atrial fibrillation is present. In mixed mitral disease
with moderate or severe (31 to 41) regurgitation, percutane-
ous mitral balloon valvotomy is contraindicated because regur-
gitation may worsen.
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3. Combined Mitral Stenosis and Aortic Regurgitation. a.
Pathophysiology. When both AR and MS coexist, severe MS
usually coexists with mild AR with pathophysiology similar to
that of isolated MS. However, the coexistent AR is occasion-
ally severe. The combination of coexistent severe MS and
severe AR may present confusing pathophysiology and often
leads to misdiagnosis. MS restricts LV filling, blunting the
impact of AR on LV volume (248). Thus, even severe AR may
fail to cause a hyperdynamic circulation, so that typical signs of
AR are absent during physical examination. Likewise, echo-
cardiographic LV cavitary dimensions may be only mildly
enlarged. Doppler half-time measurements of mitral valve area
may be inaccurate in the presence of significant AR. The
picture presented by this complex combination of lesions
usually requires all diagnostic modalities, including cardiac
catheterization, for resolution.
b. Management. Mechanical correction of both lesions is
eventually necessary in most patients. Development of symp-
toms or pulmonary hypertension is the usual indication for
intervention.
When mechanical correction is anticipated in predominant
MS, balloon mitral valvotomy followed by AVR obviates the
need for double valve replacement, which has a higher risk of
complications than single valve replacement. In most cases, it
is advisable to perform mitral valvotomy first and then follow
the patient for symptomatic improvement. If symptoms disap-
pear, correction of AR can be delayed.
4. Combined Mitral Stenosis and Tricuspid Regurgitation.
a. Pathophysiology. When TR coexists with MS, some ele-
ments of pulmonary hypertension are also usually present.
Thus, the issue arises whether TR will or will not improve when
MS is corrected and pulmonary artery pressure decreases
(448). Unfortunately, the status of the tricuspid valve after
correction of MS is difficult to predict. In general, if pulmonary
hypertension is severe and the tricuspid valve anatomy is not
grossly distorted, improvement in TR can be expected after
correction of MS (449). On the other hand, if there is severe
rheumatic deformity of the tricuspid valve, competence is
likely to be restored only by surgery.
b. Diagnosis. Once TR is suspected by physical examination
to coexist with MS, both can be further evaluated by Doppler
echocardiographic studies. The presence of TR almost guar-
antees that an estimation of pulmonary artery pressure can be
made by Doppler interrogation of the tricuspid valve. An
evaluation of the anatomy of both the mitral and tricuspid
valves can be made.
c. Management. If the mitral valve anatomy is favorable for
percutaneous balloon valvotomy and there is concomitant
pulmonary hypertension, valvotomy should be performed re-
gardless of symptom status. After successful mitral valvotomy,
pulmonary hypertension and TR almost always diminish (449).
If mitral valve surgery is performed, concomitant tricuspid
annuloplasty should be considered, especially if there are
preoperative signs or symptoms of right-heart failure, rather
than risking severe persistent TR, which may necessitate a
second operation (450). However, TR that seems severe on
echocardiography but does not cause elevation of right atrial
or right ventricular diastolic pressure will generally improve
greatly after MVR. If intraoperative assessment suggests that
TR is functional without significant dilatation of the tricuspid
annulus, it may not be necessary to perform an annuloplasty.
5. Combined Mitral and Aortic Regurgitation. a. Patho-
physiology. As noted in the previous discussions of isolated
MR and AR, these are 2 very different diseases with different
pathophysiological effects and different guidelines for the
timing of surgery. Thus, in the patient with double valve
regurgitation, proper management becomes problematic. The
most straightforward approach is the same as for mixed single
valve disease, ie, to determine which lesion is dominant and to
treat primarily according to that lesion. Although both lesions
produce LV dilatation, AR will produce modest systemic
systolic hypertension and a mild increase in LV wall thickness.
b. Diagnosis. Doppler echocardiographic interrogation
shows bivalve regurgitation and an enlarged left ventricle. 2-D
echocardiography is usually performed to assess severity of AR
and MR, LV size and function, left atrial size, pulmonary
artery pressure, and feasibility of mitral valve repair.
6. Combined Mitral and Aortic Stenosis. a. Pathophysiol-
ogy. Combined stenotic disease is almost always secondary to
rheumatic heart disease. Obstruction of flow at the mitral valve
diminishes aortic valve flow as well. Thus, the problem of
evaluating aortic valve severity in a low flow–low gradient
situation often exists.
b. Diagnosis and Therapy. In patients with significant AS
and MS, the physical findings of AS generally dominate, and
those of MS may be overlooked, whereas the symptoms are
usually those of MS. Noninvasive evaluation should be per-
formed with 2-D and Doppler echocardiographic studies to
evaluate severity of AS and MS, paying special attention to
suitability for mitral balloon valvotomy in symptomatic pa-
tients, and to assess ventricular size and function. If the degree
of AS appears to be mild and the mitral valve is acceptable for
balloon valvotomy, this should be attempted first. If mitral
balloon valvotomy is successful, the aortic valve should then be
reevaluated.
7. Combined Aortic Stenosis and Mitral Regurgitation. a.
Pathophysiology. Combined AS and MR often develop sec-
ondary to rheumatic heart disease. However, congenital AS
and MVP may occur in combination in younger patients, as
may degenerative AS and MR in the elderly. If severe, AS will
worsen the degree of MR. In addition, MR may cause difficulty
in assessing severity of AS because of reduced forward flow.
MR will also enhance LV ejection performance, thereby
masking the early development of LV systolic dysfunction
caused by AS. Development of atrial fibrillation and loss of
atrial systole may further reduce forward output because of
impaired filling of the hypertrophied left ventricle.
b. Diagnosis and Therapy. Noninvasive evaluation should
be performed with 2-D and Doppler echocardiography to
evaluate the severity of both AS and MR. Attention should be
paid to LV size, wall thickness and function, left atrial size,
right-heart function, and pulmonary artery pressure. Particular
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attention should be paid to mitral valve morphology in patients
with these combined lesions. Patients with severe AS and
severe MR (with abnormal mitral valve morphology) with
symptoms, LV dysfunction, or pulmonary hypertension should
undergo combined AVR and MVR or mitral valve repair.
However, in patients with severe AS and lesser degrees of MR,
the severity of MR may improve greatly after isolated AVR,
particularly when there is normal mitral valve morphology.
Intraoperative transesophageal echocardiography and, if nec-
essary, visual inspection of the mitral valve should be per-
formed at the time of AVR to determine whether additional
mitral valve surgery is warranted in these patients.
In patients with mild to moderate AS and severe MR in
whom surgery on the mitral valve is indicated because of
symptoms, LV dysfunction, or pulmonary hypertension, pre-
operative assessment of the severity of AS may be difficult
because of reduced forward stroke volume. If the mean aortic
valve gradient is .230 mm Hg, AVR should be performed. In
patients with less severe aortic valve gradients, inspection of
the aortic valve and its degree of opening on 2-D or trans-
esophageal echocardiography as well as visual inspection by
the surgeon may be important in determining the need for
concomitant AVR.
G. Tricuspid Valve Disease
1. Pathophysiology. Tricuspid valve dysfunction can occur
with normal or abnormal valves. When normal tricuspid valves
develop dysfunction, the resulting hemodynamic abnormality
is almost always pure regurgitation. This occurs with elevation
of right ventricular systolic and/or diastolic pressure, right
ventricular cavity enlargement, and tricuspid annular dilatation
(451,452); right ventricular systolic hypertension occurs in MS,
pulmonic valve stenosis, and the various causes of pulmonary
hypertension. Right ventricular diastolic hypertension occurs
in dilated cardiomyopathy and right ventricular failure of any
cause (451,452).
Abnormalities of the tricuspid valve leading to TR can
occur with rheumatic valvulitis, infective endocarditis, carci-
noid, rheumatoid arthritis, radiation therapy, trauma, Marfan
syndrome, tricuspid valve prolapse, papillary muscle dysfunc-
tion, or congenital disorders such as Ebstein’s anomaly (451)
or a cleft tricuspid valve as part of atrioventricular canal
malformations. Anorectic drugs may also cause TR, as indi-
cated in section III.H. of these guidelines.
Tricuspid stenosis is most commonly rheumatic in origin.
On very rare occasions, infective endocarditis (with large bulky
vegetations), congenital abnormalities, carcinoid, Fabry’s dis-
ease, Whipple’s disease, or previous methysergide therapy may
be implicated (453). Right atrial mass lesions represent a
nonvalvular cause of obstruction to the tricuspid orifice and
may also over time destroy the leaflets and cause regurgitation.
Rheumatic tricuspid involvement usually results in both steno-
sis and regurgitation.
2. Diagnosis. The clinical features of tricuspid stenosis
include a giant a wave and diminished rate of y descent in the
jugular venous pulse, a tricuspid opening snap, and a murmur
that is presystolic as well as middiastolic and that increases on
inspiration (454). Because acute rheumatic fever is the most
common cause of tricuspid stenosis, there is usually associated
mitral and/or aortic disease, and the clinical findings include
those associated with the other 2 valves, especially the mitral
valve.
The clinical features of TR include abnormal systolic c and
v waves in the jugular venous pulse, a lower left parasternal
systolic murmur (holosystolic or less than holosystolic, depend-
ing on the severity of hemodynamic derangement) that may
increase on inspiration (Carvallo’s sign), a middiastolic mur-
mur in severe regurgitation, and systolic hepatic pulsation. In
rare instances, severe TR may produce systolic propulsion of
the eyeballs (455), pulsatile varicose veins (456), or a venous
systolic thrill and murmur in the neck (457). Other associated
clinical features are related to the cause of TR.
Echocardiography is valuable in assessing tricuspid valve
structure and motion, measuring annular size, and identifying
other cardiac abnormalities that might influence tricuspid
valve function. Doppler echocardiography permits estimation
of the severity of TR (458), right ventricular systolic pressure,
and the tricuspid valve diastolic gradient. Although echocardi-
ography is a valuable diagnostic tool, it should be pointed out
that clinically insignificant TR is detected by color Doppler
imaging in many normal persons (18–22). This is not an
indication for either routine follow-up or prophylaxis against
bacterial endocarditis. Thus, clinical correlation and judgment
must accompany the echocardiographic results. Systolic pul-
monary artery pressures .255 mm Hg are likely to cause TR
with anatomically normal tricuspid valves, whereas TR occur-
ring with systolic pulmonary artery pressures ,40 mm Hg is
likely to reflect a structural abnormality of the valve apparatus.
Systolic pulmonary artery pressure estimation combined with
information about annular circumference will further improve
the accuracy of clinical assessment (452).
3. Management. The patient’s clinical status and the etiol-
ogy of the tricuspid valve abnormality usually determine the
appropriate therapeutic strategy. Medical and/or surgical man-
agement may be required. For example, in the patient with
severe MS and pulmonary hypertension with resulting right
ventricular dilatation and TR, relief of MS and the resulting
decrease in pulmonary artery pressure may result in substantial
diminution of the degree of TR. The timing of surgical
intervention for TR remains controversial as do the surgical
techniques. To some extent, this controversy has diminished
since the advent of 2-D and Doppler echocardiography for
preoperative diagnosis and assessment. Intraoperative trans-
esophageal Doppler echocardiography allows refinement of
annuloplasty techniques to optimize outcome (459–461). At
present, surgery on the tricuspid valve for TR occurs com-
monly at the time of mitral valve surgery. However, there are
no long-term data regarding the value of such an approach.
Tricuspid valve balloon valvotomy has been advocated for
tricuspid stenosis of various etiologies (462–464). However,
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severe TR is a common consequence of this procedure, and
results are poor when severe TR develops.
Patients with severe TR of any cause have a poor long-term
outcome because of RV dysfunction and/or systemic venous
congestion (465). Tricuspid valve and chordal reconstruction
can be attempted in some cases of TR resulting from endo-
carditis and trauma (466–468). In recent years, annuloplasty
has become an established surgical approach to significant TR
(469–473).
When the valve leaflets themselves are diseased, abnormal,
or destroyed, valve replacement with a low-profile mechanical
valve or bioprosthesis is often necessary (474). A biological
prosthesis is preferred because of the high rate of thrombo-
embolic complications with mechanical prostheses in the tri-
cuspid position. In patients with associated conduction defects,
insertion of a permanent epicardial pacing electrode at the
time of valve replacement can avoid the later need to pass a
transvenous lead across the prosthetic valve.
Recommendations for Surgery for Tricuspid Regurgitation
Indication Class
1. Annuloplasty for severe TR and pulmonary hypertension in
patients with mitral valve disease requiring mitral valve surgery.
I
2. Valve replacement for severe TR secondary to diseased/abnormal
tricuspid valve leaflets not amenable to annuloplasty or repair.
IIa
3. Valve replacement or annuloplasty for severe TR with mean
pulmonary artery pressure <60 mm Hg when symptomatic.
IIa
4. Annuloplasty for mild TR in patients with pulmonary
hypertension secondary to mitral valve disease requiring mitral
valve surgery
IIb
5. Valve replacement or annuloplasty for TR with pulmonary
artery systolic pressure <60 mm Hg in the presence of a normal
mitral valve, in asymptomatic patients, or in symptomatic
patients who have not received a trial of diuretic therapy.
III
H. Valvular Heart Disease Associated With
Anorectic Drugs
In addition to the common causes of the valvular lesions
described in the preceding sections, there are a number of
uncommon causes of valvular heart disease related to systemic
diseases, drugs, and toxins. It is beyond the scope of these
guidelines to discuss the specific pathology and natural history
of valve disease stemming from each of these many etiologies.
In general, the management strategies for patients with these
disorders are directed toward management of the underlying
disease process and diagnosis and management of the associ-
ated valvular disease according to the guidelines developed for
each of the valvular lesions in sections III.A. through III.G.
However, it is appropriate to address the issue of valvular
heart disease associated with anorectic agents because of the
current widespread concern of patients and healthcare profes-
sionals that has developed since this association was reported
in the summer of 1997. Investigators at the Mayo Clinic and
the MeritCare Medical Center in Fargo, ND, reported 24
patients receiving the combination of fenfluramine and phen-
termine in whom unusual valve morphology and associated
regurgitation were identified in both left-sided and right-sided
heart valves (475); all had AR and/or MR, and 12 had TR.
Eight patients had associated pulmonary hypertension. Five
patients underwent valve replacement surgery, and the his-
topathological findings of the excised valves included plaque-
like encasement of the leaflets and chordal structures with
intact valve architecture. The echocardiographic and his-
topathological findings were similar to those described in
patients with carcinoid or ergotamine-induced valvular heart
disease (476–480). All 24 patients were symptomatic and had
heart murmurs; thus, the frequency of valvular pathology
in asymptomatic patients receiving the combination of
fenfluramine-phentermine could not be determined. When
this initial series was published, it was accompanied by a letter
to the editor from the Food and Drug Administration (481)
reporting additional cases of valvular heart disease in 28
patients taking the fenfluramine-phentermine combination, as
well as a few patients taking a combination of dexfenfluramine
and phentermine, fenfluramine alone, or dexfenfluramine
alone. A left-sided heart valve was involved in all cases. A total
of 85 single cases were reported to the FDA by August 1997. In
addition, the FDA also reported 5 echocardiographic preva-
lence surveys (482) in which 86 of 271 patients (32%) receiving
combination fenfluramine-phentermine for 6 to 24 months had
evidence of significant AR and/or MR, as did 6 of 20 patients
(30%) receiving dexfenfluramine with or without phentermine.
The prevalence of valvular regurgitation was consistent among
the 5 reporting centers (range, 29% to 36%).
In light of this information, the drugs fenfluramine and
dexfenfluramine were withdrawn from the market in Septem-
ber 1997. However, a lower prevalence of valvular abnormal-
ities was reported in a survey of 21 centers that performed
echocardiography in a total of 746 patients (483); in this
survey, 21 patients (8%) were reported to have valvular
regurgitation with the same threshold definitions as in the
FDA report.
The risk of valvular heart disease associated with exposure
to fenfluramine or dexfenfluramine, alone or in combination
with phentermine, has been addressed in 3 recent peer-
reviewed studies, one of which was a case-control study (483a),
one a population-based study (483b), and one a randomized,
double-blind placebo-controlled clinical trial (483c). The prev-
alence of AR and/or MR in patients exposed to these drugs
varied widely among the 3 studies (from as high as 26% to as
low as ,1%), related primarily to differences in patient
selection and study design. The 2 studies which used Doppler
echocardiography to detect valvular regurgitation (483a, 483c)
differed considerably in terms of the prevalence of the valve
lesions and its statistical significance in comparison to control
groups, which may be related to differences in the anorectic
agents and the duration of exposure. It does appear that the
prevalence of significant valvular regurgitation may be related
to the duration of exposure to the anorectic agents (483b,
483d) and that patients exposed for only brief periods of time
have less risk of developing valvular regurgitation.
In addition to the uncertainties regarding the prevalence of
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valvular disease in patients receiving combination- or single-
drug therapy, the natural history of the valve disease during
anorectic drug treatment and the natural history after drug
withdrawal are unknown and await further clinical investiga-
tion. Thus, the risk of valvular heart disease relative to the
benefit of weight reduction in patients with morbid obesity is
unknown.
Considering these unknown variables and the rapidly evolv-
ing information linking fenfluramine and dexfenfluramine
(with or without phentermine) to valvular heart disease, it is
not possible to derive definitive diagnostic and treatment
guidelines for patients who have received these anorectic
drugs. Hence, clinical judgment is important. The US
Department of Health and Human Services (DHHS),
through the Centers for Disease Control and Prevention
and the National Institutes of Health, published interim
recommendations on November 14, 1997 (484,485). The
DHHS recommended that,
1. All persons exposed to fenfluramine or dexfenfluramine
for any period of time, either alone or in combination
with other agents, should undergo a medical history and
cardiovascular examination by their physicians to deter-
mine the presence or absence of cardiopulmonary signs
or symptoms.
2. An echocardiography evaluation should be performed on
all persons who were exposed to fenfluramine or dexfenflu-
ramine for any period of time, either alone or in combina-
tion with other agents, and who exhibit cardiopulmonary
signs (including a new murmur) or symptoms suggestive of
valvular disease (eg, dyspnea).
3. Although the clinical importance of asymptomatic valvular
regurgitation in exposed patients and the risk for developing
bacterial endocarditis in these patients are unknown, prac-
titioners should strongly consider performing echocardiog-
raphy on all persons—regardless of whether they have
cardiopulmonary signs or symptoms—who have been ex-
posed to fenfluramine or dexfenfluramine for any period of
time, either alone or in combination with other agents,
BEFORE the patient undergoes any invasive procedure for
which antimicrobial prophylaxis is recommended by the
1997 AHA guidelines. Any echocardiographic findings that
meet the AHA criteria for prophylaxis—regardless of
whether they are attributable to possible fenfluramine or
dexfenfluramine use—should be recognized as indications
for antibiotic prophylaxis. The invasive procedures include
certain medical or dental procedures in which antibiotic
prophylaxis is recommended as defined by the 1997 AHA
guidelines. For emergency procedures for which cardiac
evaluation cannot be performed, empirical antibiotic pro-
phylaxis should be administered according to the 1997 AHA
guidelines.
4. Because of the prevalence of minimal degrees of regurgita-
tion in the general population, the current case definition of
drug-associated valvulopathy should include exposed pa-
tients with echocardiographically demonstrated AR of mild
or greater severity and/or MR of moderate or greater
severity, based on published criteria (486,487).
The Committee on Management of Patients With Valvular
Heart Disease adopted the majority of the DHHS recommen-
dations. However, the committee recommends that certain
DHHS statements remain open to interpretation by individual
physicians because of the lack of conclusive scientific data for
appropriate care of patients who have taken these drugs.
Specifically, the committee interprets the DHHS statement
that practitioners should “strongly consider” performing echo-
cardiography on all persons before they undergo invasive
procedures, such as dental procedures, regardless of whether
signs or symptoms are present, as the need for the physician to
consider the findings of a patient’s cardiovascular physical
examination and any other pertinent data before ordering the
test.
All patients with a history of use of fenfluramine or
dexfenfluramine should undergo a careful history and thor-
ough cardiovascular physical examination. The physical exam-
ination should include auscultation with the patient in the
upright position at end-expiration to detect AR and in the left
lateral decubitus position to detect MR. 2-D and Doppler
echocardiography should be performed in patients with symp-
toms, cardiac murmurs, or other signs of cardiac involvement
(eg, widened pulse pressure or regurgitant cv waves in the
jugular venous pulse). Patients whose body size prevents
adequate cardiac auscultation should also undergo 2-D and
Doppler echocardiography. For example, mild AR may be
difficult to detect on auscultation in an obese patient. Patients
with clinical and echocardiographic evidence of valvular heart
disease should then undergo treatment and/or further testing
according to the recommendations developed for the specific
valve lesions addressed in the earlier sections of these guide-
lines. Modification of these recommendations may be neces-
sary as more information on the natural history of these
specific valve lesions becomes available.
In light of the current evidence, echocardiographic
screening of all patients with a history of fenfluramine or
dexfenfluramine use, especially asymptomatic patients with-
out murmurs or associated findings, is not recommended.
However, because of possible progression of subclinical
valvular disease, asymptomatic patients without murmurs
should undergo repeat physical examinations in 6 to 8
months.
Recommendations for Patients Who Have Used Anorectic Drugs*
Indication Class
1. Discontinuation of the anorectic drug(s). I
2. Cardiac physical examination. I
3. Echocardiography in patients with symptoms, heart murmurs, or
associated physical findings.
I
4. Doppler echocardiography in patients for whom cardiac
auscultation cannot be performed adequately because of body
habitus.
I
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5. Repeat physical examination in 6 to 8 months for those without
murmurs.
IIa
6. Echocardiography in all patients before dental procedures in the
absence of symptoms, heart murmurs, or associated physical
findings.
IIb
7. Echocardiography in all patients without heart murmurs. III
*Fenfluramine or dexfenfluramine or the combination of fenfluramine-
phentermine or dexfenfluramine-phentermine.
IV. Evaluation and Management of
Infective Endocarditis
Clinical suspicion of infective endocarditis may be raised by
the presence of fever and other systemic symptoms coupled
with physical findings such as Osler’s nodes, petechiae, Jane-
way lesions, Roth spots, splenomegaly, and a cardiac murmur.
At present, these physical signs are less commonly encoun-
tered, and definitive diagnosis is made by demonstrating an
offending organism by blood culture. Three sets of blood
cultures, obtained at intervals .21 hour within the first 24
hours, is the norm; however, in selected patients, 5 to 6 sets
of blood cultures may be needed, and some patients have
culture-negative endocarditis (see below). Additionally,
echocardiography has provided an important tool for rec-
ognizing both valvular structural abnormality and vegeta-
tions. The yield for visualization of vegetations for trans-
thoracic echocardiography is '60% to 77% and increases to
'96% with transesophageal imaging. The latter technique
usually provides better delineation of valvular anatomy and
function. This is especially the case for evaluation of
prosthetic valves (488). However, the absence of vegetations
on echocardiography does not exclude the diagnosis of
infective endocarditis, and the complete clinical condition
should be considered.
Criteria for the diagnosis of infective endocarditis were
proposed by Von Reyn and colleagues (489) with the results of
blood cultures, clinical signs, and symptoms. Subsequently, the
Duke criteria were developed to include evidence of endocar-
dial involvement (490). Table 21 shows the modified Duke
criteria by Bansal (27).
A. Antimicrobial Therapy
Antimicrobial therapy in endocarditis is guided by identifi-
cation of the causative organism. Eighty percent of cases of
endocarditis are due to streptococci and staphylococci. The
majority of native valve endocarditis is caused by Streptococcus
viridans (50%) and Staphylococcus aureus (20%). The latter
organism is also the most frequent organism in endocarditis
resulting from intravenous drug abuse. Eighty percent of
tricuspid valve infection is by S aureus; this organism is also a
frequent cause of infective endocarditis in patients with
insulin-dependent diabetes mellitus. With prosthetic valve
endocarditis, a wide spectrum of organisms can be responsible
within the first year of operation. However, in “early” pros-
thetic valve endocarditis, usually defined as endocarditis dur-
ing the first 2 months after surgery, Staphylococcus epidermidis
is the frequent offending organism. Late-onset prosthetic valve
endocarditis follows the profile of native valve endocarditis: ie,
streptococci (viridans) and staphylococci. Enterococcus faecalis
and Enterococcus faecium account for 90% of enterococcal
endocarditis, usually associated with malignancy or manipula-
tion of the genitourinary or gastrointestinal tract. Gram-
positive and gram-negative bacilli are relatively uncommon
causes of endocarditis. In recent years, the HACEK group of
organisms (Haemophilus, Actinobacillus, Cardiobacterium,
Eikenella, and Kingella species) have become important causes
of endocarditis. They cause large vegetations (.1 cm), large-
vessel emboli, and congestive heart failure. They should be
considered along with fungal endocarditis when large vegeta-
tions are noted. Fungi, especially candida, are important
causes of endocarditis in patients with prosthetic valves, com-
promised immune systems, and intravenous drug abuse. The
AHA recommendations for antimicrobial regimens are given
in Tables 22 through 27 (491).
Table 21. Duke Criteria* for Clinical Diagnosis of
Ineffective Endocarditis
Major Criteria
Persistently positive blood cultures
Typical organisms for endocarditis: Streptococcus viridans, S bovis,
“HACEK” group, community-acquired Staphylococcus aureus or
enterococci in the absence of primary focus
Persistent bacteremia: $2 positive cultures separated by $12 h or $3
positive cultures $1 h apart or 70% blood culture samples positive if
$4 are drawn
Evidence of endocardial involvement
Positive echocardiogram
Oscillating vegetation
Abscesses
Valve perforation
New partial dehiscence of prosthetic valve
New valvular regurgitation
Minor Criteria
Predisposing heart condition
MVP, bicuspid aortic valve, rheumatic or congenital heart disease,
intravenous drug abuse
Fever
Vascular phenomena
Major arterial emboli, septic pulmonary emboli, mycotic aneurysm,
intracranial hemorrhage, Janeway lesions
Immunologic phenomena
Glomerulonephritis, Osler’s nodes, Roth spots, rheumatoid factor
Positive blood cultures: not meeting major criteria
Echocardiogram: positive but not meeting major criteria
Diagnosis
2 major criteria or
1 major criterion plus 3 minor criteria or
5 minor criteria
*From Bansal RC (27). Infective endocarditis. Med Clin North Am.
1995;79:1205–40. With permission. Modified from Durack DT, Lukes AS, Bright
DK (490). New criteria for diagnosis of infective endocarditis. Am J Med.
1994;96:200–9. With permission.
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Table 22. Native Valve Endocarditis Involving Penicillin-Susceptible Streptococcus viridans and Streptococcus bovis (Minimum Inhibitory
Concentration ,20.1 mg/mL)*
Antibiotic Dosage and Route
Duration,
wk Comments
Aqueous crystalline penicillin
G sodium or
12–18 million U/24 h IV either continuously
or in 6 equally divided doses
4 Preferred in most patients .65 y and those with impairment of the
eighth nerve or renal function.
Ceftriaxone sodium 2 g once daily IV or IM† 4
Aqueous crystalline penicillin
G sodium
12–18 million U/24 h IV either continuously
or in 6 equally divided doses
2 When obtained 1 h after a 20–30 min IV infusion or IM injection,
serum concentration of gentamicin of approximately 3 mg/mL is
With gentamicin sulfate‡ 1 mg/kg IM or IV every 8 h 2 desirable; trough concentration should be ,1 mg/mL.
Vancomycin hydrochloride§ 30 mg/kg per 24 h IV in 2 equally divided
doses, not to exceed 2 g/24 h unless
serum levels are monitored
4 Vancomycin therapy is recommended for patients allergic to b-
lactams; peak serum concentrations of vancomycin should be
obtained 1 h after completion of infusion and should be in the
range of 30–45 mg/mL for twice-daily dosing.
Abbreviations: IV 5 intravenous; IM 5 intramuscular. *Dosages recommended are for patients with normal renal function. For nutritionally variant streptococci,
see Table 24. †Patients should be informed that IM injection of ceftriaxone is painful. ‡Dosing of gentamicin on a mg/kg basis will produce higher serum concentrations
in obese patients than in lean patients. Therefore, in obese patients, dosing should be based on ideal body weight. (Ideal body weight for men is 50 kg 1 2.3 kg/in. .5 ft;
ideal body weight for women is 45.5 kg 1 2.3 kg/in. .5 ft.) Relative contraindications to use of gentamicin are age .65 y, renal impairment, or impairment of the eighth
nerve. Other potentially nephrotoxic agents (eg, nosteroidal anti-inflammatory drugs) should be used cautiously in patients receiving gentamicin. §Vancomycin dosage
should be reduced in patients with impaired renal function. Vancomycin given on a mg/kg basis will produce higher serum concentrations in obese patients than in lean
patients. Therefore, in obese patients, dosing should be based on ideal body weight. Each dose of vancomycin should be infused over .21 h to reduce the risk of the
histamine-release “red man” syndrome. From Wilson et al (491) with permission.
Table 23. Native Valve Endocarditis Involving Streptococcus viridans and Streptococcus bovis Relatively Resistant to Penicillin G (Minimum
Inhibitory Concentration .0.1 mg/mL and ,0.5 mg/mL)*
Antibiotic Dosage and Route
Duration,
wk Comments
Aqueous crystalline
penicillin G sodium
18 million U/24 h IV either continuously or in
6 equally divided doses
4 Cefazolin or other first-generation cephalosporins may be substituted
for penicillin in patients whose penicillin hypersensitivity is not of
With gentamicin sulfate† 1 mg/kg IM or IV every 8 h 2 the immediate type.
Vancomycin
hydrochloride‡
30 mg/kg per 24 h IV in 2 equally divided
doses, not to exceed 2 g/24 h unless serum
levels are monitored
4 Vancomycin therapy is recommended for patients allergic to b-
lactams.
Abbreviations: IV 5 intravenous; IM 5 intramuscular. *Dosages recommended are for patients with normal renal function. †For specific dosing adjustment and
issues concerning gentamicin (obese patients, relative contraindications), see Table 22 footnotes. ‡For specific dosing adjustment and issues concerning vancomycin
(obese patients, length of infusion), see Table 22 footnotes. From Wilson et al (491) with permission.
Table 24. Standard Therapy for Endocarditis Due to Enterococci*
Antibiotic Dosage and Route
Duration,
wk Comments
Aqueous crystalline
penicillin G sodium
18–30 million U/24 h IV either continuously or
in 6 equally divided doses
4–6 4-wk therapy recommended for patients with symptoms ,3 mo in
duration; 6-wk therapy recommended for pts with symptoms
With gentamicin sulfate† 1 mg/kg IM or IV every 8 h 4–6 .3 mo in duration.
Ampicillin sodium 12 g/24 h IV either continuously or in 6 equally
divided doses
4–6
With gentamicin sulfate† 1 mg/kg IM or IV every 8 h 4–6
Vancomycin
hydrochloride‡
30 mg/kg per 24 h IV in 2 equally divided
doses, not to exceed 2 g/24 h unless serum
levels are monitored
4–6 Vancomycin therapy is recommended for patients allergic to b-
lactams; cephalosporins are not acceptable alternatives for
patients allergic to penicillin.
With gentamicin sulfate† 1 mg/kg IM or IV every 8 h 4–6
Abbreviations: IV 5 intravenous; IM 5 intramuscular. *All enterococci causing endocarditis must be tested for antimicrobial susceptibility to selected optimal
therapy. This table is for endocarditis due to gentamicin- or vancomycin-susceptible enterococci, Streptococci viridans with a minimum inhibitory concentration of
.0.5 mg/mL, nutritionally variant S viridans, or prosthetic valve endocarditis caused by S viridans or Streptococcus bovis. Antibiotic dosages are for patients with normal
renal function. †For specific dosing adjustment and issues concerning gentamicin (obese patients, relative contraindications), see Table 22 footnotes. ‡For specific
dosing adjustment and issues concerning vancomycin (obese patients, length of infusion), see Table 22 footnotes. From Wilson et al (491) with permission.
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Table 25. Endocarditis Due to Staphylococcus in the Absence of Prosthetic Material*
Antibiotic Dosage and Route Duration Comments
Methicillin-susceptible staphylococci
Regimens for non–b-lactam-allergic patients
Nafcillin sodium or oxacillin sodium 2 g IV every 4 h 4–6 wk Benefit of additional aminoglycosides has not been
established.
With optional addition of gentamicin sulfate† 1 mg/kg IM or IV every 8 h 3–5 d
Regimens for b-lactam-allergic patients
Cefazolin (or other first-generation
cephalosporins in equivalent dosages)
2 g IV every 8 h 4–6 wk Cephalosporins should be avoided in patients with
immediate-type hypersensitivity to penicillin.
With optimal addition of gentamicin† 1 mg/kg IM or IV every 8 h 3–5 d
Vancomycin hydrochloride‡ 30 mg/kg per 24 h IV in 2 equally divided
doses, not to exceed 2 g/24 h unless
serum levels are monitored
4–6 wk Recommended for patients allergic to penicillin.
Methicillin-resistant staphylococci
Vancomycin hydrochloride‡ 30 mg/kg per 24 h IV in 2 equally divided
doses, not to exceed 2 g/24 h unless
serum levels are monitored
4–6 wk
Abbreviations: IV 5 intravenous, IM 5 intramuscular. *For treatment of endocarditis due to penicillin-susceptible staphylococci (minimum inhibitory
concentration ,20.1 mg/mL), aqueous crystalline penicillin G sodium (Table 22, first regimen) can be used for 4 to 6 wk instead of nafcillin or oxacillin. Shorter antibiotic
courses have been effective in some drug addicts with right-sided endocarditis due to Staphylococcus aureus. †For specific dosing adjustment and issues concerning
gentamicin (obese patients, relative contraindications), see Table 22 footnotes. ‡For specific dosing adjustment and issues concerning vancomycin (obese patients,
length of infusion), see Table 22 footnotes. From Wilson et al (491) with permission.
Table 26. Endocarditis Due to Staphylococcus in the Presence of a Prosthetic Valve or Other Prosthetic Material*
Antibiotic Dosage and Route
Duration,
wk Comments
Regimen for methicillin-resistant staphylococci
Vancomycin hydrochloride† 30 mg/kg per 24 h IV in 2 or 4 equally divided
doses, not to exceed 2 g/24 h unless serum
levels are monitored
.26
With rifampin‡ and 300 mg orally every 8 h .26 Rifampin increases the amount of warfarin sodium
With gentamicin sulfate§\ 1.0 mg/kg IM or IV every 8 h 2 required for antithrombotic therapy.
Regimen for methicillin-susceptible staphylococci
Nafcillin sodium or oxacillin sodium 2 g IV every 4 h .26 First-generation cephalosporins or vancomycin
should be used in patients allergic to b-lactam.
With rifampin‡ and 300 mg orally every 8 h .26 Cephalosporins should be avoided in patients with
With gentamicin sulfate§\ 1.0 mg/kg IM or IV every 8 h 2 immediate-type hypersensitivity to penicillin or
with methicillin-resistant staphylococci.
Abbreviations: IV 5 intravenous; IM 5 intramuscular. *Dosages recommended are for patients with normal renal function. †For specific dosing adjustment and
issues concerning vancomycin (obese patients, length of infusion), see Table 22 footnotes. ‡Rifampin plays a unique role in the eradication of staphylococcal infection
involving prosthetic material; combination therapy is essential to prevent rifampin resistance. §For specific dosing adjustment and issues concerning gentamicin (obese
patients, relative contraindications), see Table 22 footnotes. \Use during initial 2 wk. From Wilson et al (491) with permission.
Table 27. Therapy for Endocarditis Due to HACEK Microorganisms (Haemophilus parainfluenzae, Haemophilus aphrophilus, Actinobacillus
actinomycetemcomitans, Cardiobacterium Hominis, Eikenella corrodens, and Kingella kingae)*
Antibiotic Dosage and Route
Duration,
wk Comments
Ceftriaxone sodium† 2 g once daily IV or IM† 4 Cefotaxime sodium or other third-generation cephalosporins
may be substituted
Ampicillin sodium‡ 12 g/24 h IV either continuously or in
6 equally divided doses
4
With gentamicin sulfate§ 1 mg/kg IM or IV every 8 h 4
Abbreviations: IV 5 intravenous, IM 5 intramuscular. *Antibiotic dosages are for patients with normal renal function. †Patients should be informed that IM
injection of ceftriaxone is painful. ‡Ampicillin should not be used if laboratory tests show b-lactamase production. §For specific dosing adjustment and issues concerning
gentamicin (obese patients, relative contraindications), see Table 22 footnotes. From Wilson et al (491) with permission.
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B. Culture-Negative Endocarditis
Culture-negative endocarditis most frequently (62%) re-
sults from prior antibiotic treatment before blood cultures
were drawn (493,494). The other reasons for negative blood
cultures are infections due to Candida; Aspergillus; or fastidious,
slow-growing organisms (492) and noninfective endocarditis such
as Libman-Sacks endocarditis in patients with systemic lupus
erythematosus. A proposed regimen for culture-negative, pre-
sumed bacterial endocarditis (492) is shown in Table 28.
C. Endocarditis in HIV-Seropositive Patients
Endocarditis in patients who are HIV-seropositive usually
occurs as a complication of injection drug use or long-term
indwelling central catheters. S aureus is the most frequent
pathogen. When endocarditis is not related to intravenous
drug use, right- and left-sided valves are equally involved.
Intravenous drug use is the most common cause of tricuspid
valve endocarditis. Endocarditis-related mortality in patients
with AIDS exceeds that of HIV-positive patients without AIDS.
Thus, it is recommended that endocarditis in patients with AIDS
be treated with maximum-duration antibiotic regimens (491).
D. Indications for Echocardiography in
Endocarditis
Echocardiography is useful for detection and characteriza-
tion of the hemodynamic and pathological consequences of
infection. These consequences include valvular vegetations;
valvular regurgitation; ventricular dysfunction; and associated
lesions such as abscesses, shunts, and ruptured chordae (495).
The indications for transthoracic and transesophageal echo-
cardiography are discussed in the ACC/AHA Guidelines for
the Clinical Application of Echocardiography (2). Transesoph-
ageal imaging is more sensitive in detecting vegetations than
transthoracic imaging (488,496). Echocardiography may be
useful in the case of culture-negative endocarditis (497) or the
diagnosis of a persistent bacteremia whose source remains
unidentified after appropriate evaluation (2).
Recommendations for Echocardiography in Infective Endocarditis:
Native Valves
Indication Class
1. Detection and characterization of valvular lesions, their
hemodynamic severity, and/or ventricular compensation.*
I
2. Detection of vegetations and characterization of lesions in
patients with congenital heart disease in whom infective
endocarditis is suspected.
I
3. Detection of associated abnormalities (eg, abscesses, shunts).* I
4. Reevaluation studies in complex endocarditis (eg, virulent
organism, severe hemodynamic lesion, aortic valve
involvement, persistent fever or bacteremia, clinical change, or
symptomatic deterioration).
I
5. Evaluation of patients with high clinical suspicion of culture-
negative endocarditis.*
I
6. Evaluation of bacteremia without a known source.* IIa
7. Risk stratification in established endocarditis.* IIa
8. Routine reevaluation in uncomplicated endocarditis during
antibiotic therapy.
IIb
9. Evaluation of fever and nonpathological murmur without
evidence of bacteremia.
III
*Transesophageal echocardiography may provide incremental value in
addition to information obtained by transthoracic imaging. From the ACC/AHA
Guidelines for the Clinical Application of Echocardiography (2).
Recommendations for Echocardiography in Infective Endocarditis:
Prosthetic Valves
Indication Class
1. Detection and characterization of valvular lesions, their
hemodynamic severity, and/or ventricular compensation.*
I
2. Detection of associated abnormalities (eg, abscesses, shunts).* I
3. Reevaluation in complex endocarditis (eg, virulent organism,
severe hemodynamic lesion, aortic valve involvement,
persistent fever or bacteremia, clinical change, or
symptomatic deterioration).
I
4. Evaluation of suspected endocarditis and negative cultures.* I
5. Evaluation of bacteremia without a known source.* I
6. Evaluation of persistent fever without evidence of bacteremia
or new murmur.*
IIa
7. Routine reevaluation in uncomplicated endocarditis during
antibiotic therapy.*
IIb
8. Evaluation of transient fever without evidence of bacteremia
or new murmur.
III
*Transesophageal echocardiography may provide incremental value in
addition to that obtained by transthoracic imaging. From the ACC/AHA
Guidelines for the Clinical Application of Echocardiography (2).
E. Outpatient Treatment
Patients with penicillin-susceptible S viridans endocarditis
who are hemodynamically stable, compliant, and capable of
managing the technical aspects of outpatient therapy may be
candidates for a single daily-dose regimen of ceftriaxone (491).
Recent clinical reports suggest that right-sided endocarditis
caused by S aureus in intravenous drug users may be amenable
to a short 2-week course of therapy (498,499). Monotherapy
with ceftriaxone or combination therapy with an aminogly-
coside has been tried as an outpatient therapeutic option
(500). However, more data are needed to determine with
Table 28. Fungal Endocarditis and Culture-Negative Endocarditis*
Agent Dosage and Route
Duration,
wk
Fungal endocarditis*
Amphotericin B
with or without
1 mg/kg per day IV (total dose
2.0–2.5 g)
6–8
flucytosine 150 mg/kg per day PO in 4
divided doses
6–8
Culture-negative endocarditis†
Vancomycin plus 15 mg/kg IV every 12 h 6
gentamicin 1 mg/kg IM or IV every 8 h 6
*Recommendations for fungal endocarditis were not part of the AHA
recommendations on infective endocarditis (491). †Proposed regimen for
culture-negative, presumed bacterial endocarditis (492).
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more certainty whether such outpatient regimens have
therapeutic effectiveness equivalent to the established
4-week regimens.
F. Indications for Surgery in Patients With Active
Infective Endocarditis
Surgery is indicated in patients with life-threatening con-
gestive heart failure or cardiogenic shock due to surgically
treatable valvular heart disease with or without proven infec-
tive endocarditis if the patient has reasonable prospects of
recovery with satisfactory quality of life after the operation
(442,501–525). Surgery should not be delayed in the setting of
acute infective endocarditis when congestive heart failure
intervenes. Surgery is not indicated if complications (severe
embolic cerebral damage) or comorbid conditions make the
prospect of recovery remote.
The indications for surgery for infective endocarditis in
patients with stable hemodynamics are less clear. Early con-
sultation with a cardiovascular surgeon is recommended as
soon as the diagnosis of aortic or mitral valve endocarditis is
made so that the surgical team is aware of the patient who may
suddenly need surgery. Surgery is recommended in patients
with annular or aortic abscesses, those with infections resistant
to antibiotic therapy, and those with fungal endocarditis. It is
recognized that the presence of valvular vegetations poses a
threat of embolic events. Echocardiography, especially with
transesophageal imaging, identifies vegetations and pro-
vides size estimation in many instances. Patients with a
vegetation diameter .10 mm have a significantly higher
incidence of embolization than those with a vegetation
diameter ,210 mm (488), and this risk appears to be higher
in patients with mitral valve endocarditis than aortic valve
endocarditis. However, operation on the basis of vegetation
size alone is controversial.
Patients with prosthetic valves receiving warfarin anticoag-
ulation who develop endocarditis should have their warfarin
discontinued and replaced with heparin. This recommendation
is less related to the possibility of hemorrhagic complications
of endocarditis (526) than the possibility of urgent surgery.
If surgery is required, the effects of warfarin will have
dissipated, and heparin can easily be reversed. Likewise,
aspirin, if part of the medical regimen, should also be
discontinued. If neurological symptoms develop, anticoagu-
lation should be discontinued until an intracranial hemor-
rhagic event is excluded by magnetic resonance imaging or
computed tomographic scanning.
Recommendations for Surgery for Native Valve Endocarditis*
Indication Class
1. Acute AR or MR with heart failure. I
2. Acute AR with tachycardia and early closure of the mitral valve. I
3. Fungal endocarditis. I
4. Evidence of annular or aortic abscess, sinus or aortic true or false
aneurysm.
I
5. Evidence of valve dysfunction and persistent infection after a
prolonged period (7 to 10 days) of appropriate antibiotic therapy,
as indicated by presence of fever, leukocytosis, and bacteremia,
provided there are no noncardiac causes for infection.
I
6. Recurrent emboli after appropriate antibiotic therapy. IIa
7. Infection with gram-negative organisms or organisms with a poor
response to antibiotics in patients with evidence of valve
dysfunction.
IIa
8. Mobile vegetations >10 mm. IIb
9. Early infections of the mitral valve that can likely be repaired. III
10. Persistent pyrexia and leukocytosis with negative blood cultures. III
*Criteria also apply to repaired mitral and aortic allograft or autograft
valves. Endocarditis defined by clinical criteria with or without laboratory
verification; there must be evidence that function of a cardiac valve is impaired.
Recommendations for Surgery for Prosthetic Valve Endocarditis*
Indication Class
1. Early prosthetic valve endocarditis (first 2 months or less after
surgery).
I
2. Heart failure with prosthetic valve dysfunction. I
3. Fungal endocarditis. I
4. Staphylococcal endocarditis not responding to antibiotic therapy. I
5. Evidence of paravalvular leak, annular or aortic abscess, sinus or
aortic true or false aneurysm, fistula formation, or new-onset
conduction disturbances.
I
6. Infection with gram-negative organisms or organisms with a poor
response to antibiotics.
I
7. Persistent bacteremia after a prolonged course (7 to 10 days) of
appropriate antibiotic therapy without noncardiac causes for
bacteremia.
IIa
8. Recurrent peripheral embolus despite therapy. IIa
9. Vegetation of any size on or near the prosthesis. IIb
*Criteria exclude repaired mitral valves or aortic allograft or autograft
valves. Endocarditis is defined by clinical criteria with or without laboratory
verification.
V. Management of Valvular Disease in
Pregnancy
A. Physiological Changes of Pregnancy
The evaluation and management of valvular heart disease
in the pregnant patient requires an understanding of the
normal physiological changes associated with gestation, labor,
delivery, and the early postpartum period. On average, there is
a 50% increase in circulating blood volume during pregnancy
that is accompanied by a commensurate increase in cardiac
output that usually peaks between the midportion of the
second and third trimesters. The augmented cardiac output
derives from an increase in the stroke volume, although there
is also a smaller increase in heart rate, averaging 10 to 20 beats
per minute. Because of the effects of uterine circulation and
endogenous hormones, systemic vascular resistance falls with a
disproportionately greater lowering of diastolic blood pressure
and a wide pulse pressure. Inferior vena caval obstruction from
a gravid uterus in the supine position can result in an abrupt
decrease in cardiac preload, leading to hypotension with
weakness and lightheadedness. These symptoms resolve
quickly with a change in position (527).
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There is a further abrupt increase in cardiac output during
labor and delivery related in part to the associated anxiety and
pain. Uterine contractions can lead to marked increases in
both systolic and diastolic blood pressure. After delivery, there
is an initial surge in preload related to the autotransfusion of
uterine blood into the systemic circulation and to caval decom-
pression (527).
Pregnancy is also associated with a hypercoagulable state
owing to relative decreases in protein S activity, stasis, and
venous hypertension (528). Estrogens may interfere with col-
lagen deposition within the media of the medium- and large-
sized muscular arteries. Circulating elastase can break up the
elastic lamellae and weaken the aortic media during preg-
nancy. Weakening of the vascular wall may in turn predispose
to dissection with or without an underlying connective tissue
disorder.
B. Physical Examination
The physical examination of the normal parturient is nota-
ble for a slightly fast resting heart rate, bounding pulses
(although not truly water-hammer), a widened pulse pressure
with a low normal peak systolic pressure, and warm extremi-
ties. Venous pressure is usually elevated above the normal
range for nonpregnant women but rarely in a clearly abnormal
range. The thyroid gland may be enlarged in the absence of
clinical hyperthyroidism. Depending on the stage of pregnancy,
the lung volumes may be low because of the raised diaphragms.
The precordial impulse is hyperkinetic, and the first heart
sound may be louder than normal, with prominent splitting.
The second heart sound is usually physiologically split but may
also widen and appear fixed during the later stages of preg-
nancy. Third heart sounds are common. A soft grade 1 to 2
midsystolic murmur that is best heard along the mid to upper
left sternal edge is a frequent finding (24). A continuous
murmur, reflecting either a venous hum or a mammary souffle´,
may sometimes be heard during careful auscultation. The
cervical venous hum is best appreciated in the right supracla-
vicular fossa and can be obliterated by movement of the chin
toward the stethoscope or digital pressure over the ipsilateral
jugular vein. The mammary souffle´ is a systolic or continuous
sound over the engorged breast that can usually be obliterated
with firm pressure applied to the diaphragm of the stetho-
scope. It is heard in the supine position and attenuates or
disappears when standing. It is appreciated in the late stages of
pregnancy or early in the puerperium. Diastolic heart murmurs
are unusual. The increased blood volume and enhanced car-
diac output associated with normal pregnancy can accentuate
the murmurs associated with stenotic heart valve lesions (eg,
MS, AS). On the other hand, murmurs of AR or MR may
actually attenuate in the face of lowered systemic vascular
resistance (529).
C. Echocardiography
Normal pregnancy is accompanied by echocardiographic
evidence of mild ventricular chamber enlargement. Pulmonic
and tricuspid valvular regurgitation, as assessed by Doppler
interrogation, is the rule rather than the exception (530). A
large minority of women will demonstrate Doppler evidence of
“physiological” MR in the absence of structural valve disease.
Atrioventricular valve incompetence may derive from the
annular dilatation that accompanies ventricular enlargement.
Appreciation of these echocardiographic and Doppler findings
in normal individuals is an important foundation for the
noninvasive evaluation of subjects with suspected valvular
disease. The use of ultrasound during pregnancy poses no risk
to the mother or fetus.
D. General Management Guidelines
Clinical experience has shown that there are several cardiac
conditions in which the physiological changes of pregnancy are
poorly tolerated. Most experts would agree that, for some
conditions, such as cyanotic heart disease, Eisenmenger syn-
drome, or severe pulmonary hypertension, pregnancy should
be discouraged. Valvular heart lesions associated with high
maternal and fetal risk during pregnancy are listed in Table 29.
Lesions associated with low risk during pregnancy are listed in
Table 30.
Individual counseling usually requires a multidisciplinary
approach and should include information regarding contracep-
tion, maternal and fetal risks of pregnancy, and expected
long-term outcomes. However, many patients with valvular
heart disease can be successfully managed throughout preg-
nancy and during labor and delivery with conservative medical
Table 29. Valvular Heart Lesions Associated With High Maternal
and/or Fetal Risk During Pregnancy
1. Severe AS with or without symptoms
2. AR with NYHA functional Class III–IV symptoms
3. MS with NYHA functional Class II–IV symptoms
4. MR with NYHA functional Class III–IV symptoms
5. Aortic and/or mitral valve disease resulting in severe pulmonary
hypertension (pulmonary pressure .75% of systemic pressures)
6. Aortic and/or mitral valve disease with severe LV dysfunction (EF ,0.40)
7. Mechanical prosthetic valve requiring anticoagulation
8. AR in Marfan syndrome
Abbreviations: EF 5 ejection fraction.
Table 30. Valvular Heart Lesions Associated With Low Maternal
and Fetal Risk During Pregnancy
1. Asymptomatic AS with low mean gradient (,50 mm Hg) in presence of
normal LV systolic function (EF .0.50)
2. NYHA functional Class I or II AR with normal LV systolic function
3. NYHA functional Class I or II MR with normal LV systolic function
4. MVP with no MR or with mild to moderate MR and with normal LV
systolic function
5. Mild to moderate MS (MVA .1.5 cm2, gradient ,5 mm Hg) without
severe pulmonary hypertension
6. Mild to moderate pulmonary valve stenosis
Abbreviations: EF 5 ejection fraction, MVA 5 mitral valve area.
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measures designed to optimize intravascular volume and sys-
temic loading conditions.
Simple interventions such as bed rest and avoidance of the
supine position should not be overlooked. Whenever possible,
symptomatic or severe valvular lesions should be addressed
and rectified before conception and pregnancy. Contempora-
neous management with a dedicated obstetrical team accus-
tomed to working with high-risk patients is encouraged. Drugs
should generally be avoided whenever possible (Table 31).
E. Specific Lesions
1. Mitral Stenosis. Young pregnant women with a previous
history of acute rheumatic fever and carditis should continue to
receive penicillin prophylaxis as indicated in the nonpregnant
state. The most common rheumatic lesion in this age group
remains MS. Patients with mild to moderate MS can almost
always be managed with judicious use of diuretics and
b-blockade. Diuretics are given to relieve pulmonary and
excess systemic venous congestion, but care must be taken to
avoid vigorous volume depletion to protect against uretero-
placental hypoperfusion. b-blockers are chiefly indicated to
treat or prevent tachycardia to optimize diastolic filling. Al-
though the nonselective b-blocker propranolol has been in use
for decades, some authorities recommend a cardioselective
b-blocker such as metoprolol or atenolol to prevent the
potential deleterious effects of epinephrine blockade on myo-
metrial activity.
Patients with severe MS who are symptomatic before
conception will not predictably tolerate the hemodynamic
burden of pregnancy and should be considered for percutane-
ous balloon mitral valvotomy before conception, provided the
valve is anatomically suitable. Patients with severe MS who
develop NYHA functional Class III-IV symptoms during preg-
nancy should undergo percutaneous balloon valvotomy.
For rare patients with MS who fail medical management
during pregnancy with repetitive or persistent heart failure,
there is now a nearly 10-year experience with balloon mitral
valvotomy, either with very limited fluoroscopy (less than 1 to
2 minutes exposure with both pelvic and abdominal shielding)
or echocardiographic guidance. The reported results with
mitral balloon valvotomy have been excellent, with few mater-
nal and/or fetal complications, although caution is advised in
interpreting outcomes from individual centers reporting rela-
tively few patients (531–540). Percutaneous mitral balloon
valvotomy should only be performed in experienced centers
and only after aggressive medical measures have been ex-
hausted. In developing countries, there is a long history of
successful surgical closed commissurotomy for pregnant
women (541).
2. Mitral Regurgitation. MVP is the most common cause
of MR in pregnant women. The physical findings pertinent to
MVP may be obscured or varied by the physiological changes
of pregnancy, especially the increased blood volume and
reduced systemic vascular resistance. Associated MR can
usually be managed medically, although on rare occasions,
Table 31. Effects of Cardiovascular Drugs Taken During Pregnancy
Drug Potential Fetal Adverse Effects Safety
Warfarin Crosses placental barrier, fetal hemorrhage in utero, embryopathy, central nervous system abnormalities Unsafe
Heparin None reported Probably safe
Digoxin Low birth weight Safe
Quinidine Toxic dose may induce premature labor and cause damage to fetal eighth cranial nerve Safe
Procainamide None reported Safe
Disopyramide May initiate uterine contractions *
Lidocaine High blood levels and fetal acidosis may cause central nervous system depression Safe
Mexiletine Fetal bradycardia, IUGR, low Apgar score, neonatal hypoglycemia, neonatal bradycardia, and neonatal
hyperthyroidism
*
Flecainide 1 reported fetal death *
Propafenone None reported *
Adenosine None reported. Use during first trimester limited to a few patients. Safe
Amiodarone IUGR, prematurity, hypothyroidism Unsafe
Calcium channel blocking agents Fetal distress due to maternal hypotension *
b-adrenergic blocking agents IUGR, apnea at birth, bradycardia, hypoglycemia, hyperbilirubinemia; b2-blockade blocking agents may
initiate uterine contractions
Safe
Hydralazine None reported Safe
Sodium nitroprusside Potential thiocyanate toxicity with high dose, fetal mortality with nitroprusside in animal studies Potentially unsafe
Organic nitrates Fetal heart rate deceleration and bradycardia *
ACE inhibitors Skull ossification defect, IUGR, premature deliveries, low birth weight, oligohydramnios, neonatal renal
failure, anemia and death, limb contractures, patent ductus arteriosus
Unsafe
Diuretic agents Impairment of uterine blood flow and danger of placental hypoperfusion, thrombocytopenia, jaundice
hyponatremia, bradycardia
Potentially unsafe
Abbreviation: IUGR 5 intrauterine growth retardation. *To date, only limited information is available, and safety during pregnancy cannot be established. Adapted
from Elkayam U (527). Pregnancy and cardiovascular disease. In: Braunwald E, ed. Heart Disease. A Textbook of Cardiovascular Medicine. 5th ed. Philadelphia, Pa:
WB Saunders; 1997:1857, with permission. The guidelines committee added warfarin, heparin, and hydralazine to this list.
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mitral valve surgery is required because of ruptured chordae
and acute, severe worsening of the regurgitant lesion. Medical
management includes diuretics for the rare patient with pul-
monary congestion. Vasodilator therapy is indicated only in
the presence of concomitant systemic hypertension and should
not be advised in the setting of normal or low systemic blood
pressure. ACE inhibitors are considered unsafe because of
their multiple adverse effects on fetal development. There is
wide experience with hydralazine, an agent generally consid-
ered safe. When mitral valve surgery is required, repair is
always preferred, as would be the case for any young patient
but especially in relation to the desirability of avoiding the
potential need for anticoagulation.
3. Aortic Stenosis. The most common cause of AS in
pregnant women is congenital bicuspid disease. Patients with
mild to moderate obstruction and normal LV systolic function
can usually be managed conservatively through the entire
pregnancy. Patients with more severe obstruction (pressure
gradient .50 mm Hg) or symptoms should be advised to delay
conception until relief of AS can be obtained. For those rare
women with severe AS whose disease is first appreciated
during pregnancy, consideration may have to be given to either
percutaneous aortic balloon valvotomy (542,543) or surgery
(depending on the anatomic findings) before labor and
delivery if heart failure has developed or syncope has
occurred. These procedures are fraught with danger to both
the mother and fetus, although successful outcomes have
been reported. Neither is to be undertaken without caution
and forewarning. There is an association between the pres-
ence of a bicuspid aortic valve and cystic medial necrosis,
which may predispose to spontaneous aortic dissection,
usually in the third trimester.
4. Aortic Regurgitation. Isolated AR, like MR, can usually
be managed medically with a combination of diuretics and, if
necessary, vasodilator therapy (544). Women with symptoms
and/or signs of LV failure should be carefully monitored
throughout labor and delivery with strict attention to volume
status and blood pressure. As is true for MR, surgery during
pregnancy should be contemplated only for control of refrac-
tory Class III or IV symptoms. Consideration regarding LV
size or systolic function in less symptomatic patients should not
apply.
5. Pulmonary Valve Stenosis. Pulmonary valve stenosis
may exist in isolation but frequently accompanies other con-
genital heart lesions. In general, patients with cyanotic congen-
ital heart disease tolerate the stresses of pregnancy far less well
than those with acyanotic lesions. Isolated pulmonic stenosis is
rarely a significant impediment to a successful pregnancy. This
lesion can be approached with percutaneous valvotomy under
echocardiographic guidance when necessary.
6. Tricuspid Valve Disease. Tricuspid valve disease may be
congenital (Ebstein’s anomaly, tricuspid atresia) or acquired
(endocarditis, myxomatous replacement/proliferation, carci-
noid). The approach to the patient with tricuspid valve involve-
ment as part of a more complex congenital heart disease
syndrome is predicated on the features of the associated
lesions. Isolated TR should not pose a significant problem,
although greater care may be necessary to protect against
diuretic-induced hypoperfusion.
7. Marfan Syndrome. The Marfan syndrome is an inherit-
able disorder of connective tissue that stems from abnormali-
ties in the fibrillin gene on chromosome 15. It is transmitted in
an autosomal dominant fashion and is recognized clinically by
its ocular, skeletal, and cardiovascular expressions. Spontane-
ous aortic dissection and/or rupture are the most feared
cardiovascular complications associated with pregnancy
(545,546). Dissection can occur at any point along the aorta but
most commonly originates in the ascending portion. Enlarge-
ment of the aortic root to .4.0 cm identifies a particularly
high-risk group, although a normal dimension is by no means
a guarantee against this catastrophic complication. Aortic root
enlargement may or may not be accompanied by regurgitation
and an audible heart murmur. MVP with regurgitation is also
frequently detected.
Any woman with Marfan syndrome who is contemplating
pregnancy should have a screening transthoracic echocardio-
gram with careful assessment of aortic root dimensions. En-
largement .25.0 cm is considered an indication for elective
repair before conception, usually with a composite valve-graft
conduit and reimplantation of the coronary arteries. If aortic
root enlargement (.4.0 cm) is first detected during pregnancy,
some authorities recommend termination with prompt aortic
repair, especially if serial echocardiographic studies demon-
strate progressive dilatation over time. Dissection and rupture
are most likely to occur during the third trimester or near the
time of delivery. Special care must be taken to provide
adequate analgesia to prevent wide surges in blood pressure
and its rate of rise (dP/dt) during labor and delivery. Obstet-
rical techniques to shorten the second stage of labor are
appropriate. General anesthesia and caesarean section may
allow more optimal hemodynamic control. The use of prophy-
lactic b-blockade throughout the pregnancy is strongly recom-
mended. Such treatment has been shown to slow the rate of
aortic dilatation and reduce the cumulative incidence of car-
diovascular complications in nonpregnant adolescents and
adults (547). Finally, it should be pointed out that patients with
Marfan syndrome and no identifiable cardiovascular abnor-
malities on examination or echocardiographic study can be
safely shepherded through pregnancy and a normal vaginal
delivery.
F. Endocarditis Prophylaxis
The Committee on Rheumatic Fever, Endocarditis, and
Kawasaki Disease of the American Heart Association does not
recommend routine antibiotic prophylaxis in patients with
valvular heart disease undergoing uncomplicated vaginal de-
livery or caesarean section unless infection is suspected. Anti-
biotics are optional for high-risk patients with prosthetic heart
valves, a previous history of endocarditis, complex congenital
heart disease, or a surgically constructed systemic-pulmonary
conduit (36). Many practitioners routinely provide antibiotics.
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G. Cardiac Valve Surgery
The performance of cardiac valve surgery is a difficult and
complex undertaking in the pregnant patient. Even under ideal
conditions, including the use of cardiopulmonary bypass tech-
niques that promote high flow rates and warm perfusion
temperatures, there is a high incidence of fetal distress, growth
retardation, or wastage (548–550). If possible, it is always
preferable to delay surgery until the time the fetus is viable
and a caesarean section can be performed as part of a
concomitant procedure (551,552). Surgery should be pur-
sued only in the setting of medically refractory symptoms
(pulmonary congestion), especially if a low output syndrome
intervenes.
For suitable valve lesions, repair is always preferred over
replacement. If valve replacement is necessary, the choice of a
heart valve substitute can be problematic. Bioprosthetic valves
degenerate more quickly in younger patients, a process that
can be further accelerated during pregnancy (553). Although
such valves may not require longer-term anticoagulation, they
do expose the young patient to an earlier risk of failure and
need for reoperation. Mechanical valve substitutes are more
durable, but the obligate need for anticoagulation may com-
plicate current and future pregnancies. For aortic valve dis-
ease, homograft valves or pulmonary autografts should be
considered (554).
H. Anticoagulation
Pregnant patients with mechanical valve prostheses have an
obligate need for anticoagulation. Unfortunately, there remain
significant problems and an impressive risk to both the mother
and fetus of either hemorrhage or thrombosis with the use of
either warfarin or heparin. For example, maternal thrombo-
embolic phenomena may complicate from 4% to 14% of
pregnancies in women with mechanical prostheses despite
adequate anticoagulation as measured by the serum INR or
aPTT (555,556).
Guidelines for the management of the pregnant patient
with a mechanical prosthesis have been difficult to formulate
due to the lack of adequate prospective randomized controlled
trial data. Practice patterns vary widely and no consensus exists, as
might be expected from the disparate results and claims of the
retrospective and selective case series that have been reported to
date. Appropriately designed trials are needed.
1. Warfarin. Warfarin crosses the placenta and has been
associated with an increased incidence of spontaneous abor-
tion, prematurity, and stillbirth. The manufacturer considers
its use during pregnancy to be strictly contraindicated by virtue
of its association with fetal deformity (embryopathy) and
central nervous system abnormalities. The true incidence of
warfarin embryopathy has been difficult to ascertain from the
reported case series and has ranged from ,5% to 67%
(556,557). An estimate of 4% to 10% seems reasonable,
based on recent reports (558,559). Its risk may be dose
related and appears to be highest if exposure occurs during
the 6th to 12th week of gestation. Fetal cerebral hemorrhage
can complicate labor and delivery, especially if forceps
evacuation is necessary.
2. Heparin. Heparin does not cross the placenta and is
generally considered safer (558,560). Its longer-term use,
however, is complicated by sterile abscesses, osteoporosis (albeit
with a small risk of fracture), thrombocytopenia, and bleeding.
Although heparin was previously considered the preferred anti-
thrombotic agent, numerous case series and patient registries
attest to an unacceptable incidence of thromboembolic compli-
cations, including fatal valve thrombosis, in high-risk pregnant
women managed with subcutaneous heparin (12% to 24%)
(558,561–564). Criticisms have been levied against these
studies because of the inclusion of a predominant popula-
tion of women with older-generation and more thrombo-
genic prostheses, inadequate heparin dosing, and/or the lack
of meticulous monitoring strategies. Unfortunately, the
efficacy of adjusted-dose subcutaneous heparin has not been
definitively established.
The choice of anticoagulant must be carefully considered
and should derive from a consideration of maternal prefer-
ences regarding the competing risks to the mother and to the
fetus. For many women, a 4% to 10% risk of warfarin
embryopathy is unacceptable. These women may be unwill-
ing to take warfarin at any time during the first trimester or
throughout the entire pregnancy. Implicit in their choice of
heparin, however, is the acceptance of increased risk of maternal
hemorrhage or prosthetic valve thrombosis. Certainly, a full
discussion of these issues is indicated before conception. The
hazards of anticoagulation are considered by many to be so
odious as to argue that mechanical prosthetic valves are relatively
contraindicated in women of child-bearing potential.
Recommendations for Anticoagulation During Pregnancy in Patients
With Mechanical Prosthetic Valves: Weeks 1 Through 35
Indication Class
1. The decision whether to use heparin during the first trimester
or to continue oral anticoagulation throughout pregnancy
should be made after full discussion with the patient and her
partner; if she chooses to change to heparin for the first
trimester, she should be made aware that heparin is less safe
for her, with a higher risk of both thrombosis and bleeding,
and that any risk to the mother also jeopardizes the baby.*
I
2. High-risk women (a history of thromboembolism or an older-
generation mechanical prosthesis in the mitral position) who
choose not to take warfarin during the first trimester should
receive continuous unfractionated heparin intravenously in a
dose to prolong the midinterval (6 hours after dosing) aPTT to 2
to 3 times control. Transition to warfarin can occur thereafter.
I
3. In patients receiving warfarin, INR should be maintained
between 2.0 and 3.0 with the lowest possible dose of warfarin,
and low-dose aspirin should be added.
IIa
4. Women at low risk (no history of thromboembolism, newer
low-profile prosthesis) may be managed with adjusted-dose
subcutaneous heparin (17,500 to 20,000 U BID) to prolong the
mid-interval (6 hours after dosing) aPTT to 2 to 3 times control.
IIb
*From the European Society of Cardiology Guidelines for Prevention of
Thromboembolic Events in Valvular Heart Disease (304).
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Recommendations for Anticoagulation During Pregnancy in
Patients With Mechanical Prosthetic Valves: After the 36th Week
Indication Class
1. Warfarin should be stopped no later than week 36 and heparin
substituted in anticipation of labor.
IIa
2. If labor begins during treatment with warfarin, a caesarian
section should be performed.
IIa
3. In the absence of significant bleeding, heparin can be resumed
4 to 6 hours after delivery and warfarin begun orally.
IIa
Low-molecular-weight heparins offer several potential ad-
vantages over unfractionated heparin, including greater bio-
availability, ease of administration, lack of need for laboratory
monitoring, and a lower incidence of thrombocytopenia and
osteoporosis. They do not cross the placenta. Although they
have been used to treat deep venous thrombosis in pregnant
patients, there are no data to guide their use in the manage-
ment of patients with mechanical heart valves (563). The
recommendation to add low-dose aspirin to a regimen of warfarin
or intravenous or adjusted-dose subcutaneous heparin is based on
an extrapolation of the results of a single randomized controlled
trial of antithrombotic therapy in high-risk patients with pros-
thetic heart valves (564). Dipyridamole should not be considered
as an alternative antiplatelet agent because of its harmful effects
on the fetus. Neither warfarin nor heparin is contraindicated in
postpartum mothers who breast-feed (560).
VI. Management of Valvular Heart Disease
in Adolescents and Young Adults
Although the majority of valvular heart disease in older
adults is acquired, the predominant etiology is congenital in
children, adolescents, and young adults. It has been estimated
that the prevalence of congenital heart disease is '440,000 in
the United States (exclusive of bicuspid aortic valves; see
below) (565). Many patients with congenital heart disease have
some valvular involvement. Frequently, it is part of a more
complex congenital cardiac anomaly, ie, tricuspid stenosis in
children with pulmonary atresia and an intact ventricular
septum or AS from aortic valve atresia as part of a hypoplastic
left-heart syndrome. The management of these complex dis-
eases with multiple valve involvement is beyond the scope of
these guidelines. Rather, this section concerns isolated valve
involvement where it is the primary anatomic abnormality.
In evaluating valvular stenosis in children, the severity of
valvular obstruction is usually reported as peak-to-peak systolic
gradient at cardiac catheterization or maximum instantaneous
gradient by Doppler rather than valve area. In the catheteriza-
tion laboratory, the variation in body size from the neonate to
the adult, difficulties in measuring cardiac output (especially in
young children), and the relatively rare patient with low
cardiac output have made peak ventricular–to–peak great-
vessel pressure gradients for semilunar valves and mean pres-
sure gradients for atrioventricular valves the reference stan-
dards. With the development of Doppler echocardiographic
assessment of valvular obstruction, most pediatric cardiologists
have continued to rely on gradients calculated from peak
velocity using the formula gradient54V2 for the semilunar
valves and mean gradients for the atrioventricular valves rather
than on valve area. The peak gradient measured by Doppler
velocity (based on maximum instantaneous velocity) is higher
than the peak-to-peak gradient measured at catheterization. In
contrast to children and adolescents, valve area is used by
many centers in evaluation of the young adult.
Ventricular end-systolic or end-diastolic diameter or vol-
umes used in evaluating patients with valvular regurgitation
are frequently corrected for the large variations in body size
among children, adolescents, and young adults. Chamber size is
corrected for body surface area (m2) or commonly by the number
of standard deviations (Z score) above or below the mean with
standard nomograms that correct for body size (566).
The management of the neonate, infant, and young child
differs significantly from that of the adolescent and young
adult. This section will deal exclusively with adolescents and
young adults.
A. Aortic Stenosis
Although most adults with aortic valve stenosis have a
degenerative-calcific process that produces immobilization of
the valve cusps, adolescents and young adults with isolated
aortic valve stenosis almost always have congenital fusion of
one or more commissures resulting in a bicuspid or unicuspid
valve. Although the prevalence of bicuspid and unicuspid
valves may be as high as 2%, only 1 of 50 children born with
these abnormalities will actually have significant obstruction or
regurgitation by adolescence.
Much of what has been written in these guidelines for adults
with acquired AS may be transferred to the adolescent or
young adult. However, certain important differences must be
emphasized. Throughout childhood, the aortic annulus and
aortic valve must grow parallel with somatic growth. If growth
of either the annulus or valve leaflets lags, increased obstruc-
tion may occur. Therefore, the rate of progression during
childhood and adolescent growth may be different from that in
the adult with acquired heart disease. The report from the joint
study on the Natural History of Congenital Heart Defects (567)
followed 473 patients (before the advent of echocardiography),
60% of whom were initially evaluated between 2 and 11 years of
age and 34% between 11 and 21 years of age. One third of the
children had an increase in the transaortic gradient measured by
cardiac catheterization during the 4- to 8-year follow-up period.
However, the 54 patients .12 years of age showed very small
increases. Those with higher initial gradients had a greater
likelihood of demonstrating an increase in the gradient.
Recently, long-term results of the original cohort have been
reported (568), with a mean follow-up period of 20 years. Only
20% of those with initial peak LV–to–peak aortic pressure
gradients ,25 mm Hg at initial catheterization had any
intervention. However, in those with an initial peak gradient
.50 mm Hg, arrhythmias, sudden death, and other morbid
events (including endocarditis, congestive heart failure, syn-
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cope, angina, myocardial infarction, stroke, and pacemaker
insertion) occurred at a rate of '1.2% per year. Sudden
cardiac death occurred in 25 of the 370 patients followed over
'8,000 patient years, an incidence of '0.3% per year. The
severity of obstruction in those who died could not be deter-
mined, and a higher-risk subgroup could not be excluded.
The diagnosis of AS can usually be made clinically, with
severity estimated by ECG and Doppler echocardiographic stud-
ies. Diagnostic cardiac catheterization is occasionally required if
there is a discrepancy among clinical evaluation, ECG, and/or
Doppler echocardiographic findings. Exercise testing may be
useful, especially in those interested in athletic participation.
Recommendations for Diagnostic Evaluation of the Adolescent or
Young Adult With Aortic Stenosis*
Indication Class
1. ECG.* I
2. Echo-Doppler study.* I
3. Graded exercise test.† IIa
4. Cardiac catheterization† for evaluation of gradient. IIa
5. Chest x-ray.* IIb
6. Coronary arteriography in the absence of history suggestive
of concomitant CAD.
III
*Yearly if echo-Doppler gradient >36 mm Hg (velocity >23 m/s). Every 2
years if echo-Doppler gradient <36 mm Hg (peak velocity <3 m/s). †If
echo-Doppler gradient >36 mm Hg (velocity >3 m/s) and patient interested in
athletic participation or if clinical findings and echo-Doppler are disparate.
Balloon valvotomy for calcific AS in older adults has been at
best very short-term palliation. In contrast, the results of
balloon valvotomy in children and adolescents with obstruction
due to fusion of commissures have been considerably more
efficacious. In a large collaborative registry involving 606
patients from 23 institutions, the peak LV–to–peak aortic
pressure gradients at catheterization were reduced by a mean
of 60% (569). In a single-institution study of 148 patients
dilated at age 1 month to 20 years (570), midterm results
showed an 8-year actuarial survival of 95%, with 3 of the 4
deaths occurring in infants who were dilated at ,1 year of age.
Seventy percent of patients were free from operation and 50%
were free from intervention 8 years after dilation, which was
similar to results reported with surgical valvuloplasty. Long-
term follow-up is incomplete because balloon valvotomy was
introduced in the 1980s.
Although balloon dilation has become standard in children
and adolescents with AS, it is rarely recommended in older
adults because even short-term palliation is uncommon. There
are insufficient published data to establish an age cutoff. Until
more information becomes available, recommendations for
balloon valvotomy should be limited to adolescents and young
adults in their early 20s, although some older young adults
without heavily calcified valves may also benefit.
Because balloon valvotomy has resulted in good long-term
palliation with little morbidity and little or no short- or
intermediate-term mortality in children, adolescents, and
young adults in their early 20s, the indications for intervention
are considerably more liberal than those in older adults in
whom intervention usually involves valve replacement. Al-
though data are not yet available, reducing the gradient is
likely to reduce the small incidence of sudden unexpected
death (usually while exercising) (571) as well as the extent of
interstitial myocardial fibrosis, which has been observed in
children and adolescents who died and had evidence of
repolarization abnormalities on ECG.
Children and young adults with Doppler gradients of 70 to
80 mm Hg or more (peak velocity .4.2 m/s), those who
develop LV repolarization or ischemic changes on the ECG
(T-wave inversion or ST depression) at rest or with exercise,
and those with symptoms may be considered for cardiac
catheterization and possible balloon dilation. The gradient
should be confirmed hemodynamically before proceeding with
dilation, and it is reasonable to perform valvotomy in patients
with catheterization gradients .60 mm Hg. Patients with less
severe gradients (50 to 70 mm Hg by Doppler echocardiog-
raphy) who are interested in participating in vigorous
athletics or those contemplating pregnancy are also com-
monly referred for balloon dilation. Surgical valvotomy has
now been replaced in most centers by balloon valvotomy but
is a reasonable alternative if skilled interventional cardiol-
ogists are not available.
Recommendations for Aortic Balloon Valvotomy in the
Adolescent or Young Adult (<221) With Normal Cardiac Output*
Indication Class
1. Symptoms of angina, syncope, and dyspnea on exertion, with
catheterization peak gradient >250 mm Hg.†
I
2. Catheterization peak gradient >60 mm Hg. I
3. New-onset ischemic or repolarization changes on ECG at rest
or with exercise (ST depression, T-wave inversion over left
precordium) with a gradient >50 mm Hg).†
I
4. Catheterization peak gradient >50 mm Hg if patient wants to
play competitive sports or desires to become pregnant.
IIa
5. Catheterization gradient <50 mm Hg without symptoms or
ECG changes.
III
*Adolescents and young adults almost invariably have normal or increased
cardiac output. If cardiac index <2 L/min/m2, lower gradients should be used.
†If gradient <50 mm Hg, other causes of symptoms should be explored.
When balloon aortic valvotomy is ineffective or significant
AR is present, valve replacement may be necessary. Because
bioprostheses have reduced durability in the young, mechani-
cal valves have been commonly used. The long-term cumula-
tive risks of endocarditis, thromboembolism, and bleeding
from anticoagulation over a 20- to 40-year time frame have
been problematic. Recently, the approach of replacing the aortic
valve with a pulmonary autograft by means of a pulmonary or
aortic homograft to replace the native pulmonary valve, as first
performed by Ross, has gained acceptance in some centers
(115,572–575). Preliminary results indicate low surgical risk, with
the majority of autografts performing well for at least a decade.
This approach has the advantage of not requiring anticoagulation,
an important issue for active adolescents and younger adults,
including women contemplating pregnancy.
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B. Aortic Regurgitation
AR is an uncommon isolated congenital lesion, although it
may occasionally be found in adolescents and young adults
with a bicuspid aortic valve, discrete subaortic obstruction, or
prolapse of one aortic cusp into a ventricular septal defect. It
is commonly the consequence of attempts to relieve stenosis of
the valve by either balloon dilation or surgical valvulotomy.
The indications for surgery with isolated AR or mixed aortic
valve disease are at present similar to adults, that is,
symptoms, LV dysfunction (ejection fraction ,0.50), or very
increased LV end-diastolic or end-systolic diameter, taking
into account variations in body size. If the durability of
pulmonary autograft and homograft valves in the right
ventricular outflow tract is substantiated in long-term stud-
ies, the indications for autograft valve replacement are likely
to become more liberal.
Recommendations for Aortic Valve Surgery (Replacement With
Mechanical Valve, Homograft, or Pulmonary Autograft) in the
Adolescent or Young Adult With Chronic Aortic Regurgitation
Indication Class
1. Onset of symptoms. I
2. Asymptomatic patients with LV systolic dysfunction (ejection
fraction <0.50) on serial studies 1 to 3 months apart.
I
3. Asymptomatic patients with progressive LV enlargement (end-
diastolic dimension >4 SD above normal).
I
4. Moderate AS (gradient >40 mm Hg) (peak-to-peak gradient at
cardiac catheterization).
IIb
5. Onset of ischemic or repolarization abnormalities (ST
depression, T-wave inversion) over left precordium at rest.
IIb
C. Mitral Regurgitation
Isolated congenital MR is an extremely uncommon cardiac
condition. MR can be associated with MVP in adolescents or
young adults with connective tissue, metabolic, or storage
diseases. MR can be seen with acquired inflammatory diseases
such as rheumatic fever, endocarditis, or Kawasaki disease or
with certain collagen vascular disorders.
The most common cause of MR in children is atrioventric-
ular septal defects. This is a defect caused by a deficiency of the
atrioventricular septum in the embryonic heart. There may be
an isolated ostium primum atrial septal defect; ventricular
septal defect in the inlet (posterior) septum; abnormalities of
the mitral or tricuspid valve, including clefts; or some combi-
nation of the above. In a complete atrioventricular septal
defect, there is a combination of a large primum atrial septal
defect, a large inlet (posterior) ventricular septal defect, and a
common atrioventricular valve that failed to develop into
separate mitral and tricuspid valves. Repair of the defects in
early childhood, with low mortality and morbidity, is now
possible. The most common long-term sequela of surgery is
MR, which may be mild, moderate, or severe.
The pathophysiology, diagnosis, and medical therapy of
residual MR in atrioventricular septal defects, rheumatic fever,
or MVP are similar to those discussed for the adult with MR
(section III.E.). When associated with congestive heart failure
or deteriorating LV systolic function on echocardiography or
angiography, surgery should be performed. In children with
atrioventricular septal defects, MR can usually be reduced or
eliminated with surgery. In the postoperative atrioventricular
septal defect or MR secondary to MVP, rheumatic fever, or
inflammatory disease, it is frequently possible to decrease the
regurgitation with mitral annuloplasty. Occasionally, MVR
with a mechanical or biological valve is necessary. When valve
repair rather than replacement is likely, surgery for severe MR
may be contemplated in the absence of heart failure or LV
dysfunction.
Recommendations for Mitral Valve Surgery in the Adolescent or
Young Adult With Congenital Mitral Regurgitation With Severe MR
Indication Class
1. NYHA functional Class III or IV symptoms. I
2. Asymptomatic patients with LV systolic dysfunction
(ejection fraction <20.60).
I
3. NYHA functional Class II symptoms with preserved
LV systolic function if valve repair rather than
replacement is likely.
IIa
4. Asymptomatic patients with preserved LV systolic
function in whom valve replacement is highly likely.
IIb
D. Mitral Stenosis
In developed countries, virtually all MS in adolescents and
young adults is congenital in origin. In developing areas of the
world, MS is more likely to result from rheumatic fever.
Congenital MS is usually classified by the component of the
mitral apparatus that is abnormal, that is, the leaflets, annulus,
chordae, or papillary muscles. Frequently, multiple valve com-
ponents are involved, resulting in rolled, thickened leaflet
margins; shortened and thickened chordae tendineae; obliter-
ation of the interchordal spaces with abnormal chordal inser-
tions; papillary muscle hypoplasia; and fusion of the anterolat-
eral and posteromedial papillary muscles (576). This latter
condition causes the mitral apparatus to appear like a funnel
or a parachute. MS results from the inability of blood to pass
unobstructed from the left atrium to the left ventricle through
a very abnormal mitral apparatus.
Congenital MS may be associated with a wide variety of
other congenital cardiac malformations of the left side of the
heart, including coarctation of the aorta.
The clinical, electrocardiographic, and radiologic features
of congenital MS are similar to acquired MS in adults. The
echocardiogram is beneficial in evaluating the mitral valve
apparatus and papillary muscles and may provide consider-
able insight into the feasibility of successful valve repair.
The information obtained from transthoracic imaging is
usually sufficient, but in older children, adolescents, and
young adults, a transesophageal echocardiogram is some-
times necessary.
Medical management is of limited utility in these patients,
but it is important to prevent and treat common complica-
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tions such as pulmonary infections, endocarditis, and atrial
fibrillation. Surgical intervention may be necessary in severe
cases.
Recommendations for Mitral Valve Surgery in the Adolescent or
Young Adult With Congenital Mitral Stenosis
Indication Class
1. Symptomatic patients (NYHA functional Class III or IV)
and mean mitral valve gradient >10 mm Hg on Doppler
echocardiography.
I
2. Mildly symptomatic patients (NYHA functional Class II)
and mean mitral valve gradient >10 mm Hg on Doppler
echocardiographic study.
IIa
3. Systolic pulmonary artery pressure 50 to 60 mm Hg with a
mean mitral valve gradient >210 mm Hg.
IIa
4. New-onset atrial fibrillation or multiple systemic emboli
while receiving adequate anticoagulation.
IIb
The surgical management of congenital MS has improved
considerably with the improved appreciation of the mechanism
of mitral valve function and the improved ability to visualize
the valve afforded by transesophageal echocardiography. In
those with a parachute mitral valve, creation of fenestra-
tions among the fused chordae may increase effective orifice
area and improve symptoms dramatically. MVR may occa-
sionally be necessary but is especially problematic in those
with a hypoplastic mitral annulus in whom an annulus-
enlarging operation may be necessary. Recently, balloon
dilation of congenital MS has been attempted (577), but its
utility is unproved. This is one of the most difficult and
dangerous therapeutic catheterization procedures and
should be undertaken only in centers with operators who
have established experience and skill in this interventional
procedure.
E. Tricuspid Valve Disease
Acquired disease of the tricuspid valve is very uncommon in
adolescents and young adults. Other than occasional cases of
TR secondary to trauma, bacterial endocarditis in intravenous
drug abusers, and small ventricular septal defects in children in
whom the jet through the ventricular septum creates endothe-
lial damage to the tricuspid valve, virtually all cases of acquired
TR are limited to case reports.
Most cases of tricuspid valve disease are congenital, with
Ebstein’s anomaly of the tricuspid valve being the most com-
mon. In Ebstein’s anomaly, there is inferior displacement of
the septal and posterior leaflets of the valve into the right
ventricle. If there is significant adherence of the leaflets to the
right ventricular wall, the normal or relatively normal anterior
leaflet fails to coapt with the abnormal posterior leaflet,
creating severe TR. If the valve leaflets are not adherent, there
is redundancy of valve tissue with severe prolapse associated
with varying degrees of TR.
There is variation in the severity of valve leaflet abnormal-
ities. Some children may have severe TR, especially in the
perinatal period, when pulmonary vascular resistance and
resulting right ventricular pressures are high. Others have very
mild abnormalities that may not be recognized until a chest
x-ray obtained for other reasons shows cardiomegaly. An
interatrial communication, usually in the form of a patent
foramen ovale, is present in most cases. If TR elevates right
atrial pressure above left atrial pressure, right-to-left shunting
can occur, with resulting hypoxemia. One or more accessory
conduction pathways are quite common, with a risk of parox-
ysmal atrial tachycardia of '25%.
Patients with Ebstein’s anomaly may be asymptomatic with
no cyanosis and no atrial arrhythmias. More commonly, they
are cyanotic due to right-to-left shunting, which is associated
with exercise intolerance. Right ventricular dysfunction may
eventually lead to right-sided congestive heart failure fre-
quently exacerbated by an atrial arrhythmia such as atrial
tachycardia, atrial flutter, or atrial fibrillation.
Recommendations for Diagnostic Evaluation* of Ebstein’s Anomaly
of the Tricuspid Valve in the Adolescent or Young Adult
Indication Class
1. ECG. I
2. Chest x-ray. I
3. Echo-Doppler study. I
4. Pulse oximetry at rest and/or during exercise. IIa
5. Electrophysiological study if documented or suspected atrial
arrhythmia.
IIa
*Initial evaluation and every 1 to 3 years, depending upon severity.
The natural history of Ebstein’s anomaly varies. In patients
who present in the perinatal period, the 10-year actuarial
survival is 61% (578). In a study that included more children
who presented after the perinatal period, the probability of
survival was 50% at 47 years of age (579). Predictors of poor
outcome were NYHA functional Class III or IV symptoms,
cardiothoracic ratio .65%, or atrial fibrillation. However,
patients with Ebstein’s anomaly who reach late adolescence
and adulthood often have an excellent outcome (579).
Surgical management of Ebstein’s anomaly remains chal-
lenging. For older children, adolescents, and young adults,
tricuspid valve repair has been attempted. Reconstruction of
the valve is occasionally possible, especially when there is a
mobile anterior leaflet free of tethering to the ventricular
septum. Valvuloplasty may be performed with positioning of
the displaced leaflet of the tricuspid valve to the normal level,
sometimes with placation of the atrialized portion of the right
ventricle to reduce its size.
Occasionally, the tricuspid valve is not reparable, and valve
replacement with a bioprosthesis or a mechanical valve may be
necessary. When present, atrial communications should be
closed. If an accessory pathway is present, this should be
mapped and obliterated either preoperatively in the electro-
physiology laboratory or at the time of surgery.
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Recommendations for Surgery in the Adolescent or Young Adult
With Ebstein’s Anomaly With Severe Tricuspid Regurgitation
Indication Class
1. Congestive heart failure. I
2. Deteriorating exercise capacity (NYHA functional Class III or IV). I
3. Progressive cyanosis with arterial saturation <80% at rest or
with exercise.
I
4. Progressive cardiac enlargement with cardiothoracic ratio >60%. IIa
5. Systemic emboli despite adequate anticoagulation. IIa
6. NYHA functional Class II symptoms with valve probably
reparable.
IIa
7. Atrial fibrillation. IIa
8. Deteriorating exercise tolerance (NYHA functional Class II). IIa
9. Asymptomatic patients with increasing heart size. IIb
10. Asymptomatic patients with stable heart size. III
F. Pulmonic Stenosis
1. Pathophysiology. Because the pulmonary valve is the
least likely valve to be affected by acquired heart disease,
virtually all cases of pulmonary valve stenosis are congenital in
origin. Most patients with stenosis have a conical or dome-
shaped pulmonary valve formed by fusion of the valve leaflets,
which project superiorly into the main pulmonary artery.
Occasionally, the valve may be thickened and dysplastic, with
the stenosis caused by inability of the valve leaflets to move
sufficiently during ventricular systole (580).
Symptoms are unusual in children or adolescents with
pulmonary valve stenosis even when severe. Adults with
long-standing severe obstruction may have dyspnea and
fatigue secondary to an inability to increase cardiac output
adequately with exercise. Exertional syncope or light-
headedness may rarely be seen, but sudden death is very
unusual. Eventually, in the neonate or adult with long-
standing untreated severe obstruction, TR and right ventric-
ular failure may occur.
At any age, if the foramen ovale is patent, right ventricular
compliance may be reduced sufficiently to elevate right atrial
pressure, allowing right-to-left shunting and cyanosis. This
increases the risk of paradoxical emboli.
2. Diagnosis. The clinical diagnosis of pulmonary valve
stenosis is straightforward, and the severity can usually be
determined accurately by 2-D and Doppler echocardiography
(see below). Diagnostic catheterization is rarely required.
Recommendations for Initial Diagnostic Workup of
Pulmonic Stenosis
Indication
Severity of Pulmonic Stenosis
Mild*
Class
Moderate-Severe†
Class
1. ECG. I I
2. Echo-Doppler study (transthoracic). I I
3. Chest x-ray. IIa IIa
4. Diagnostic cardiac catheterization. III IIb‡
*Right ventricular to pulmonary artery maximum instantaneous gradient
<30 mm Hg by Doppler echocardiography. †Right ventricular to pulmonary
artery gradient >230 mm Hg by Doppler echocardiography. ‡If catheterization
gradient >250 mm Hg, balloon valvuloplasty should be performed (see recom-
mendations for intervention).
3. Clinical Course. The clinical course of children and
young adults with pulmonary valve stenosis has been well
described. The Natural History of Congenital Heart Defects
study (581) in the mid 1960s and early 1970s followed 564
patients with valvular pulmonary stenosis with cardiac cathe-
terization at 4- and 8-year intervals. On admission to the study,
'15% were ,2 years old; 20%, 12 to 21 years old; and the
remainder, 2 to 11 years old. At initial cardiac catheterization,
they were divided into 4 groups based on severity:,25 mm Hg
peak-to-peak gradient between the right ventricle and the
pulmonary artery, trivial; 25 to 49 mm Hg, mild; 50 to
79 mm Hg, moderate; and .280 mm Hg, severe.
Of the 261 patients (46% of the total) treated medically,
most had trivial, mild, or moderate obstruction. None of these
patients had cyanosis or congestive heart failure, and only 6%
had symptoms. There were no deaths during the study. The
pressure gradients were stable in the majority, with 14% of
patients manifesting a significant increase and 14% a signifi-
cant decrease. Most of the increases were in children ,2 years
old and/or those with initial gradients .40 mm Hg. Those not
in either category had only a 4% chance of an increase in the
gradient .20 mm Hg. There was little or no change in the
overall status of the medically treated patients. During the
period of observation, 304 patients, most with moderate or
severe disease, were treated surgically. Only 1 death occurred
among the 245 patients in this group who underwent surgery
beyond infancy. At postoperative follow-up, the gradient had
been reduced to insignificant levels in .90%, with no
recurrence of pulmonary stenosis in those followed up to 14
years.
In 1993, the second Natural History of Congenital Heart
Defects study (582) reported on a 16- to 29-year (mean, 22
years) follow-up of the same group of patients. The probability
of 25-year survival was 96%, not statistically different from the
normal control group. Less than 20% of patients managed
medically during the first Natural History Study subse-
quently required a valvotomy, and only 4% of the operated
patients required a second operation. Most patients,
whether managed medically or surgically, had mild obstruc-
tion by Doppler echocardiography. For patients who had an
initial transpulmonary gradient ,25 mm Hg in the first
Natural History Study, 96% were free of cardiac operation
over a 25-year period.
Infective endocarditis was uncommon. Only 1 case de-
veloped in the 592 patients followed a median of 18 years,
an incidence of 0.94 per 10,000 patient years. Although
endocarditis prophylaxis has been recommended for pa-
tients with PS, the incidence and severity of infection are
such that the morbidity from anaphylactic reactions to
endocarditis prophylaxis may be as problematic as the
disease itself.
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Recommendations for Intervention in the Adolescent or Young
Adult With Pulmonic Stenosis (Balloon Valvotomy or Surgery)
Indication Class
1. Patients with exertional dyspnea, angina, syncope, or presyncope. I
2. Asymptomatic patients with normal cardiac output (estimated
clinically or determined by catheterization).
a. Right ventricular to pulmonary artery peak gradient
>50 mm Hg
I
b. Right ventricular to pulmonary artery peak gradient 40 to
49 mm Hg
IIa
c. Right ventricular to pulmonary artery peak gradient 30 to
39 mm Hg
IIb
d. Right ventricular to pulmonary artery peak gradient
<30 mm Hg
III
Surgical relief of severe obstruction by valvotomy with a
transventricular (583) or transpulmonary (584) artery ap-
proach predates the introduction of cardiopulmonary bypass.
A nonsurgical approach with balloon valvotomy was described
in 1982 (585) and by the late 1980s had become the procedure
of choice for the typically domed, thickened valve virtually
everywhere in the United States, both for children (586) and
adults (587,588). Surgery is still required for the dysplastic
valve often seen in Noonan’s syndrome. Although long-term
follow-up of pulmonary balloon valvotomy is not yet available,
the early and midterm results (up to 10 years) (589) suggest
results similar to surgical valvotomy, that is, little or no
recurrence over a 22- to 30-year period.
In those with severe or long-standing valvular obstruction,
infundibular hypertrophy may cause secondary obstruction when
the pulmonary valve is successfully dilated. This frequently re-
gresses over time without treatment. Some have advocated tran-
sient pharmacological b-blockade, but there is insufficient infor-
mation to determine whether this is effective or necessary.
From the Natural History Study data, it would appear that
congenital mild pulmonary stenosis is a benign disease that
rarely progresses, that moderate or severe pulmonary stenosis
can be improved with either surgery or balloon valvotomy at
very low risk, and that patients who undergo surgery or balloon
valvotomy have an excellent prognosis and a low rate of
recurrence. Thus, the goal of the clinician is to ascertain the
severity of the disease, treat those in whom it is severe, and
infrequently follow up those with mild disease (590).
Recommendations for Follow-up Exams in Pulmonic Stenosis
Indication
Severity of Pulmonic Stenosis
Mild* Class
Moderate to
Severe† Class
1. ECG. I I
2. Echo Doppler. I I
3. Chest x-ray. IIb IIa
4. Catheterization (for evaluation of
gradient).
III III
*<29 mm Hg gradient; testing every 5 to 10 years. †>30 mm Hg gradient;
testing every 3 years (consideration should be given to balloon or surgical
valvuloplasty).
G. Pulmonary Regurgitation
Pulmonary valve regurgitation is an uncommon congenital
lesion seen occasionally with what has been described as
idiopathic dilation of the pulmonary artery. In this condition,
the annulus of the pulmonary valve dilates, causing the leaflets
to fail to coapt during diastole. Mild pulmonary regurgitation
may be a normal finding on Doppler echocardiography.
Although pulmonary regurgitation is unusual as an isolated
congenital defect, it is an almost unavoidable result of either
surgical or balloon valvuloplasty of valvular pulmonic stenosis
or surgical repair of tetralogy of Fallot. Among patients with
pulmonic stenosis who underwent surgical valvotomy in the
first Natural History Study, 87% had pulmonary regurgitation
by Doppler echocardiography in the second Natural History
Study, although it was audible in only 58%. The echocardio-
gram tended to overestimate severity when compared with
auscultation, with 20% considered moderate to severe by
Doppler but only 6% by auscultation. In those with pulmonary
regurgitation, the right ventricle tended to be larger but right
ventricular systolic dysfunction was uncommon; it was present
in only 9%.
Pulmonary regurgitation also commonly occurs after suc-
cessful repair of tetralogy of Fallot. Several studies have
documented that the vast majority of children and young adults
operated on in the late 1950s and 1960s continue to do well for
up to 35 years after surgery (591). However, a small group with
long-standing pulmonary regurgitation has developed a very
dilated right ventricle and diminished right ventricular systolic
performance, which can lead to an inadequate ability to
augment cardiac output with exercise and in some cases
congestive heart failure. This group has also been shown to
have a significant incidence of ventricular arrhythmias known
to be associated with late sudden death. Increased pulmonary
artery pressure from LV dysfunction or residual peripheral
pulmonary artery stenosis will increase the amount of regurgi-
tation, and these conditions should be treated when present.
Pulmonary valve replacement, usually with a homograft, has
been attempted, but follow-up data are too preliminary to
develop recommendations at this time.
VII. Management of Patients With Prosthetic
Heart Valves
A. Classification of Prosthetic Heart Valves
Heart valve prostheses consist of an orifice, through which
blood flows, and an occluding mechanism that closes and
opens the orifice. There are 2 classes of heart valve: mechan-
ical prostheses, with rigid, manufactured occluders, and bio-
logical or tissue valves, with flexible leaflet occluders of animal
or human origin. A list of FDA-approved prosthetic heart
valves is given in Table 32.
1. Mechanical Valves. a. Ball Valves. The first successful
valve replacement devices used a ball-in-cage design (592,593).
Of these, only the Starr-Edwards valve has endured; it has
been used more than 200,000 times. The ball is a silicone
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rubber polymer impregnated with barium sulfate for radio-
opacity that oscillates in a cage of cobalt chromium alloy.
b. Disk Valves. Tilting disk valves use a circular disk as an
occluder, which is retained by wirelike arms or closed loops
that project into the orifice. The disks are graphite with a
coating of pyrolytic carbon, and the housings are stainless steel
or titanium. The first successful low-profile design was the
standard Bjo¨rk-Shiley tilting disk valve, introduced in 1969
(594). Approximately 360,000 standard valves were implanted.
In the United States, Bjo¨rk-Shiley models have been discon-
tinued but are mentioned because many patients with standard
or subsequently modified Bjo¨rk-Shiley valves are still alive. The
Medtronic Hall valve has a titanium housing and a carbon-
coated disk with a unique central hole. The disk is retained and
guided by a guide strut that protrudes through this hole. It has
been used clinically since 1977.
c. Bileaflet Valves. Current development of mechanical
valves is based on the bileaflet design, introduced by St. Jude
Medical in 1977 and used .600,000 times. Unlike the free-
floating occluders in ball and disk valves, the 2 semicircular
leaflets of a bileaflet valve are connected to the orifice housing
by a butterfly hinge mechanism. The leaflets swing apart during
opening, creating 3 flow areas, 1 central and 2 peripheral.
2. Biological Valves. There is a wide variety of biological
valves. The autograft valve refers to a translocation within the
same individual, eg, of the pulmonary valve into the aortic
valve position. The autologous (or autogenous) tissue valve
involves fabricating a valve from the patient’s own nonvalvular
tissue, eg, pericardium. The homograft (or allograft) valve
refers to transplantation from a donor of the same species; eg,
a donor’s aortic or pulmonary valve into a recipient’s aortic or
pulmonary position. The heterograft (or xenograft) valve is a
transplant from another species, either an intact valve, eg, a
porcine aortic valve, or a valve fashioned from heterologous
tissue, eg, bovine pericardium.
The goal of biological valves is to reduce the complications
associated with thromboembolism and the need for anticoag-
ulation and in the aortic position to optimize hemodynamics.
a. Autograft Valves. The pulmonary autograft procedure
consists of an autotransplant of the pulmonary valve to the
aortic position; the pulmonary valve is then replaced by an
aortic or pulmonary homograft or a heterograft. First de-
scribed in 1967 (572), this operation is called the Ross proce-
dure. Favorable long-term results have been reported
(115,573–575). This procedure involves a double valve replace-
ment with attendant early and late risks. However, late prob-
lems are likely to be related to the pulmonary valve prosthesis,
which is easier to remedy but may require a second operation.
The Ross procedure does not require FDA approval for
clinical use; if a heterograft valve is used in the pulmonary
position, it needs to be an FDA-approved device.
b. Autologous Pericardial Valves. This new category of
prosthetic valve is an innovative attempt to combine the
reproducibility and ease of insertion of a commercial stented
heterograft valve with the benefits of autologous tissue. It is a
frame-mounted autologous pericardial valve assembled from a
kit in the operating room.
c. Homograft (or Allograft) Valves. Homograft valves were
first used in the early 1960s (595,596). Three techniques of
homograft AVR are used: (1) replacing only the valve in the
subcoronary position; (2) complete aortic root replacement
with reimplantation of the coronary arteries; and (3) miniroot
replacement with the donor valve and attached aortic wall
inserted within the host aorta below the coronary ostia. The
homograft does not require FDA approval for clinical use.
The homograft valve is considered by many a preferable
substitute for AVR in younger patients, especially those in
whom anticoagulation is undesirable. It achieves excellent
hemodynamics and has low thrombogenicity, and there is no
need for anticoagulation. The drawbacks are a more techni-
cally demanding operation and low availability; however, the
latter has been alleviated by commercial availability.
d. Porcine Heterograft (or Xenograft) Valves. Glutaralde-
hyde sterilizes valve tissue, renders it bioacceptable by destroy-
ing antigenicity, and stabilizes the collagen crosslinks for
durability. The term bioprosthesis is used for a nonviable tissue
of biological origin such as the Hancock and Carpentier-
Edwards porcine valves (597).
Most porcine valves are mounted on rigid or flexible stents
to which the leaflets and sewing ring are attached. However,
Table 32. FDA-Approved Prosthetic Heart Valves
Type Manufacturer Model
Year of
First Clinical
Use
Implants*
(thousands)
Mechanical
Ball Baxter Edwards Starr-Edwards 1965 200
Disk Medtronic Medtronic Hall 1977 178
Medical Inc. Omniscience 1978 48
Alliance Monostrut 1982 94
Bileaflet St. Jude St. Jude 1977 580
Baxter Edwards Duromedics 1982† 20
CarboMedics CarboMedics 1986 110
Biological
Porcine Medtronic Hancock Standard 1970 177
Hancock MO 1978 32
Baxter Edwards CE Standard 1971 400
CE SupraAnnular 1982 45
St. Jude Toronto Stentless
(TSP)
1991 5
Medtronic Free Style
Stentless
1992 5
Pericardial Baxter Edwards CE 1982 35
Homograft noncommercial‡ 1962 12?
Cryolife‡ 1984 14
Autologous noncommercial‡ Pulmonary
autograft
1967 2?
Abbreviations: MO 5 modified orifice, CE 5 Carpentier-Edwards. *Ap-
proximate number of implants through part or all of 1994. †Discontinued in
1988. ‡Does not require FDA approval for clinical use. Adapted from Grunke-
meier G, Starr A, Rahimtoola SH (616). Replacement of heart valves. In:
O’Rourke RA, ed. The Heart: Update I. New York, NY: McGraw-Hill Publish-
ing Co; 1996:98–123.
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unstented versions have also been devised by several manufac-
turers and have been approved by the FDA for clinical use.
Their goal is to achieve some of the potential benefit of a
homograft valve, especially hemodynamics and perhaps dura-
bility, with an easily available commercial product. As with
homografts, there are potentially 3 ways of implanting a
stentless porcine valve (valve only, aortic root, miniroot). The
standard porcine bioprosthesis is inserted into the annulus.
The Carpentier-Edwards SupraAnnular Valve is implanted
above the aortic annulus but sutured to it.
e. Bovine Pericardial Valves. Pericardial valves are tailored
and sewn into a valvular configuration on a stented frame, with
bovine pericardium as a fabric. This produces a valve that
opens more completely than a porcine valve for better hemo-
dynamics. Greater durability is also expected because there is
extra tissue to allow for shrinkage and a higher percentage of
collagen to be cross-linked during fixation. The Ionescu-Shiley,
the first commercially available pericardial valve, experienced
a higher failure rate than porcine valves and was taken off the
market after '10 years. However, the failures were partly due
to aspects of the design rather than an intrinsic problem with
pericardial tissue itself.
The Carpentier-Edwards Pericardial Bioprosthesis is con-
structed without stitches passing through the leaflets that are
present in the Ionescu-Shiley pericardial valve. Instead, the
leaflets are anchored behind the stent pillars.
B. Complications of Prosthetic Heart Valves
1. Guidelines for Reporting Clinical Results. The analytic
aspects of reporting clinical results of heart valves have evolved
consistently since the first successful implants in 1960. Near the
end of the first decade, as late (posthospital) experience
accumulated, the need to analyze time-related events resulted
in the introduction of actuarial analysis (598), which had been
used for some time to analyze the results of cancer therapy
(599). Later the use of linearized (constant hazard) rates
(600,601), Cox regression (602), and multivariable parametric
models (603) was advocated. However, the effectiveness of
these refined statistical methods in comparing results from
different series was limited by the lack of standardization in
definitions and follow-up methods.
a. AATS/STS Guidelines for Clinical Reporting. In 1988,
standards for defining and reporting complications were pro-
posed by the Ad Hoc Liaison Committee for Standardizing
Definitions of Prosthetic Heart Valve Morbidity, a joint com-
mittee of the American Association for Thoracic Surgery
(AATS) and the Society of Thoracic Surgeons (STS) (604).
These guidelines were revised in 1996 (605,606). The compli-
cations determined to be of critical importance in the 1996
guidelines are summarized as follows:
1. Structural valvular deterioration refers to any change in
function of an operated valve resulting from an intrinsic
abnormality causing stenosis or regurgitation.
2. Nonstructural dysfunction is a composite category that in-
cludes any abnormality resulting in stenosis or regurgitation
of the operated valve that is not intrinsic to the valve itself
exclusive of thrombosis and infection. This includes inap-
propriate sizing, also called valve prosthesis–patient mis-
match (607).
3. Valve thrombosis is any thrombus, in the absence of infec-
tion, attached to or near an operated valve that occludes
part of the blood flow path or interferes with function of the
valve.
4. Embolism is any embolic event that occurs in the absence of
infection after the immediate perioperative period (when
anesthesia-induced unconsciousness is completely re-
versed). This includes any new, temporary or permanent,
focal or global neurological deficit and peripheral embolic
event; emboli proven to consist of nonthrombotic material
are excluded.
5. Bleeding event (formerly anticoagulant hemorrhage) is any
episode of major internal or external bleeding that causes
death, hospitalization, or permanent injury (eg, vision loss)
or requires transfusion. The complication bleeding event
applies to all patients, whether or not they are taking
anticoagulants or antiplatelet drugs.
6. Operated valvular endocarditis is any infection involving an
operated valve. Morbidity associated with active infection,
such as valve thrombosis, thrombotic embolus, bleeding
event, or paravalvular leak, is included under this category
and not in other categories of morbidity.
The consequences of the above morbid events include
reoperation; valve-related mortality; sudden unexpected, un-
explained death; cardiac death; total deaths; and permanent
valve-related impairment (605,606). In addition, valve prosthe-
sis may produce hemolysis due either to the valve itself or
associated perivalvular leak.
2. Valve-Related Complications. There is a wide range in
the reported incidence of complications with the same pros-
thetic valve and between different valves (608). This is most
likely due to variation among series rather than to valve type
and model (609). It has been emphasized (610) that these
include factors associated with patients (eg, ventricular func-
tion, comorbidities), medical center (eg, surgical variables,
definitions of complications, thoroughness of follow-up), and
data analysis (eg, influences of patient-related factors) (609).
In addition, published data represent only a small fraction of
valves implanted (610).
Many types of bias affect reported results (611), which
might be overcome with randomized trials. However, random-
ized trials also have difficulties (612,613). The number of
randomized studies of prosthetic heart valves is small, and the
majority of those that have been reported are of insufficient
size to add importantly to the knowledge already obtained
from careful observational studies.
a. Major Randomized Trials. The 2 major randomized
clinical trials that have been reported are the Edinburgh Heart
Valve Trial (121) and the Veterans Affairs Cooperative Study
1557JACC Vol. 32, No. 5 BONOW ET AL.
November 1, 1998:1486–588 ACC/AHA TASK FORCE REPORT
on Valvular Heart Disease (124). Both studies compared
mechanical valves with porcine bioprostheses.
The Edinburgh trial (121) compared the Bjo¨rk-Shiley stan-
dard valve with porcine valves (initially the Hancock and later
the Carpentier-Edwards) and reported actuarial comparisons
at 5 and 12 years for 211 aortic and 261 mitral valve patients.
Survival was better, but not significantly so, with the mechan-
ical valve than the porcine valve (72% versus 52%, P 5 0.08);
this was somewhat offset by the increased risk of bleeding
events. However, survival without reoperation was better with
mechanical than bioprosthetic valves for MVR (74% versus
42%, P 5 0.04) and AVR (75% versus 55%, P 5 0.052).
The VA Study (124) compared the standard Bjo¨rk-Shiley
valve with the Hancock porcine valve in 575 men. The Han-
cock modified-orifice valve was used for sizes 21 to 23 mm in
the aortic position, and the Hancock standard valve was used
for all other sizes. Table 33 contains actuarial comparisons of
the end point variables at 11 years. The risk for all valve-
related complications is higher for mechanical valves during
the first 5 years, but the cumulative risks converge by '10
years. At 11 years, the rates of both mortality and all valve-
related complications were similar with mechanical and por-
cine valves, but the types of complication differed between the
two; bleeding rates were higher with mechanical valves, and
structural valve deterioration (and reoperation) rates were
higher with bioprostheses.
Comparison of the actuarial event rates between these 2
trials (124) showed that bleeding and thromboembolism rates
were higher in the VA study and reoperation rates were higher
in the Edinburgh study. These differences could be partially
accounted for by the composition of the 2 patient populations:
patients in the Edinburgh trial were younger and received less
anticoagulation, and this trial included women, double valve
replacements, and a higher percentage of porcine valves in the
mitral position.
Late long-term results show better survival in patients with
mechanical valves compared with those with bioprostheses
(particularly those in younger age groups). In the Edinburgh
trial (121), 12-year survival was 42% versus 24% (P , 0.05) in
patients with mechanical and porcine valves, respectively, in
the mitral position, probably because of the high rate of
bioprosthetic degeneration. In the VA trial (614), 15-year
survival was 34% versus 23% (P 5 0.02) in patients with
mechanical and porcine valves, respectively, in the aortic
position.
Nonrandomized studies in patients .265 years of age show a
lower rate of structural valvular deterioration with the pericar-
dial valve than with a porcine bioprosthesis (615).
C. Management of Patients With Prosthetic
Heart Valves
1. Antibiotic Prophylaxis. a. Infective Endocarditis. All pa-
tients with prosthetic valves need appropriate antibiotics for
prophylaxis against infective endocarditis (section II.B.).
b. Recurrence of Rheumatic Carditis. Patients with rheu-
matic heart disease continue to need antibiotics as prophylaxis
against recurrence of rheumatic carditis (section II.B.).
2. Antithrombotic Therapy. All patients with mechanical
valves require warfarin therapy, as indicated in Table 34 (617).
Even with the use of warfarin, risk of thromboemboli is 1% to
2% per year (119,121,124,618), but the risk is considerably
higher without treatment with warfarin (619). The risk of a
clinical thromboembolism is '0.7% per year in patients with
biological valves in sinus rhythm; this figure is derived from
several studies in which the majority of patients were not on
warfarin therapy (119,121,124,620). Almost all studies have
shown that risk of embolism is greater with a valve in the mitral
position (mechanical or biological) than with one in the aortic
position (121,608,619,621). With either type of prosthesis or
valve location, the risk of emboli is probably higher in the first
few days and months after valve insertion (620), before the
valve is fully endothelialized.
a. Mechanical Valves. All patients with mechanical valves
require warfarin. For mechanical prostheses in the aortic
position, the INR should be maintained between 2.0 and 3.0
Table 33. Probability of Death Due to Any Cause, Any Valve-Related Complications, and Individual
Valve-Related Complications 11 Years After Randomization
Event
Aortic Valve Mitral Valve
Mechanical
(n 5 198)
Porcine
(n 5 196) P
Mechanical
(n 5 88)
Porcine
(n 5 93) P
Death from any cause 53 6 4 59 6 4 0.26 64 6 5 67 6 5 0.41
Any valve-related complications 62 6 4 64 6 4 0.64 71 6 5 79 6 6 0.34
Systemic embolism 16 6 4 15 6 3 0.49 18 6 5 15 6 4 0.61
Bleeding 43 6 4 24 6 4 , 0.001 41 6 6 28 6 7 0.02
Endocarditis 7 6 2 8 6 2 0.79 11 6 4 17 6 5 0.37
Valve thrombosis 2 6 1 1 6 1 0.33 1 6 1 1 6 1 0.95
Perivalvular regurgitation 4 6 2 2 6 1 0.28 17 6 5 9 6 6 0.05
Reoperation 7 6 2 16 6 4 0.07 21 6 5 47 6 9 0.23
Structural valve failure 0 6 0 15 6 4 , 0.001 0 6 0 36 6 8 , 0.001
Values are actuarial percentages 6 standard error. Note: P values are for differences between mechanical and porcine
valves; P , 0.001. Data from Hammermeister et al (124) as summarized in Grunkemeier et al (616) with permission.
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for bileaflet valves and Medtronic Hall valves and between 2.5
and 3.5 for other disk valves and Starr-Edwards valves; for
prostheses in the mitral position, the INR should be main-
tained between 2.5 and 3.5 for all mechanical valves
(121,124,608,621–630). There was a difference of opinion
regarding the Starr-Edwards valve in the aortic position, with a
minority opinion to maintain the INR between 2.0 and 3.0. The
recommendation for higher INR values in the mitral position
is based on the greater risk of thromboembolic complications
with mechanical valves in the mitral position (121,608,619,
621,624,625,629,630) and the greater risk of bleeding at
higher INRs (625). In patients with aortic mechanical
prostheses who are at higher risk of thromboembolic com-
plications, INR should be maintained at 2.5 to 3.5, and the
addition of aspirin should be considered (see below). These
include patients with atrial fibrillation, previous thrombo-
embolism, and a hypercoagulable state. Many would also
include patients with severe LV dysfunction in this higher-
risk group (631). Some valves are thought to be more
thrombogenic than others (particularly the tilting disk
valves), and a case could be made for increasing the INR to
between 3 and 4.5; however, this is associated with a
considerably increased risk of bleeding (621,632).
The addition of low-dose aspirin (80 to 100 mg/d) to
warfarin therapy (INR 2.0 to 3.5) not only further decreases
the risk of thromboembolism (564,625,633–637) but also de-
creases mortality due to other cardiovascular diseases. A slight
increase in the risk of bleeding with this combination should be
kept in mind (635,638). The risk of gastrointestinal irritation
and hemorrhage with aspirin is dose dependent over the range
of 100 to 1000 mg/d, and the antiplatelet effects are indepen-
dent of dose over this range (639,640). There are no data in
patients with prosthetic heart valves receiving warfarin and
aspirin in doses of 100 to 325 mg/d. Doses of 500 to 1000 mg/d
clearly increase the risk of bleeding (641–643). The addition of
aspirin (80 to 100 mg/d) to warfarin should be strongly
considered unless there is a contraindication to the use of
aspirin (ie, bleeding or aspirin intolerance). This combination
is particularly appropriate in patients who have had an embo-
lus while on warfarin therapy, those with known vascular
disease, and/or those who are known to be particularly hyper-
coagulable. As an example, such combination therapy is rec-
ommended by a committee addressing antithrombotic therapy
in women during pregnancy (560). Anticoagulation in pregnant
patients is controversial and is discussed in section V.H. of
these guidelines.
It is important to note that thromboembolic risk is in-
creased early after insertion of the prosthetic valve. The use
of heparin early after prosthetic valve replacement before
warfarin achieves therapeutic levels is controversial. In
some patients, achievement of therapeutic INR can be
delayed several days postoperatively because of mitigating
complications.
b. Biological Valves. Because of an increased risk of throm-
boemboli during the first 3 months after implantation of a
biological prosthetic valve, anticoagulation with warfarin is
usually recommended (620), although in several centers only
aspirin is used for biological valves in the aortic position. The
risk is particularly high in the first few days after surgery and
heparin should be started as soon as the risk of increased
surgical bleeding is reduced (usually within 24 to 48 hours),
with maintenance of PTT between 55 and 70 seconds. After an
overlap of heparin and warfarin for 3 to 5 days, heparin may be
discontinued when an INR of 2.0 to 3.0 is achieved. After 3
months, the tissue valve can be treated like native valve
disease, and warfarin can be discontinued in more than two
thirds of patients with biological valves (121,124,620,644). In
the remaining patients with associated risk factors for
thromboembolism, such as atrial fibrillation, previous thrombo-
embolism, or hypercoagulable condition, lifelong warfarin ther-
apy is indicated to achieve an INR of 2.0 to 3.0. Many would also
recommend continuing anticoagulation in patients with severe
LV dysfunction (ejection fraction ,0.30) (631).
Recommendations for Antithrombotic Therapy in Patients With
Prosthetic Heart Valves
Indication Class
1. First 3 months after valve
replacement:
Warfarin, INR 2.5 to
3.5
I
2. >23 months after valve replacement:
A. Mechanical valve
AVR and no risk factor*
Bileaflet valve or Medtronic
Hall valve
Warfarin, INR 2 to 3 I
Other disk valves or Starr-
Edwards valve
Warfarin, INR 2.5 to
3.5
I
AVR 1 risk factor* Warfarin INR 2.5 to 3.5 I
MVR Warfarin INR 2.5 to 3.5 I
Table 34. Antithrombotic Therapy: Prosthetic Heart Valves
Warfarin
(INR 2–3)
Warfarin
(INR 2.5–3.5)
Aspirin
(80–100 mg)
Mechanical Prosthetic Valves
A. First 3 months after replacement 1 1
B. After first 3 months
1. Aortic valve† 1 1
2. Aortic valve 1 “risk factor”* 1 1
3. Mitral valve 1 1
4. Mitral valve 1 “risk factor”* 1 1
Biological Prosthetic Valves
A. First 3 months after replacement 1 1
B. After first 3 months
1. Aortic valve 1
2. Aortic valve 1 “risk factor”* 1 1
3. Mitral valve 1
4. Mitral valve 1 “risk factor”* 1 1
Note: Depending on patient’s clinical status, antithrombotic therapy must be
individualized (see special situations in text). *Risk factors: Atrial fibrillation, LV
dysfunction, previous thromboembolism, and hypercoagulable condition. †INR
should be maintained between 2.5 and 3.5 for aortic disk valves and Starr-
Edwards valves. Reprinted with permission from McAnulty JH, Rahimtoola SH
(617). Antithrombotic therapy in valvular heart disease. In: Schlant R, Alexander
RW, eds. Hurst’s The Heart, Arteries, and Veins. 9th ed. New York, NY:
McGraw-Hill Publishing Co; 1998:1867–74.
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B. Bioprosthesis
AVR and no risk factor* Aspirin, 80 to 100 mg/d I
AVR and risk factor* Warfarin, INR 2 to 3 I
MVR and no risk factor* Aspirin, 80 to 100 mg/d I
MVR and risk factor* Warfarin, INR 2.5 to
3.5
I
3. Addition of aspirin, 80 to 100 mg once daily if not on aspirin. IIa
4. Warfarin, INR 3.5 to 4.5 in high-risk patients when aspirin
cannot be used.
IIa
5. Warfarin, INR 2.0 to 3.0 in patients with Starr-Edwards AVR and
no risk factor.
IIb
6. Mechanical valve, no warfarin therapy. III
7. Mechanical valve, aspirin therapy only. III
8. Bioprosthesis, no warfarin and no aspirin therapy. III
*Risk factors: Atrial fibrillation, LV dysfunction, previous thromboembo-
lism, and hypercoagulable condition.
c. Difficulties in Maintaining Anticoagulant Therapy. It is
frequently difficult to maintain a patient at a fixed or relatively
fixed level of anticoagulation due to changes in absorption of
medication, the effects of various foods and medications, and
changes in liver function. Therefore, in clinical practice, the
patient is maintained within a certain therapeutic range. This
can be optimized through a program of patient education and
close surveillance by an experienced healthcare professional.
d. Embolic Events During Adequate Antithrombotic Therapy.
In the patient who has a definite embolic episode(s) while on
adequate antithrombotic therapy, the dosage of antithrom-
botic therapy should be increased as follows:
● Warfarin, INR 2 to 3: warfarin dose increased to achieve
INR of 2.5 to 3.5.
● Warfarin, INR 2.5 to 3.5: warfarin dose may need to be
increased to achieve INR of 3.5 to 4.5.
● Not on aspirin: aspirin 80 to 100 mg/d should be initiated.
● Warfarin plus aspirin 80 to 100 mg/d: aspirin dose may
also need to be increased to 325 mg/d if the higher dose
of warfarin is not achieving the desired clinical result.
● Aspirin alone: aspirin dose may need to be increased to
325 mg/d and/or warfarin added to achieve INR of 2 to 3.
e. Excessive Anticoagulation. In most patients with INR
above the therapeutic range, excessive anticoagulation can be
managed by withholding warfarin and following the level of
anticoagulation with serial INR determinations. Excessive
anticoagulation (INR.5) greatly increases the risk of hemor-
rhage. However, rapid decreases in INR that lead to INR
falling below the therapeutic level increase the risk of throm-
boembolism. Patients with prosthetic heart valves with an INR
of 5 to 10 who are not bleeding can be managed by withholding
warfarin and administering 2.5 mg of oral vitamin K1 (phyton-
adione) (645). INR should be determined after 24 hours and
subsequently as needed. Warfarin therapy is restarted and
dose adjusted appropriately to ensure that INR is in the
therapeutic range. In emergency situations, the use of fresh
frozen plasma is preferable to high-dose vitamin K1, especially
parenteral vitamin K1, because use of the latter increases the
risk of overcorrection to a hypercoagulable state.
f. Antithrombotic Therapy in Patients Requiring Noncardiac
Surgery/Dental Care. The risk of increased bleeding during a
procedure performed with a patient receiving antithrombotic
therapy has to be weighed against the increased risk of a
thromboembolism caused by stopping the therapy. The risk of
stopping warfarin can be estimated and is relatively slight if the
drug is withheld for only a few days. As an example, in a worst
case scenario (eg, a patient with a mechanical prosthesis with
previous thromboemboli), the risk of a thromboembolus off
warfarin could be 10% to 20% per year. Thus, if therapy were
stopped for 3 days, the risk of an embolus would be 0.08% to
0.16%. There are theoretical concerns that stopping the drug
and then reinstituting it might result in hypercoagulability or
that there might be a thrombotic “rebound.” An increase in
markers for activation of thrombosis with abrupt discontinua-
tion of warfarin therapy has been observed (646), but it is not
clear that this increases the clinical risk of thromboembolism
(647). In addition, when reinstituting warfarin therapy, there
are theoretic concerns about a hypercoagulable state caused by
suppression of protein C and protein S before the drug affects
the thrombotic factors. Although these risks are only hypothet-
ical, individuals at very high risk should be treated with heparin
until INR returns to the desired range.
Management of antithrombotic therapy must be individu-
alized, but some generalizations apply, as indicated in Table 35
(617). Antithrombotic therapy should not be stopped for
procedures in which bleeding is unlikely or would be inconse-
quential if it occurred, for example, surgery on the skin, dental
cleaning, or simple treatment for dental caries. Eye surgery,
particularly for cataracts or glaucoma, is usually associated
with very little bleeding and thus is frequently performed
without altering antithrombotic treatment. When bleeding is
likely or its potential consequences are severe, antithrombotic
treatment should be altered. If a patient is taking aspirin, it
should be discontinued 1 week before the procedure and
restarted as soon as it is considered safe by the surgeon or
dentist.
For most patients on warfarin, the drug should be stopped
before the procedure so that the INR is ,21.5 (which is often 48
to 72 hours after warfarin is discontinued) (617,648) and
restarted within 24 hours after a procedure. Admission to the
hospital or a delay in discharge to give heparin is usually
unnecessary (633,647,649–651). Determining which patients
are at very high risk of thrombosis and require heparin until
warfarin can be reinstated may be difficult, and clinical judg-
ment is required. Heparin can usually be reserved for those
who have had a recent thrombosis or embolus (arbitrarily
within 1 year), those with demonstrated thrombotic problems
when previously off therapy, those with the Bjo¨rk-Shiley valve
(652–654), and those with .23 “risk factors.” Such risk factors
include atrial fibrillation, previous thromboembolism, hyper-
coagulable condition, and mechanical prosthesis; many would
also include LV dysfunction (ejection fraction ,0.30) as a risk
factor. A lower threshold for recommending heparin should be
considered in patients with mechanical valves in the mitral
position, in whom a single risk factor would be sufficient
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evidence of high risk. When heparin is used, it should be
started when INR falls below 2.0 (ie, 48 hours before surgery)
and stopped 4 to 6 hours before the procedure. Heparin should
be restarted as early after surgery as bleeding stability allows,
and the aPPT should be maintained at 55 to 70 seconds until
warfarin is restarted. After an overlap of 3 to 5 days, heparin
may be discontinued when the desired INR is achieved. Home
administration and management of heparin (and warfarin) can
be arranged to minimize time in the hospital. Low-molecular-
weight heparin is attractive because it is even more easily used
outside the hospital; however, there are no data on patients
with prosthetic heart valves (617), and low-molecular-weight
heparin cannot be recommended at this time.
High-dose vitamin K1 should not be given routinely, as this
may create a hypercoagulable condition. For emergency situ-
ations, fresh frozen plasma is preferable to high-dose vitamin
K1.
g. Antithrombotic Therapy in Patients Needing Cardiac Cath-
eterization/Angiography. Although some centers do not discon-
tinue heparin before cardiac catheterization, most stop heparin
6 hours before the procedure and resume it 12 hours after the
procedure. Under most circumstances, protamine should not
be given. Antiplatelet therapy does not have to be stopped for
these procedures.
In an emergent or semiemergent situation, cardiac cathe-
terization can be performed in a patient taking warfarin, but
preferably the drug should be stopped '72 hours before the
procedure so that INR is ,21.5 (see above). The drug should be
restarted as soon as the procedure is completed. This is true
for patients with biological valves receiving antithrombotic
therapy as well as those with mechanical valves. If a patient has
.21 risk factor(s) that predispose to thromboembolism, heparin
should be started when INR falls below 2.0 and continued
when warfarin is restarted. After an overlap of 3 to 5 days,
heparin may be discontinued when the desired INR is
achieved. If the catheterization procedure is to include a
transseptal puncture (especially in a patient who has not had
previous opening of the pericardium), patients should be off all
antithrombotic therapy and INR should be ,21.2; the same is
also true if an LV puncture is to be performed (655). In
patients who are to undergo transseptal or LV puncture and
are receiving heparin therapy, heparin should be discontinued
4 to 6 hours before the procedure(s) and can be restarted
without a bolus .24 hours after the sheath in the peripheral
vessel has been removed.
h. Thrombosis of Prosthetic Heart Valves. Prosthetic valve
obstruction may be caused by thrombus formation, pannus
ingrowth, or a combination of both. The cause may be difficult
to determine and requires knowledge of the clinical presenta-
tion and findings on echocardiography, including transesoph-
ageal echocardiography. If the prosthesis is obstructed by
pannus, thrombolytic therapy will be ineffective, and the valve
needs to be replaced. Thrombolytic therapy for a prosthetic
valve obstructed by thrombus is associated with significant risks
and is often ineffective. Two recent extensive reviews (656,657)
of thrombolytic therapy for left-sided prosthetic valve throm-
bosis reported that thrombolytic therapy is ineffective in 16%
to 18% and acute mortality is 6%. The risk of thromboembo-
lism is 12%; stroke, 3% to 10%; major bleeding episodes, 5%;
nondisabling bleeding, 14%; and recurrent thrombosis, 11%.
Patients who have a large clot, those with evidence of valve
obstruction, and those in NYHA functional Classes III or IV
because of prosthetic thrombosis should undergo early/
immediate reoperation. Thrombolytic therapy in such patients
is reserved for those in whom surgical intervention carries a
high risk and those with contraindications to operation (656–
659). Streptokinase and urokinase are the most frequently
used thrombolytic agents. The duration of thrombolytic ther-
apy depends on resolution of pressure gradients and valve
areas to near-normal by Doppler echocardiography. Throm-
bolytic therapy should be stopped at 24 hours if there is no
hemodynamic improvement or after 72 hours even if hemody-
namic recovery is incomplete (656). If thrombolytic therapy is
successful, it should be followed by intravenous heparin until
warfarin achieves an INR of 3 to 4 for aortic prosthetic valves
and 3.5 to 4.5 for mitral prosthetic valves. If partially success-
ful, thrombolytic therapy may be followed by a combination of
subcutaneous heparin twice daily (to achieve an aPTT of 55 to
80 seconds) plus warfarin (INR 2.5 to 3.5) for a 3-month
period (656).
Patients with a “small clot” who are in NYHA functional
Table 35. Antithrombotic Therapy in Patients Requiring Noncardiac
Surgery/Dental Care
Usual Approach
If patient on warfarin z Stop 72 h before procedure
z Restart in the afternoon on the day of
procedure or after control of active
bleeding
If patient on aspirin z Stop 1 wk before procedure
z Restart the day after procedure or after
control of active bleeding
Unusual Circumstances
1. Very high risk of thrombosis z Stop warfarin 72 h before procedure
if off warfarin* z Start heparin when INR falls below 2.0†
z Stop heparin 6 h before procedure
z Restart heparin within 24 h of
procedure and continue until warfarin
can be restarted and INR .22.0
2. Surgery complicated by
postoperative bleeding
z Start heparin as soon after surgery as
deemed safe and maintain PTT at
55–70 s until warfarin restarted and INR
.22.0.
3. Very low risk from bleeding‡ z Continue antithrombotic therapy
*Clinical judgment: consider this approach if recent thromboembolus,
Bjo¨rk-Shiley valve, or 3 “risk factors” are present. Risk factors are atrial
fibrillation, LV dysfunction, previous thromboembolism, hypercoagulable con-
dition, and mechanical prosthesis. One risk factor is sufficient to consider heparin
in patients with mechanical valves in mitral position. †Heparin can be given in
outpatient setting before and after surgery. ‡Eg, local skin surgery, teeth
cleaning, and treatment for caries. From McAnulty JH, Rahimtoola SH (617).
Antithrombotic therapy in valvular heart disease. In: Schlant R, Alexander RW,
eds. Hurst’s The Heart, Arteries, and Veins. 9th ed. New York, NY: McGraw-Hill
Publishing Co; 1998:1867–1874. With permission.
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Class I or II and those with LV dysfunction should have
in-hospital, short-term intravenous heparin therapy. If this is
unsuccessful, they may receive a trial of continuous infusion
thrombolytic therapy over several days. If this is unsuccessful
or there is an increased risk associated with thrombolytic
therapy, they may need reoperation. An alternative to throm-
bolytic therapy in patients who remain hemodynamically stable
is to convert intravenous heparin to combined therapy with
subcutaneous heparin (twice daily to an aPTT of 55 to 80
seconds) and warfarin (INR 2.5 to 3.5) for 1 to 3 months on an
outpatient basis to allow for endogenous thrombolysis (656). If
intravenous heparin, heparin/thrombolytic therapy, or heparin/
warfarin is successful, warfarin doses should be increased so
that INR is between 3.0 and 4.0 (around 3.5) for prosthetic
aortic valves and between 3.5 and 4.5 (around 4.0) for pros-
thetic mitral valves. These patients should also receive low-
dose aspirin.
3. Follow-up Visits. a. First Outpatient Postoperative Visit.
The first outpatient evaluation after valve surgery usually
occurs 3 to 4 weeks after hospital discharge. By this time, the
patient’s physical capabilities and expected improvement in
functional capacity can be assessed.
The workup on this visit should include an interval or
complete history and physical examination, ECG, chest x-ray,
2-D and Doppler echocardiography, complete blood count,
BUN/creatinine, electrolytes, LDH, and INR, if indicated. The
main focus of the examination is on signs that relate to
functioning of the prosthesis or that might suggest the pres-
ence of infection or a myocardial infarction, conduction, or
valvular disorder. Severe perivalvular mitral regurgitation may
be inaudible on physical examination, a fact to remember when
considering possible causes of functional deterioration in a
patient.
Echocardiography is the most useful noninvasive test. It
provides information about prosthesis stenosis/regurgitation,
valve area, assessment of other valve disease(s), pulmonary
hypertension, atrial size, left and right ventricular hypertrophy,
left and right ventricular size and function, and pericardial
effusion/thickening. It is an essential component of the first
postoperative visit because it allows an assessment of the
effects and results of surgery as well as serving as a baseline for
comparison should complications and/or deterioration occur
later.
Every prosthetic valve has an intrinsic degree of obstruction
(607,660), and one reason for obtaining a baseline Doppler
echocardiogram early after valve replacement is so that this
intrinsic gradient can be measured and compared with subse-
quent measurements if necessary. The gradient varies among
different types of prosthetic valves. Doppler echocardiography
also detects the prosthetic valve regurgitation that is normal
for various types of mechanical valve.
Multiple other noninvasive tests have emerged for assessing
valvular and ventricular function, but these should be per-
formed only in selected patients for specific indications. Fluo-
roscopy can reveal abnormal rocking of a dehiscing prosthesis,
limitation of the occluder if the latter is opaque, and strut
fracture of the convexoconcave Bjo¨rk-Shiley valve. Phonocar-
diography can detect variant poppets if “normal” sounds were
previously established but is rarely used in the 1990s. Radio-
nuclide angiography is useful to determine whether functional
deterioration is the result of reduced ventricular function and
is performed if the same data cannot be obtained by echocar-
diography.
b. Follow-up Visits in Patients Without Complications. Pa-
tients who have undergone valve replacement are not cured
but still have serious heart disease. They have exchanged
native valve disease for prosthetic valve disease and must be
followed with the same care as patients with native valve
disease (661). The clinical course of patients with prosthetic
heart valves is influenced by several factors (609), including
ventricular dysfunction, progression of other valve disease,
pulmonary hypertension, other cardiac diseases, complications
of prosthetic heart valves, and clinical heart failure. The
interval between routine follow-up visits depends on the
patient’s needs. Anticoagulant regulation does not require
visits to the physician’s office but should be closely supervised
by an experienced healthcare professional.
The asymptomatic uncomplicated patient needs to be seen
only at 1-year intervals, at which time a complete history and
thorough physical examination should be performed. ECG and
chest x-ray examinations are not routinely indicated but are
valuable in individual patients. Additional tests that are often
performed include hemoglobin, hematocrit, and LDH. The
frequency with which 2-D and Doppler echocardiography
should be routinely performed in uncomplicated patients is
uncertain, and there are no data on which to base this decision.
The Committee on Management of Patients With Valvular
Heart Disease did not reach consensus on this issue. The
majority recommended no further echocardiographic testing
after the initial postoperative evaluation in patients with
mechanical valves who are stable and who have no symptoms
or clinical evidence of LV dysfunction, prosthetic valve dys-
function, or dysfunction of other heart valves in keeping with
the ACC/AHA Guidelines for the Clinical Application of
Echocardiography (2). However, a minority opinion recom-
mended routine echocardiograms every year. The committee
also failed to reach consensus on serial echocardiography in
patients with bioprosthetic valves for whom there is an increas-
ing risk of structural deterioration of the valve after 5 years in
the mitral position and after 8 years in the aortic position. A
minority opinion recommended annual echocardiography,
whereas the majority recommended detailed histories and
cardiac physical examinations with echocardiography when
dictated by clinical circumstances such as a regurgitant
murmur or change in symptoms. Once regurgitation is
detected, close follow-up with 2-D and Doppler echocardi-
ography every 3 to 6 months is indicated. The committee
agreed that echocardiography is indicated in any patient
with a prosthetic heart valve whenever there is evidence of
a new murmur, there are questions about prosthetic valve
integrity and function, or there are concerns about ventric-
ular function.
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Recommendations for Follow-up Strategy of Patients With
Prosthetic Heart Valves
Indication Class
1. History, physical exam, ECG, chest X-ray, echocardiogram,
complete blood count, serum chemistries, and INR (if
indicated) at first postoperative outpatient evaluation.*
I
2. Radionuclide angiography or magnetic resonance imaging to
assess LV function if result of echocardiography is
unsatisfactory.
I
3. Routine follow-up visits at yearly intervals with earlier
reevaluations for change in clinical status.
I
4. Routine serial echocardiograms at time of annual follow-up
visit in absence of change in clinical status.
IIb
5. Routine serial fluoroscopy. III
*This evaluation should be performed 3 to 4 weeks after hospital discharge.
In some settings, the outpatient echocardiogram may be difficult to obtain; if so,
an inpatient echocardiogram may be obtained before hospital discharge.
c. Follow-up Visits in Patients With Complications. LV dys-
function and clinical heart failure after valve replacement may
be the result of (1) preoperative LV dysfunction that persists
or improves only partially; (2) perioperative myocardial dam-
age; (3) other valve disease that has progressed; (4) complica-
tions of prosthetic heart valves; and (5) associated heart
disease such as CAD and systemic hypertension.
Any patient with a prosthetic heart valve who does not
improve after surgery or who later shows deterioration of
functional capacity should undergo appropriate testing, includ-
ing 2-D and Doppler echocardiography and, if necessary,
transesophageal echocardiography and cardiac catheterization
with angiography to determine the cause.
4. Reoperation to Replace a Prosthetic Valve. Reoperation
to replace a prosthetic heart valve is a serious clinical event. It
is usually required for moderate to severe prosthetic dysfunc-
tion (structural and nonstructural), dehiscence, and prosthetic
endocarditis. Reoperation may also be needed for recurrent
thromboembolism, severe intravascular hemolysis, severe re-
current bleeding from anticoagulant therapy, thrombosed
prosthetic valves, and valve prosthesis–patient mismatch
(607,660).
The patient who is in stable condition without prosthetic
valve endocarditis under many circumstances undergoes reop-
eration with only slightly greater risk than that accompanying
the initial surgery. For the patient with catastrophic prosthetic
valvular dysfunction, surgery is clearly indicated and urgent.
The patient without endocarditis or severe prosthetic valve
dysfunction requires careful hemodynamic evaluation, and the
decision about reoperation should then be based on hemo-
dynamic abnormalities, symptoms, ventricular function, and
current knowledge of the natural history of the particular
prosthesis.
D. Major Criteria for Valve Selection
In general, mitral valve repair is preferable to MVR,
provided it is feasible and the appropriate skill and experience
are available to perform the procedure successfully. Carefully
selected patients with AR or AS in whom the valve is not
calcified are also candidates for valve repair, with the same
provisos as mitral valve repair and with the recognition that
information regarding the early and late results of aortic valve
repair for AR is quite limited at this time.
The major advantages of a mechanical valve are an ex-
tremely low rate of structural deterioration and a better
survival rate in patients younger than 65 years after AVR, and
for MVR in patients ,250 years of age after MVR. The major
disadvantages are the increased incidence of bleeding due to
the need for antithrombotic therapy and the cost and disad-
vantages of antithrombotic therapy.
The major advantages of a bioprosthesis (whether porcine
or pericardial) are a lower bleeding rate and lack of need for
antithrombotic therapy. In addition, the rate of structural valve
deterioration in patients .265 years is lower than in patients
,65, especially in the aortic position (662–671). The influence
of age on structural deterioration of porcine bioprosthetic
valves is shown in Table 36. In patients .265 years undergoing
AVR with a porcine bioprosthesis, the rate of structural
deterioration is ,10% at 10 years (663–665,668–671). The
major disadvantage is the increased rate of structural valve
deterioration and hence the need for reoperation in patients
,65 years, particularly in those aged ,250 years. Pericardial
bioprostheses may have a lower rate of structural valve dete-
rioration than porcine bioprostheses in patients .265 years
(672,673).
Women who are contemplating pregnancy after valve re-
placement pose a difficult problem. The disadvantages of a
mechanical valve are that the patient is at risk for complica-
tions of warfarin therapy that may affect the patient and/or
fetus and for complications of heparin therapy (see section
V.H. of these guidelines). It is likely that the risks may be lower
in women who are compliant and have access to good medical
care (674). If the patient needs warfarin therapy for another
reason, then the anticoagulation required for a mechanical
valve may not pose an additional risk. However, a mechanical
valve may pose an additional risk if it requires a higher INR
level than the underlying condition for which warfarin was
initiated or if the initial indication for warfarin is not absolute.
For example, for a patient in sinus rhythm with a previous
history of atrial fibrillation and no previous history of
systemic emboli, aspirin may be substituted for warfarin
during pregnancy. In this situation, a mechanical valve
would pose an additional risk. The disadvantage of a
bioprosthesis is the relatively higher rate of early structural
valve deterioration (553). As a result, reoperation for
prosthetic valve replacement will likely be required with its
attendant risks, including disability and death of young
mothers. The Ross procedure (pulmonary autograft) or an
aortic valve homograft is associated with a lower rate of such
complications in young women and does not require anti-
coagulation. These procedures are strongly recommended
for women who wish to become pregnant, provided that the
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necessary surgical skill and experience in performing these
procedures are available. The options for prosthetic valves
should be explained and discussed with younger women
before valve replacement and pregnancy.
Pulmonary autograft and homograft valves have a very low
rate of thromboemboli and possibly endocarditis. The long-
term (20-year) incidence of structural valve deterioration is
not certain. The autograft, if feasible to perform and if the
appropriate skill and experience are available, is preferable
in children because of the possibility of growth of the valve
as the patient grows. These valves are available only for
AVR.
If the patient needs antithrombotic therapy for any reason,
for example, atrial fibrillation or presence of a mechanical
valve in another position, then the major advantage of a
biological valve is reduced substantially.
If the patient is small or has a small valve annulus that will
not permit use of an adequately sized valve (.223 mm for AVR,
.231 mm for MVR), consideration should be given to aortic
root/annular enlargement or use of an autograft/homograft in
the aortic position. If a mechanical valve or bioprosthesis is
used in such patients, then one with the best hemodynamic
profile should be chosen.
Biological valves have a much higher rate of structural
deterioration when implanted in patients with renal failure,
those on hemodialysis, and those with hypercalcemia. Adoles-
cent patients who are still growing have a high risk for
accelerated biological valve calcification.
In patients undergoing repeat valve replacement, dysfunc-
tion of a biological valve may be a consideration for a
mechanical valve, and a previously thrombosed mechanical
valve is a consideration for a biological valve.
The above factors should be considered in choosing
a prosthetic valve. Patients should be informed of the
known risks and benefits of each device, and patient pref-
erences and individual circumstances should be considered
in deciding which prosthetic heart valve to use for each
patient.
Table 36. Structural Valve Deterioration of Bioprosthetic Valves
Study, year
Mean
follow-up,
year
Number of
valves Time of
SVD estimate,
year
Age,
year
Freedom from
SVD (%)
CommentsAVR MVR AVR MVR
Jamieson et al 1988 (663) 5.6 572 509 10 30–59 81 6 4 78 6 5 Carpentier-Edwards standard porcine bioprosthesis
.60 91 6 3 71 6 9
Cohn et al 1989 (664) 6.0 971 708 15 ,240 68 6 9 68 6 10 Hancock porcine bioprosthesis (includes 146
combined AVR 1 MVR procedures)41–69 86 6 2 84 6 13
.270 94 6 3 84 6 10
Jones et al 1990 (665) 8.3 610 528 10 ,40 46 6 7 47 6 8 Hancock or Carpentier-Edwards porcine
bioprosthesis (includes 88 combined AVR 1
MVR procedures)
40–49 60 48 6 8
50–59 79 61
60–69 92 6 2 80 6 6
Burr et al 1992 (668) — 574 500 7 ,65 94 6 1 88 6 2 Carpentier-Edwards standard porcine bioprosthesis
(similar results were obtained with Carpentier-
Edwards supra-annular porcine bioprosthesis)
65–69 98 6 1 90 6 4
70–79 100 95 6 3
.280 100 100
13–15 ,65 62 6 8 37 6 7
65–69 98 6 3 63 6 8
70–79 95 6 5 74 6 19
.280 100 —
Pelletier et al 1992 (669) 7.0 451 547 10 ,45 70 55 Carpentier-Edwards standard (302 AVR, 324 MVR),
improved annulus (97 AVR, 135 MVR), and
supra-annular (52 AVR, 88 MVR) porcine
bioprostheses (includes 121 combined AVR 1
MVR and 5 combined MVR 1 TVR procedures)
45–54 84 64
55–64 84 69
.265 93 95
Burdon et al 1992 (670) 7.3 857 793 15 16–39 33 6 7 37 6 6 Hancock I and Hancock modified orifice porcine
bioprosthesis40–49 54 6 10 38 6 12
50–59 57 6 6 38 6 5
60–69 73 6 6 61 6 15
.70 93 6 3 62 6 6
Abbreviations: AVR 5 aortic valve replacement, MVR 5 mitral valve replacement, SVD 5 structural valve deterioration, TVR 5 tricuspid valve replacement.
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Recommendations for Valve Replacement With a
Mechanical Prosthesis
Indication Class
1. Patients with expected long life spans. I
2. Patients with a mechanical prosthetic valve already in place in
a different position than the valve to be replaced.
I
3. Patients in renal failure, on hemodialysis, or with
hypercalcemia.
II
4. Patients requiring warfarin therapy because of risk factors*
for thromboembolism.
IIa
5. Patients <265 years for AVR and <270 years for MVR.† IIa
6. Valve rereplacement for thrombosed biological valve. IIb
7. Patients who cannot or will not take warfarin therapy. III
*Risk factors: atrial fibrillation, severe LV dysfunction, previous thrombo-
embolism, and hypercoagulable condition. †The age at which patients may be
considered for bioprosthetic valves is based on the major reduction in rate of
structural valve deterioration after age 65 (662–671) and the increased risk of
bleeding in this age group.
Recommendations for Valve Replacement With a Bioprosthesis
Indication Class
1. Patients who cannot or will not take warfarin therapy. I
2. Patients >265 years* needing AVR who do not have risk factors
for thromboembolism.†
I
3. Patients considered to have possible compliance problems with
warfarin therapy.
IIa
4. Patients >70 years* needing MVR who do not have risk factors
for thromboembolism.†
IIa
5. Valve rereplacement for thrombosed mechanical valve. IIb
6. Patients <65 years.* IIb
7. Patients in renal failure, on hemodialysis, or with hypercalcemia. III
8. Adolescent patients who are still growing. III
*The age at which patients should be considered for bioprosthetic valves is
based on the major reduction in rate of structural valve deterioration after age
65 (662–671) and increased risk of bleeding in this age group. †Risk factors:
atrial fibrillation, severe LV dysfunction, previous thromboembolism, and
hypercoagulable condition.
VIII. Evaluation and Treatment of Coronary
Artery Disease in Patients With Valvular
Heart Disease
Many patients with valvular heart disease have concomitant
CAD, but there are only limited data regarding the optimal
strategies for diagnosis and treatment of CAD in such patients.
Thus, management decisions are usually developed by blend-
ing information from the randomized studies of treatment of
CAD and the smaller published series of patients undergoing
surgical treatment of valvular heart disease.
A. Probability of Coronary Artery Disease in
Patients With Valvular Heart Disease
The probability of developing CAD in the general popula-
tion (675) and the prevalence of CAD in patients coming to
medical attention (676) can be estimated on the basis of age,
sex, and clinical risk factors. The prevalence of CAD in
patients with valvular heart disease is determined by these
same variables (677). Risk factors for coronary atherosclerosis
in patients with valvular disease should be approached with the
prevention and risk reduction strategies that have been recom-
mended for the general population (678).
Ischemic symptoms are important markers of CAD in the
general population. Thus, the prevalence of CAD in middle-
aged men with typical angina has been estimated at '90%, in
those with atypical angina at '50%, in those with nonanginal
chest pain at '16%, and in asymptomatic subjects at '4%
(676). In contrast, ischemic symptoms in patients with valvular
heart disease may have multiple causes such as LV chamber
enlargement, increased wall stress or wall thickening with suben-
docardial ischemia (376,679), and right ventricular hypertrophy
(680). Angina is thus a less specific indicator of CAD in patients
with valvular heart disease than in the general population.
Among patients with severe AS, angina is a common
symptom in young patients with normal coronary arteries and
congenital or rheumatic AS. On the other hand, CAD is a
common finding in older symptomatic men with AS. Among
patients with AS, the prevalence of CAD is 40% to 50% in
those with typical angina, '25% in those with atypical chest
pain, and '20% in those without chest pain (681–688). Even
in patients ,40 years old with no chest pain and no coronary
risk factors, the prevalence of CAD is 3% to 5% (677,688,689).
In general, because angina is a poor marker of CAD in patients
with AS, coronary arteriography is recommended in symptom-
atic patients before AVR, especially in men .35 years old,
premenopausal women .35 years old with coronary risk
factors, and postmenopausal women.
CAD is less prevalent in patients with AR than in those with
AS (681–688,690–697), which is related in part to the younger
age of patients with AR. The prevalence of CAD in patients
with MS ('20%) is lower than in patients with aortic valve
disease (690,692,697–699), an observation explained princi-
pally on the basis of differences in age and gender. Nonethe-
less, because of the impact of untreated CAD on perioperative
and long-term postoperative survival, preoperative identifica-
tion of CAD is of great importance in patients with AR or MS
as well as those with AS. Thus, in symptomatic patients and/or
those with LV dysfunction, preoperative coronary angiography
is recommended in men .35, premenopausal women .35 with
coronary risk factors, and postmenopausal women.
The relation between MR and CAD is unique in that CAD
is frequently the cause of this valve lesion. The management of
these patients is discussed in section III.E.5. of these guide-
lines. Neither angina nor heart failure symptoms are reliable
markers of CAD in these patients. In patients undergoing
catheterization to evaluate etiology and severity of MR, CAD
is present in '33% (700,701). In patients undergoing cathe-
terization for acute ischemic syndromes, '20% have associ-
ated MR (702). Those with chronic CAD and MR usually have
lower LV ejection fractions and more extensive CAD than
those without MR (700,703).
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B. Diagnosis of Coronary Artery Disease
The resting ECG in patients with valvular heart disease
frequently shows ST-segment changes due to LV hypertrophy,
LV dilatation, or bundle branch block, which reduce the
accuracy of the ECG at rest and during exercise for the
diagnosis of concomitant CAD.
Similarly, resting or exercise-induced regional wall motion
abnormalities are nonspecific markers for CAD in patients
with underlying valvular heart disease who have LV hypertro-
phy and/or chamber dilatation (704–706), as are myocardial
perfusion abnormalities induced by exercise or pharmacologi-
cal stress (707–711). Thus, there are few indications for
myocardial perfusion imaging with thallium 201 or technetium
99m perfusion agents in patients with severe valvular disease,
and coronary arteriography remains the most appropriate
method for the definitive diagnosis of CAD (1). Noninvasive
imaging is useful when CAD is suspected in patients with mild
valve stenosis or regurgitation and normal LV cavity size and
wall thickness.
Recommendations for Coronary Angiography in Patients With
Valvular Heart Disease
Indication Class
1. Before valve surgery (including infective endocarditis) or
mitral balloon commissurotomy in patients with:
I
z Chest pain
z Other objective evidence of ischemia
z Decreased LV systolic function
z History of CAD
z Coronary risk factors* (including advanced age)†
2. Patients with apparently mild to moderate valvular heart
disease but with
I
z Progressive (Class II or greater) angina
z Objective evidence of ischemia
z Decreased LV systolic function
z Overt congestive heart failure
3. Patients undergoing catheterization to confirm the severity of
valve lesions before valve surgery without preexisting
evidence of CAD, multiple coronary risk factors, or advanced
age.†
IIb
4. Young patients† undergoing nonemergent valve surgery when
no further hemodynamic assessment by catheterization is
deemed necessary and no coronary risk factors, no history of
CAD, and no evidence of ischemia are present.
III
5. Asymptomatic patients with valvular heart disease when
valve surgery or balloon commissurotomy is not being
considered.
III
6. Patients having emergency valve surgery for acute valve
regurgitation, aortic root disease, or infective endocarditis
when there are no coronary risk factors, angina, objective
evidence of ischemia, evidence of coronary embolization, LV
systolic dysfunction, or age <35 years.
III
*Patients undergoing mitral balloon valvotomy need not undergo coronary
angiography based only on coronary risk factors. †The age at which coronary
angiography should be performed before valve surgery is difficult to define. The
committee recommends coronary angiography in men >235 years of age,
premenopausal women >235 years of age with coronary risk factors, and
postmenopausal women.
C. Treatment of Coronary Artery Disease at the
Time of Aortic Valve Replacement
As noted previously, .233% of patients with AS undergoing
AVR have concomitant CAD. More than 50% of patients .70
years old have CAD. Several studies have reported the out-
comes of patients undergoing combined coronary artery bypass
surgery and AVR. Although combined myocardial revascular-
ization and AVR increases cross clamp time (712) and has the
potential to increase perioperative myocardial infarction and
early postoperative mortality in comparison with patients
without CAD undergoing isolated AVR (713–716), in several
series combined coronary artery bypass surgery has had little
or no adverse effect on operative mortality (717–724). More-
over, combined coronary bypass grafting and AVR reduces the
rates of perioperative myocardial infarction, operative mortal-
ity, and late mortality and morbidity compared with patients
with significant CAD who did not undergo revascularization at
the time of AVR (723–726). In addition to severity of CAD,
the multivariate factors for late postoperative mortality include
severity of AS, severity of LV dysfunction, age .70 (especially
in women), and presence of NYHA functional Class IV
symptoms (724,727,728). Incomplete revascularization is asso-
ciated with greater postoperative systolic dysfunction (729,730)
and reduced survival rates (731) after surgery compared with
patients who receive complete revascularization. For over a
decade, improved myocardial preservation techniques have been
associated with reduced overall operative mortality (732), and it
has become standard practice to bypass all significant coronary
artery stenoses when possible in patients undergoing AVR. The
committee recommends this approach.
D. Aortic Valve Replacement in Patients
Undergoing Coronary Artery Bypass Surgery
Patients undergoing coronary artery bypass surgery who
have severe AS should undergo AVR at the time of revascu-
larization. Decision making is less clear in patients who have
CAD requiring coronary bypass surgery who have mild to
moderate AS. Controversy persists regarding the indications
for “prophylactic” AVR at the time of coronary bypass surgery
in such patients. This decision should be made only after the
severity of AS is determined carefully by Doppler echocardi-
ography and cardiac catheterization.
Confirmation by cardiac catheterization is especially impor-
tant in patients with reduced stroke volumes, mixed valve
lesions, or intermediate mean aortic valve gradients (between
30 and 50 mm Hg) by Doppler echocardiography, as many such
patients may actually have severe AS (as discussed in detail in
section III.A. of these guidelines). The more complex and
controversial issue is the decision to replace the aortic valve for
only mild AS at the time of coronary bypass surgery because
the degree of AS may become more severe within a few years,
necessitating a second, more difficult AVR operation in a
patient with patent bypass grafts.
It is difficult to predict whether a given patient with CAD
and mild AS is likely to develop significant AS in the years after
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revascularization surgery. As noted previously (section III.A.3.
of these guidelines), the natural history of mild AS is variable,
with some patients manifesting a relatively rapid progression of
AS with a decrease in valve area of up to 0.3 cm2 per year and
an increase in pressure gradient of up to 15 to 19 mm Hg per
year; however, the majority may show little or no change
(72–84). The average rate of reduction in valve area is '0.12
cm2 per year (84), but the rate of change in an individual
patient is difficult to predict.
Retrospective studies of patients who have come to AVR
after previous coronary bypass surgery have been reported in
whom the mean time to reoperation was 5 to 8 years (733–
737). The aortic valve gradient at the primary operation was
small, ,220 mm Hg, but the mean gradient increased signifi-
cantly to .50 mm Hg at the time of the second operation. It is
important to note that these represent selected patients in
whom AS progressed to the point that AVR was warranted.
The number of patients in these surgical series who had similar
gradients at the time of the primary operation but who did not
have significant progression of AS is unknown.
Although definitive data are not yet available, patients with
intermediate aortic valve gradients (30 to 50 mm Hg mean
gradient at catheterization or 3 to 4 m/s transvalvular velocity
by Doppler echocardiography) who are undergoing coronary
artery bypass surgery may warrant AVR at the time of
revascularization, but this is controversial because there are
limited data to indicate the wisdom of this general policy. In most
patients with normal stroke volumes and small mean gradients
(,30 mm Hg and/or ,3 m/s), there is greater controversy
regarding AVR at the time of coronary artery bypass surgery, and
the strength of this recommendation is reduced.
Recommendations for Aortic Valve Replacement in Patients
Undergoing Coronary Artery Bypass Surgery
Indication Class
1. In patients undergoing coronary artery bypass surgergy (CABG)
who have severe AS who meet the criteria for valve replacement
(section III. of these guidelines).
I
2. In patients undergoing CABG who have moderate AS (mean
gradient 30 to 50 mm Hg or Doppler velocity 3 to 4 m/s).
IIa
3. In patients undergoing CABG who have mild AS (mean gradient
<30 mm Hg or Doppler velocity <3 m/s).
IIb
E. Management of Concomitant Mitral Valve
Disease and Coronary Artery Disease
Most patients with both mitral valvular disease and CAD
have ischemic MR, as discussed in section III.E.5. of these
guidelines. In patients with 1 to 21 MR, ischemic symptoms
usually dictate the need for revascularization, and the mitral
valve is rarely repaired or replaced unless intraoperative
echocardiography indicates more severe MR. In patients with
more severe MR, the mitral valve is addressed surgically, and
all obstructed coronary arteries are revascularized.
In patients with mitral valve disease due to diseases other
than ischemia, significantly obstructed coronary arteries iden-
tified at preoperative cardiac catheterization are generally
revascularized at the time of mitral valve surgery. There are no
data to indicate the wisdom of this general policy, but because
revascularization usually adds little morbidity or mortality to
operation, the additional revascularization surgery is usually
recommended.
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